Process for preparing pharmaceutical compositions for the treatment of diseases mediated by CFTR

专利摘要:

公开号:ES2865600T9
申请号:ES14862504T
申请日:2014-10-31
公开日:2021-11-29
发明作者:Kelly Swinney；Patricia Hurter；David Nadig；David Smith；Vance Thomas；Martin Warman
申请人:Vertex Pharmaceuticals Inc；
IPC主号:

专利说明:

[0001] Process for preparing pharmaceutical compositions for the treatment of diseases mediated by CFTR TECHNICAL FIELD OF INVENTION
[0002] The invention relates to a process for the preparation of pharmaceutical compositions comprising Form I acid 3- (6- (1- (2,2-difluorobenzo [d] [1,3] dioxol-5-yl) cyclopropanecarboxamido) -3 -methylpyridin-2-yl) benzoic (Compound 1) and a solid dispersion comprising N- (5-hydroxy-2,4-di-tert-butyl-phenyl) -4-oxo-1H-quinoline-3-carboxamide (Compound 2 ) substantially amorphous, methods of treatment, methods of administration and kits thereof.
[0003] BACKGROUND
[0004] Cystic fibrosis (CF) is a recessive genetic disease that affects approximately 30,000 children and adults in the United States and approximately 30,000 children and adults in Europe. Despite advances in the treatment of CF, there is no cure.
[0005] In CF patients, endogenously expressed CFTR mutations in the respiratory epithelium lead to reduced apical anion secretion causing an imbalance in ion and fluid transport. The resulting decrease in anion transport contributes to increased mucus accumulation in the lung and the accompanying microbial infections that ultimately cause death in CF patients. In addition to respiratory disease, CF patients typically suffer from gastrointestinal problems and pancreatic insufficiency that, if left untreated, lead to death. Also, most men with cystic fibrosis are infertile, and fertility decreases among women with cystic fibrosis. In contrast to the severe effects of two copies of the CF-associated gene, individuals with a single copy of the CF-associated gene show increased resistance to cholera and dehydration resulting from diarrhea, perhaps explaining the relatively high frequency of CF CF gene within the population.
[0006] Sequence analysis of the CFTR gene of CF chromosomes has revealed a variety of disease-causing mutations (Cutting, GR et al. (1990) Nature 346: 366-369; Dean, M. et al. (1990) Cell 61 : 863: 870 and Kerem, BS et al. (1989) Science 245: 1073-1080; Kerem, BS et al (1990) Proc. Natl. Acad. Sci. USA 87: 8447-8451). To date, more than 1000 disease-causing mutations have been identified in the CF gene (http://www.genet.sickkids.on.ca/cftr/app). The most prevalent mutation is a phenylalanine deletion at position 508 of the CFTR amino acid sequence, and is commonly referred to as AF508-CFTR. This mutation occurs in approximately 70% of cystic fibrosis cases and is associated with severe disease.
[0007] The deletion of residue 508 in AF508-CFTR prevents the nascent protein from folding correctly. This results in the inability of the mutant protein to leave the ER and transit to the plasma membrane. As a result, the number of channels present in the membrane is much less than that observed in cells expressing wild-type CFTR. In addition to altered traffic, the mutation results in faulty channel regulation. Together, the reduced number of channels in the membrane and poor regulation lead to reduced anion transport through the epithelium leading to defective ion and fluid transport. (Quinton, P.M. (1990), FASEB J. 4: 2709-2727). Studies have shown, however, that reduced numbers of AF508-CFTR in the membrane are functional, although less than wild-type CFTRs. (Dalemans et al. (1991), Nature Lond. 354: 526-528; Denning et al., Supra; Pasyky Foskett (1995), J. Cell. Biochem. 270: 12347-50). In addition to AF508-CFTR, other disease-inducing mutations in CFTR that result in defective channel trafficking, synthesis, and / or regulation could be up-or-down-regulated to alter anion secretion and modify the progression and / or severity of the illness.
[0008] Compound 1 in salt form is disclosed in PCT International Publication WO2007056341 and US Patent 7,741,321 as an inducer of CFTR activity and therefore as a useful treatment for CFTR-mediated diseases such as cystic fibrosis. . Form I of Compound 1, which is a substantially crystalline and salt-free form, is disclosed in PCT International Publication WO2009073757 and US Patent No. 8,507,534. Compound 2 is disclosed in PCT International Publication WO2006002421 and US Patent No. 7,495,103 as an inducer of CFTR activity and therefore as a useful treatment for CFTR-mediated diseases such as cystic fibrosis. A solid dispersion comprising substantially amorphous Compound 2 is disclosed in PCT International Publication WO2010019239 and United States Published Patent Application No. US20100074949.
[0009] Compounds that are CFTR enhancers, such as Compound 2, and compounds that are CFTR correctors, such as Compound 1, have independently been shown to have utility in treating CFTR-related diseases, such as cystic fibrosis.
[0010] Accordingly, there is a need for new treatments of CFTR-mediated diseases involving CFTR-correcting and enhancing compounds.
[0011] In particular, there is a need for combination therapies to treat CFTR-mediated diseases, such as cystic fibrosis, that include CFTR-enhancing and correcting compounds.
[0012] More particularly, there is a need for combination therapies to treat CFTR-mediated diseases, such as cystic fibrosis, that include CFTR-enhancing compounds, such as substantially amorphous Compound 2, in combination with CFTR-correcting compounds, such as Compound Form I one.
[0013] Compound 1 as part of a combination with Compound 2 has received an Advanced Therapy Designation from the Food and Drug Administration (FDA) for the treatment of cystic fibrosis, one of only two such grants at the time of filing this application (the other being for Compound 2). This demonstrates a significant unmet need for effective treatment of the cause of cystic fibrosis versus symptomatic treatments. Additionally, a common challenge for FDA-approved drugs is the occasional unavailability of drugs to patients who need them. Accordingly, there is a significant unmet need for the currently disclosed Compound 1 and Compound 2 formulations and processes to prepare them in a continuous and controlled manner.
[0014] Furthermore, patient compliance with treatment schedules and dosage amounts is highly dependent on the ease of drug administration. A pharmaceutical composition comprising fixed amounts of dosage of a corrector CFTR and enhancer CFTR, in which the solid forms of said corrector and enhancer are stable, is a significant advance in the treatment of diseases mediated by CFT ^r as fibrosis cystic.
[0015] SUMMARY
[0016] The invention presents a process for the preparation of pharmaceutical compositions comprising 3- (6- (1- (2,2-difluorobenzo [d] [1,3] dioxol-5-yl) cyclopropanecarboxamido) -3-methylpyridine-2- yl) benzoic, Form I of Compound 1, having the following structure:
[0020] a solid dispersion of substantially amorphous N- (5-hydroxy-2,4-di-tert-butyl-phenyl) -4-oxo-1H-quinoline-3-carboxamide, Compound 2, having the following structure:
[0024] treatment methods, administration methods and kits thereof.
[0025] In one aspect, the present invention features a process for preparing a pharmaceutical composition comprising:
[0026] to. Form I of Compound 1;
[0027] b. a solid dispersion comprising Compound 2 substantially amorphous;
[0028] c. a load;
[0029] d. a disintegrant;
[0030] and. a surfactant; Y
[0031] F. a binder
[0032] referred to as PC-I .
[0033] In one embodiment, the process for preparing pharmaceutical compositions of the present invention comprises from 30 to 55 percent by weight of Form I of Compound 1 and from 10 to 45 percent by weight of a solid dispersion comprising substantially Compound 2 amorphous.
[0034] In one embodiment, the filler is selected from cellulose, modified cellulose, sodium carboxymethyl cellulose, ethyl cellulose, hydroxymethyl cellulose, hydroxypropyl cellulose, cellulose acetate, microcrystalline cellulose, dibasic calcium phosphate, sucrose, lactose, cornstarch, potato starch, or any combination of potato starch. the same. In another embodiment, the filler is microcrystalline cellulose and is present in an amount ranging from 10 to 20 percent by weight.
[0035] In one embodiment, the disintegrant is selected from agar-agar, alginines, calcium carbonate, carboxymethylcellulose, cellulose, hydroxypropylcellulose, low-substituted hydroxypropylcellulose, clays, croscarmellose sodium, crospovidone, gums, aluminum magnesium silicate, methylcellulose, polacrylin potassium, sodium alginate sodium starch glycolate, corn starch, potato starch, tapioca starch, or any combination thereof. In another embodiment, the disintegrant is croscarmellose sodium and is present in an amount ranging from 1 to 3 percent by weight.
[0036] In one embodiment, the surfactant is selected from sodium lauryl sulfate, sodium stearyl fumerate, polyoxyethylene sorbitan monooleate, or any combination thereof. In another embodiment, the surfactant is sodium lauryl sulfate and is present in an amount ranging from 0.5 to 2 percent by weight.
[0037] In one embodiment, the binder is selected from polyvinylpyrrolidone, dibasic calcium phosphate, sucrose, cornstarch, modified cellulose, or any combination thereof. In another embodiment, the binder is polyvinylpyrrolidone and is present in an amount ranging from 0 to 5 percent by weight.
[0038] In one embodiment, the present invention features a process for preparing a pharmaceutical composition having the following formulation:
[0043] referred to as PC-II .
[0044] In another aspect, the present invention presents a process for preparing a pharmaceutical composition comprising:
[0045] to. Form I of Compound 1;
[0046] b. a solid dispersion comprising Compound 2 substantially amorphous;
[0047] c. a load;
[0048] d. a disintegrant;
[0049] and. a surfactant;
[0050] F. a binder and
[0051] g. a lubricant;
[0052] referred to as PC-III .
[0053] In one embodiment, the process for preparing pharmaceutical compositions of the present invention comprises about 100 to 250 mg of Compound 1 Form I, and about 100 to 150 mg of substantially amorphous Compound 2. In another embodiment, the pharmaceutical compositions of the present invention comprise about 200 mg of Compound 1 Form I and about 125 mg of substantially amorphous Compound 2. In another embodiment, the pharmaceutical compositions of the present invention comprise about 150 mg of Compound 1 Form I and about 125 mg of substantially amorphous Compound 2.
[0054] In one embodiment, the process for preparing pharmaceutical compositions of the present invention comprises 25 to 50 percent by weight of Form I of Compound 1 and 15 to 35 percent by weight of a solid dispersion comprising substantially Compound 2 amorphous.
[0055] In one embodiment, the filler is selected from cellulose, modified cellulose, sodium carboxymethyl cellulose, ethyl cellulose, hydroxymethyl cellulose, hydroxypropyl cellulose, cellulose acetate, microcrystalline cellulose, dibasic calcium phosphate, sucrose, lactose, corn starch, potato starch, or any combination. the same. In another embodiment, the filler is microcrystalline cellulose and is present in an amount ranging from 20 to 30 percent by weight.
[0056] In one embodiment, the disintegrant is selected from agar-agar, alginines, calcium carbonate, carboxymethylcellulose, cellulose, hydroxypropylcellulose, low-substituted hydroxypropylcellulose, clays, croscarmellose sodium, crospovidone, gums, magnesium aluminum silicate, methylcellulose, polacrylin potassium, sodium alginate sodium starch glycolate, corn starch, potato starch, tapioca starch, or any combination thereof. In another embodiment, the disintegrant is croscarmellose sodium and is present in an amount ranging from 3 to 10 percent by weight.
[0057] In one embodiment, the surfactant is selected from sodium lauryl sulfate, sodium stearyl fumerate, polyoxyethylene sorbitan monooleate, or any combination thereof. In another embodiment, the surfactant is sodium lauryl sulfate and is present in an amount ranging from 0.5 to 2 percent by weight.
[0058] In one embodiment, the binder is selected from polyvinylpyrrolidone, dibasic calcium phosphate, sucrose, cornstarch, modified cellulose, or any combination thereof. In another embodiment, the binder is polyvinylpyrrolidone and is present in an amount ranging from 0 to 5 percent by weight.
[0059] In one embodiment, the lubricant is selected from magnesium stearate, calcium stearate, zinc stearate, sodium stearate, stearic acid, aluminum stearate, leucine, glyceryl behenate, hydrogenated vegetable oil, or any combination thereof. In another embodiment, the lubricant is magnesium stearate and is present in an amount ranging from 0.5 to 2 percent by weight.
[0060] In one embodiment, the present invention features a process for preparing a pharmaceutical composition having the following formulation:
[0065] referred to as PC-IV .
[0066] In one embodiment, the process for preparing pharmaceutical compositions of the present invention further comprises a colorant and optionally a wax. In another embodiment, the colorant is present in an amount ranging from 2 to 4 percent by weight. In another embodiment, the wax is carnauba wax present in an amount ranging from 0 to 0.020 percent by weight.
[0067] In one embodiment, the process for preparing pharmaceutical compositions of the present invention are solid oral pharmaceutical compositions. In another embodiment, the solid oral pharmaceutical compositions are a granular pharmaceutical composition or a tablet.
[0068] In one embodiment, the process for preparing granular pharmaceutical compositions of the present invention has the following formulation:
[0073] referred to as PC-V .
[0074] In one embodiment, the process for preparing granular pharmaceutical compositions of the present invention has the following formulation:
[0079] referred to as PC-VI .
[0080] In one embodiment, the process for preparing granular pharmaceutical compositions of the present invention has the following formulation:
[0083] referred to as PC-VII .
[0084] In one embodiment, the tabletting process of the present invention has the following formulation:
[0089] referred to as PC-VIII .
[0090] In one embodiment, the tabletting process of the present invention has the following formulation:
[0094] referred to as PC-IX .
[0095] In one embodiment, the tabletting process of the present invention has the following formulation:
[0099] referred to as PC-XI .
[0100] In one embodiment, the tabletting process of the present invention has the following formulation:
[0104] referred to as PC-XII .
[0105] In one embodiment, the tabletting process of the present invention has the following formulation:
[0109] referred to as PC-XIII .
[0110] In one embodiment, the tabletting process of the present invention has the following formulation:
[0114] referred to as PC-XIV .
[0115] In one embodiment, the tabletting process of the present invention has the following formulation:
[0117] referred to as PC-XV .
[0118] In one embodiment, the tabletting process of the present invention has the following formulation:
[0122] referred to as PC-XVI .
[0123] In one embodiment, the tabletting process of the present invention has the following formulation:
[0127] referred to as PC-XVII .
[0128] In one embodiment, the tabletting process of the present invention has the following formulation:
[0132] referred to as PC-XVIII .
[0133] In one embodiment, the tabletting process of the present invention has the following formulation:
[0137] referred to as PC-XIX .
[0138] In one embodiment, the tabletting process of the present invention has the following formulation:
[0142] referred to as PC-XX .
[0143] In one embodiment, the tabletting process of the present invention has the following formulation:
[0145] referred to as PC-XXI .
[0146] In one embodiment, the tabletting process of the present invention has the following formulation:
[0151] referred to as PC-XXII .
[0152] In one embodiment, the tabletting process of the present invention has the following formulation:
[0155] referred to as PC-XXIII .
[0156] In one embodiment, the tabletting process of the present invention has the following formulation:
[0160] referred to as PC-XXIV .
[0161] In one embodiment, the tabletting process of the present invention has the following formulation:
[0165] referred to as PC-XXV .
[0166] In one aspect, the present invention features a method of treating, lessening the severity, or symptomatically treating cystic fibrosis in a patient which comprises administering to the patient an effective amount of the pharmaceutical composition, granular pharmaceutical composition, or tablet of the present invention.
[0167] In one embodiment, the present invention features a method of treating, lessening the severity, or symptomatically treating cystic fibrosis in a patient comprising administering to the patient an effective amount of the pharmaceutical composition, granular pharmaceutical composition, or tablet of any of the PC formulations. -I to PC-XXV .
[0168] In one embodiment, the patient has an AF508 CFTR mutation. In another embodiment, the patient is homozygous at AF508. In another embodiment, the patient is heterozygous at AF508. In another embodiment, two tablets are administered to the patient per day.
[0169] In one aspect, the present invention features a method of preparing a granular pharmaceutical composition comprising wet granulating the following components:
[0170] to. Form I of Compound 1;
[0171] b. a solid dispersion comprising Compound 2 substantially amorphous;
[0172] c. a load;
[0173] d. a disintegrant;
[0174] and. a surfactant; Y
[0175] F. a binder.
[0176] In one aspect, the present invention features a method of preparing a tablet comprising compressing:
[0177] i) a plurality of granular pharmaceutical compositions comprising the following components: a. Form I of Compound 1;
[0178] b. a solid dispersion comprising Compound 2 substantially amorphous;
[0179] c. a load;
[0180] d. a disintegrant;
[0181] and. a surfactant; Y
[0182] F. a binder
[0183] ii) a disintegrant;
[0184] iii) a charge; Y
[0185] iv) a lubricant.
[0186] In one aspect, the present invention features a kit comprising pharmaceutical compositions, granular or tablet pharmaceutical compositions of the present invention, and a separate therapeutic agent or pharmaceutical composition thereof.
[0187] In one embodiment, the pharmaceutical compositions, granular pharmaceutical compositions or tablets of the present invention and the separate therapeutic agent or pharmaceutical composition thereof are in separate containers. In another embodiment, the separate containers are bottles. In another embodiment, the separate containers are vials. In another embodiment, the separate packages are blister packages.
[0188] In another aspect, the invention provides a continuous or semi-continuous process for making the pharmaceutical compositions described herein by a twin screw wet granulation process comprising the steps of screening and weighing Compound 1, Compound 2, and excipients; mix Compound 1, Compound 2 and excipients in a mixer and feed the mixture into a continuous granulator while adding a granulating fluid comprising surfactant and a binder at a suitable rate for a suitable period of time and mincing the mixture into granules; dry the granules; mixing the granules with extragranular excipients for a suitable period of time; compress the mixture into tablets; coat the tablets; and, optionally, printing a monogram on one or both sides of the tablet.
[0189] BRIEF DESCRIPTION OF THE DRAWINGS
[0190] Figure 1 is an X-ray diffraction pattern calculated from a monocrystalline structure of Compound 1 Form I.
[0191] Figure 2 is an actual powder X-ray diffraction pattern of Compound 1 Form I.
[0192] Figure 3 is a graph depicting the pH gradient dissolution profiles of Compound 1 for a tablet made by a high shear granulation process (HSG) and a twin screw wet granulation process (TSWG) (LOD means loss by drying, a measure to define the amount of water in a powder / granule).
[0193] Figure 4 is a graph depicting the stability of the substantially amorphous form of Compound 2 in the PC-XVII tablet formulation at 50 ° C after pre-equilibration at 60% relative humidity showing only a small amount of crystallinity throughout the weather.
[0194] Figure 5 is a graph depicting the stability of the substantially amorphous form of Compound 2 in the PC-XVII tablet formulation at 60 ° C after pre-equilibration at 60% relative humidity showing only a small amount of crystallinity throughout the weather.
[0195] Figure 6 is a graph depicting the stability of the substantially amorphous form of Compound 2 in the PC-XX tablet formulation at 60 ° C after pre-equilibrating at 60% relative humidity showing only a small amount of crystallinity throughout the weather.
[0196] Figure 7 is a graph depicting the stability of the substantially amorphous form of Compound 2 in the PC-XX tablet formulation at 50 ° C after pre-equilibration at 60% relative humidity showing only a small amount of crystallinity throughout the weather.
[0197] Figure 8 is a 1HNMR spectrum of Compound 1.
[0198] Figure 9 is a 1HNMR spectrum of HCl salt Compound 1.
[0199] Figure 10 is a differential scanning calorimetry (DSC) trace of Form I of Compound 1.
[0200] Figure 11 is a conformational image of Compound 1 Form I based on single crystal X-ray analysis.
[0201] Figure 12 is a schematic drawing of a process analytical technique (PAT) enabled in a continuous manufacturing process where in step 1) feeder / mixer one, PAT1 NIR measures material attributes during raw material screening; step 2) twin screw granulator, PAT2 NIR measures composition and BU; step 3) fluidized bed dryer, PAT3a NIR measures granule uniformity, LOD, solid state shape and physical attributes of granules, PAT 3b laser diffraction measures particle size distribution; step 4) grinding, PAT4 NIR measures composition and BU; step 5) feeder / mixer two, PAT 5a Raman measures the test and CU, PAT 5b weight, hardness, thickness; step 6) compression, PAT6 Raman measures the thickness of the layer; and step 7) coating.
[0202] Figure 13 is a schematic drawing showing a Sentronics NIR in-line PAT located after mixer one, the pellet mill, and the additional pellet mixer. Each probe has 7 points that are cycled sequentially to maximize sampling and NIR with multiplexer-NIR that ensures robust and comprehensive sampling using controlled powder flow through the probe's optics.
[0203] Figure 14 is a representation of NIR powder in flow.
[0204] Figure 15 is a Kaiser Raman spectrum of Form I of Compound 1 and Form II of Compound 1 (Form II of Compound 1 is a different polymorph disclosed in US 201131588 incorporated herein in its entirety by reference) taken after pressing tablets. The Kaiser Raman spectrometer is mounted on the Kraemer UTS tablet tester.
[0205] Figure 16 is a graph showing a good correlation between the predicted and reference off-line NIR samples of the Compound 2 pellets.
[0206] Figure 17 is a series of NIR spectra measuring water content in granule samples of Compound 1.
[0207] Figure 18 is a series of NIR spectra measuring a range of compositions comprising different proportions of Compound 1 Form I and solid dispersions comprising substantially amorphous Compound 2 on the left, and pretreated spectra on the right representing the Range A to identify Compound 1 Form I and Range B to identify amorphous Compound 2.
[0208] Figure 19 depicts a calibration curve for the content of Form I of Compound 1 predicted versus the content of Form I of reference (actual) Compound 1 using partial least squares (PLS) techniques.
[0209] Figure 20 depicts the actual results of unknown samples comprising different contents of Compound 1 Form I (Reference Y) versus the predicted content using the calibration curve calculated from Figure 19 (Predicted Y).
[0210] Figure 21 depicts the percent transmission of a laser diffraction measurement in response to changes in line speed (flow velocity) for a composition comprising Compound 1 Form I and solid dispersions comprising substantially amorphous Compound 2. which shows the expected reduction in transmission percentage as line speed increases.
[0211] Figure 22 depicts laser diffraction measurements of particles comprising Compound 1 Form I and solid dispersions comprising substantially amorphous Compound 2 at different line speeds showing that mean particle size (Dv (50) is not affected by line speed.
[0212] Figure 23 depicts laser diffraction measurements of particles comprising Compound 1 Form I and solid dispersions comprising substantially amorphous Compound 2 under different processing parameters showing that particle size measurements are sensitive to such changes.
[0213] Figure 24 depicts the predictive capabilities of process analytical technology models using Raman spectroscopy, both non-continuous and continuous, to monitor the identity of the solid form of Compound 1 in a tablet.
[0214] Figure 25 depicts the predictive capabilities of process analytical technology models using Raman spectroscopy, both non-continuous and continuous, to monitor the identity of the solid form of Compound 2 in a tablet.
[0215] DETAILED DESCRIPTION DEFINITIONS
[0216] As used herein, "CFTR" stands for cystic fibrosis transmembrane conductance regulator.
[0217] As used herein, an "AF508 mutation" or "F508-del mutation" is a specific mutation within the CFTR protein. The mutation is a deletion of the three nucleotides that comprise the codon for the amino acid phenylalanine at position 508, resulting in the CFTR protein lacking this phenylalanine residue.
[0218] As used herein, a patient who is "homozygous" for a particular mutation, eg, AF508, has the same mutation on each allele.
[0219] As used herein, a patient who is "heterozygous" for a particular mutation, eg, AF508, has this mutation on one allele and a different mutation on the other allele.
[0220] As used herein, the term "CFTR corrector" refers to a compound that increases the amount of functional CFTR protein on the cell surface, resulting in improved ion transport.
[0221] As used herein, the term "CFTR enhancer" refers to a compound that increases the activity of the CFTR protein channel located on the cell surface, resulting in improved ion transport.
[0222] As used herein, the term "active pharmaceutical ingredient" or "API" refers to a compound biologically active.
[0223] As used herein, the term "PAT" stands for Process Analytical Technology.
[0224] As used herein, the term "CU" means uniformity of content.
[0225] The terms "solid form", "solid forms" and related terms, when used herein, refer to Compound 1 or Compound 2, in a particular solid form, eg, crystals, amorphous states, and the like.
[0226] As used herein, the term "substantially amorphous" refers to a solid material that has little or no long rank order in the position of its molecules. For example, substantially amorphous materials have less than about 15% crystallinity (eg, less than about 10% crystallinity or less than about 5% crystallinity). It is also noted that the term 'substantially amorphous' includes the descriptor "amorphous", which refers to materials that do not have crystallinity (0%).
[0227] As used herein, the term "substantially crystalline" (as in the phrase Form I of Compound 1 substantially crystalline refers to a solid material that has a predominantly long rank order in the position of its molecules. For example, the Substantially crystalline materials have greater than about 85% crystallinity (eg, greater than about 90% crystallinity or greater than about 95% crystallinity) The term 'substantially crystalline' is also indicated to include the descriptor 'crystalline' , which refers to materials that have 100% crystallinity.
[0228] The term "crystalline" and related terms used herein, when used to describe a substance, component, product, or form, means that the substance, component, or product is substantially crystalline as determined by X-ray diffraction. (See, for example, Remington: The Science and Practice of Pharmacy, 21st ed., Lippincott Williams & Wilkins, Baltimore, Md. (2003); The United States Pharmacopeia, 32nd ed., 1843-1844 (1995)).
[0229] As used herein, an "excipient" includes functional and non-functional ingredients in a pharmaceutical composition.
[0230] As used herein, a "disintegrant" is an excipient that hydrates a pharmaceutical composition and aids in the dispersion of the tablet. As used herein, a "diluent" or "filler" is an excipient that adds bulk to a pharmaceutical composition.
[0231] As used herein, a "surfactant" is an excipient that imparts improved solubility and / or wettability to pharmaceutical compositions.
[0232] As used herein, a "binder" is an excipient that imparts improved cohesion or tensile strength (eg, toughness) to a pharmaceutical composition.
[0233] As used herein, a "glider" is an excipient that imparts improved flow properties to pharmaceutical compositions.
[0234] As used herein, a "colorant" is an excipient that imparts to a pharmaceutical composition, eg, a tablet, the desired color. Examples of colorants include commercially available pigments such as FD&C Blue No. 1 Aluminum Lake, F ^d &C Blue No. 2, other FD&C Blue colors, titanium dioxide, iron oxide, and / or combinations thereof. In one embodiment, the tablet provided by the invention is pink.
[0235] As used herein, a "lubricant" is an excipient that is added to pharmaceutical compositions that are compressed into tablets. The lubricant aids in the compaction of granules into tablets and in the expulsion of a tablet of a pharmaceutical composition from a die press.
[0236] As used herein, "cubic centimeter" and "cc" are used interchangeably to represent a unit of volume. Take into account that 1 cc = 1 ml.
[0237] As used herein, "kilopond" and "kP" are used interchangeably and refer to the measure of force where one kP = approximately 9.8 Newtons.
[0238] As used herein, "friability" refers to the property of a tablet to remain intact and maintain its shape despite an external pressing force. Friability can be quantified using the mathematical expression presented in equation 1:
[0239] ^{(W f)} % friability ₌ 100 _{x —----} ^or _- ^{~ W} _{-------- (} 1 ₎
[0241] where Wo is the original weight of the tablet and Wf is the final weight of the tablet after passing through the refrigerator. Friability is measured using a standard USP test apparatus rotating test tablets for 100 or 400 revolutions. Some tablets of the invention have a friability of less than 5.0%. In another embodiment, the friability is less than 2.0%. In another embodiment, the target friability is less than 1.0% after 400 revolutions.
[0242] As used herein, "mean particle diameter" is the mean particle diameter measured using techniques such as laser light scattering, image analysis, or sieve analysis. In one embodiment, the granules used to prepare the pharmaceutical compositions provided by the invention have a mean particle diameter of less than 1.0 mm.
[0243] As used herein, "bulk density" is the mass of material particles divided by the total volume that the particles occupy. The total volume includes the volume of particles, the volume of voids between particles, and the volume of internal pores. Bulk density is not an intrinsic property of a material; it may change depending on how the material is processed. In one embodiment, the granules used to prepare the pharmaceutical compositions provided by the invention have a bulk density of about 0.5-0.7 g / cc.
[0244] An "effective amount" or "therapeutically effective amount" of a compound of the invention may vary according to factors such as the disease state, age and weight of the subject, and the ability of the compound of the invention to elicit a desired response in the subject. Dosage regimens can be adjusted to provide the optimal therapeutic response. An effective amount is also one in which the therapeutically beneficial effects outweigh any harmful or toxic effects (eg, side effects) of the compound of the invention.
[0245] As used herein, and unless otherwise specified, the terms "therapeutically effective amount" and "effective amount" of a compound mean an amount sufficient to provide a therapeutic benefit in the treatment or management of a disease or disorder. or to delay or minimize one or more symptoms associated with the disease or disorder. A "therapeutically effective amount" and "effective amount" of a compound mean an amount of therapeutic agent, alone or in combination with one or more agents, that provides a therapeutic benefit in the treatment or management of the disease or disorder. The terms "therapeutically effective amount" and "effective amount" can encompass an amount that improves overall therapy, reduces or prevents symptoms or causes of disease or disorder, or improves the therapeutic efficacy of another therapeutic agent.
[0246] "Substantially pure" as used in the phrase "Substantially pure Compound 1 Form I" means greater than about 90% purity. In another embodiment, "substantially pure" refers to greater than about 95% purity. In another embodiment, "substantially pure" refers to greater than about 98% purity. In another embodiment, "substantially pure" refers to greater than about 99% purity.
[0247] With respect to Compound 1 Form I, or a solid dispersion comprising substantially amorphous Compound 2, the terms "about" and "about", when used in relation to doses, amounts, or weight percent of ingredients in a composition or dosage form, mean a dose, amount or percentage by weight that is recognized by one of ordinary skill in the art that provides a pharmacological effect equivalent to that obtained from the specified dose, amount or percentage by weight. Specifically, the term "about" or "about" means an acceptable error for a particular value as determined by one of ordinary skill in the art, which depends in part on how the value is measured or determined. In certain embodiments, the term "about" or "about" means within 1, 2, 3, or 4 standard deviations. In certain embodiments, the term "about" or "about" means within 30%, 25%, 20%, 15%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.5%, 0.1%, or 0.05% of a given value or range.
[0248] PHARMACEUTICAL COMPOSITIONS
[0249] The invention provides pharmaceutical compositions comprising Compound 1 Form I and a solid dispersion comprising substantially amorphous Compound 2. In some embodiments of this aspect, the amount of Compound 1 Form I that is present in the pharmaceutical composition is 100mg, 125mg, 150mg, 200mg, 250mg, 300mg or 400mg. In some embodiments of this aspect, the weight percent of Compound 1 Form I present in the pharmaceutical composition is 10 to 75 percent. In these and other embodiments, Form I of Compound 1 is present as Form I of Compound 1 substantially pure. In some embodiments of this aspect, the amount of substantially amorphous Compound 2 that is present in the pharmaceutical composition is 100 mg, 125 mg, 150 mg, 200 mg, or 250 mg. In some embodiments of this aspect, the weight percent of the substantially amorphous Compound 2 that is present in the pharmaceutical composition is 10 to 75 percent. In these and other embodiments, the substantially amorphous Compound 2 is present as substantially pure and amorphous Compound 2. "Substantially pure" means greater than ninety percent purity; preferably more than 95 percent purity; more preferably more than 99.5 percent purity.
[0250] Thus, in one aspect, the invention provides a pharmaceutical composition comprising:
[0251] to. Form I of Compound 1;
[0252] b. a solid dispersion of Compound 2 substantially amorphous;
[0253] c. a load;
[0254] d. a disintegrant;
[0255] and. a surfactant; Y
[0256] F. a binder.
[0257] In one embodiment of this aspect, the pharmaceutical composition comprises 25 mg of Form I of Compound 1. In another embodiment of this aspect, the pharmaceutical composition comprises 50 mg of Form I of Compound 1. In another embodiment of this aspect, the pharmaceutical composition comprises 100 mg of Form I of Compound 1. In another embodiment of this aspect, the pharmaceutical composition comprises 125 mg of Form I of Compound 1. In another embodiment of this aspect, the pharmaceutical composition comprises 150 mg of Form I of Compound 1. In another embodiment of this aspect, the pharmaceutical composition comprises 200 mg of Form I of Compound 1. In another embodiment of this aspect, the pharmaceutical composition comprises 250 mg of Form I of Compound 1. In another embodiment of this aspect, the pharmaceutical composition comprises 400 mg of Compound 1 Form I.
[0258] In one embodiment of this aspect, the pharmaceutical composition comprises 25 mg of the substantially amorphous Compound 2. In another embodiment of this aspect, the pharmaceutical composition comprises 50 mg of the substantially amorphous Compound 2. In another embodiment of this aspect, the pharmaceutical composition comprises 100 mg of the substantially amorphous Compound 2. In another embodiment of this aspect, the pharmaceutical composition comprises 125 mg of the substantially amorphous Compound 2. In another embodiment of this aspect, the pharmaceutical composition comprises 150 mg of the substantially amorphous Compound 2. In another embodiment of this aspect, the pharmaceutical composition comprises 200 mg of the substantially amorphous Compound 2. In another embodiment of this aspect, the pharmaceutical composition comprises 250 mg of the substantially amorphous Compound 2.
[0259] In some embodiments, the pharmaceutical compositions comprise Form I of Compound 1, wherein Form I of Compound 1 is present in an amount of at least 15% by weight (eg, at least 20% by weight, at least 30% by weight, at least 40% by weight, at least 50% by weight, or at least 60% by weight) of the composition.
[0260] In some embodiments, the pharmaceutical compositions comprise substantially amorphous Compound 2, wherein the substantially amorphous Compound 2 is present in an amount of at least 15% by weight (eg, at least 20% by weight, at least less 30% by weight, at least 40% by weight, at least 50% by weight, or at least 60% by weight) by weight of the composition.
[0261] In some embodiments, the pharmaceutical composition comprises Compound 1 Form I, a solid dispersion comprising substantially amorphous Compound 2, a filler, a disintegrant, a surfactant, and a binder. In this embodiment, the composition comprises from about 25% by weight to about 55% by weight (eg, about 30-50% by weight) of Compound 1 Form I by weight of the composition, and more typically , from 40% by weight to about 45% by weight of Form I of Compound 1 by weight of the composition. In this embodiment, the composition comprises from about 15% by weight to about 40% by weight (eg, about 20-35% by weight) of the substantially amorphous Compound 2 by weight of the composition, and more typically, of the 25% by weight to about 30% by weight of the substantially amorphous Compound 2 by weight of the composition.
[0262] The concentration of Compound 1 Form I and substantially amorphous Compound 2 in the composition depends on several factors such as the amount of pharmaceutical composition needed to provide a desired amount of Compound 1 Form I and substantially amorphous Compound 2 and the profile. dissolution rate of the pharmaceutical composition.
[0263] In another embodiment, the pharmaceutical composition comprises Form I of Compound 1, wherein Form I of Compound 1 in its solid form has a mean particle diameter, measured by light scattering (for example, using a Malvern Mastersizer available from Malvern Instruments in England) from 0.1 microns to 10 microns. In another embodiment, the particle size of Compound 1 Form I is 1 micron to 5 microns. In another embodiment, Form I of Compound 1 has a D50 particle size of 2.0 microns.
[0265] As indicated, in addition to Form I of Compound 1 and a solid dispersion of Compound 2 substantially amorphous, in some embodiments of the invention, pharmaceutical compositions that are oral formulations also comprise one or more excipients such as fillers, disintegrants, surfactants, diluents. , binders, glidants, lubricants, colorants or fragrances and any combination thereof.
[0267] Fillers suitable for the invention are compatible with the ingredients of the pharmaceutical composition, that is, they do not substantially reduce the solubility, hardness, chemical stability, physical stability or biological activity of the pharmaceutical composition. Exemplary fillers include: celluloses, modified celluloses (eg, sodium carboxymethylcellulose, ethylcellulose, hydroxymethylcellulose, hydroxypropylcellulose), cellulose acetate, microcrystalline cellulose, calcium phosphates, dibasic calcium phosphate, starches (eg, cornstarch, cornstarch, potato), sugars (eg cornstarch, potato starch), sugars, (eg sorbitol) lactose, sucrose or the like), or any combination thereof.
[0269] Thus, in one embodiment, the pharmaceutical composition comprises at least one filler in an amount of at least 5% by weight (eg, at least about 20% by weight, at least about 30% by weight). weight, or at least about 40% by weight) by weight of the composition. For example, the pharmaceutical composition comprises from about 10% by weight to about 60% by weight (eg, from about 20% by weight to about 55% by weight, from about 25% by weight to about 50% by weight, or from about 27% by weight to about 45% by weight) filler, by weight of the composition. In another example, the pharmaceutical composition comprises at least about 20% by weight (eg, at least 30% by weight or at least 40% by weight) of microcrystalline cellulose, for example MCC Avicel PH102, in composition weight. In yet another example, the pharmaceutical composition comprises from about 10% by weight to about 60% by weight (eg, from about 20% by weight to about 55% by weight, from about 25% by weight to about 45% by weight) microcellulose, by weight of the composition.
[0271] Disintegrators suitable for the invention improve the dispersion of the pharmaceutical composition and are compatible with the ingredients of the pharmaceutical composition, that is, they do not substantially reduce the chemical stability, physical stability, hardness or biological activity of the pharmaceutical composition. Exemplary disintegrators include croscarmellose sodium, sodium starch glycolate, or a combination thereof.
[0273] Thus, in one embodiment, the pharmaceutical composition comprises disintegrant in an amount of about 10% by weight or less (for example, about 7% by weight or less, about 6% by weight or less, or about 5% wt% or less) by weight of the composition. For example, the pharmaceutical composition comprises from about 1% by weight to about 10% by weight (eg, from about 1.5% by weight to about 7.5% by weight or from about 2.5 wt% to about 6 wt%) disintegrant, by weight of the composition. In another example, the pharmaceutical composition comprises about 10% by weight or less (eg, 7% by weight or less, 6% by weight or less, or 5% by weight or less) of croscarmellose sodium, in composition weight. In yet another example, the pharmaceutical composition comprises from about 1% by weight to about 10% by weight (eg, from about 1.5% by weight to about 7.5% by weight or from about 2% by weight , 5% by weight to about 6% by weight) croscarmellose sodium, by weight of the composition. In some examples, the pharmaceutical composition comprises from about 0.1% to about 10% by weight (for example, from about 0.5% by weight to about 7.5% by weight or from about 1, 5% by weight to about 6% by weight) disintegrant, by weight of the composition .. In still other examples, the pharmaceutical composition comprises from about 0.5% to about 10% by weight (eg, of about 1.5% by weight to about 7.5% by weight or from about 2.5% by weight to about 6% by weight) disintegrant, by weight of the composition.
[0275] Surfactants suitable for the invention improve the wettability of the pharmaceutical composition and are compatible with the ingredients of the pharmaceutical composition, that is, they do not substantially reduce the chemical stability, physical stability, hardness, or biological activity of the pharmaceutical composition. Exemplary surfactants include sodium lauryl sulfate (SLS), sodium stearyl fumarate (SSF), polyoxyethylene sorbitan monooleate (eg, Tween ™), any combination thereof, or the like.
[0276] Thus, in one embodiment, the pharmaceutical composition comprises a surfactant in an amount of about 10% by weight or less (for example, about 5% by weight or less, about 2% by weight or less, about 1 % by weight or less, about 0.8% by weight or less, or about 0.6% by weight or less) by weight of the composition. For example, the pharmaceutical composition includes from about 10% by weight to about 0.1% by weight (eg, from about 5% by weight to about 0.2% by weight or from about 2% by weight). weight to about 0.3% by weight) surfactant, by weight of the composition. In another example, the pharmaceutical composition comprises 10% by weight or less (for example, about 5% by weight or less, about 2% by weight or less, about 1% by weight or less, about 0, 8% by weight or less, or about 0.6% by weight or less of sodium lauryl sulfate, by weight of the composition In yet another example, the pharmaceutical composition comprises from about 10% by weight to about 0, 1% by weight (eg, from about 5% by weight to about 0.2% by weight or from about 2% by weight to about 0.3% by weight) sodium lauryl sulfate, by weight of the composition.
[0278] Binders suitable for the invention improve the strength of the tablet of the pharmaceutical composition and are compatible with the ingredients of the pharmaceutical composition, that is, they do not substantially reduce the chemical stability, the physical stability or the biological activity of the pharmaceutical composition. Exemplary binders include polyvinylpyrrolidone, dibasic calcium phosphate, sucrose, cornstarch, modified cellulose (eg, hydroxymethylcellulose), or any combination thereof.
[0280] Thus, in one embodiment, the pharmaceutical composition comprises a binder in an amount of at least about 0.1% by weight (eg, at least about 1% by weight, at least about 3% by weight, at least about 4% by weight, or at least about 5% by weight) by weight of the composition. For example, the pharmaceutical composition comprises from about 0.1% by weight to about 10% by weight (eg, from about 1% by weight to about 10% by weight or from about 2% by weight to about 7% by weight) of binder, by weight of the composition. In another example, the pharmaceutical composition comprises at least about 0.1% by weight (eg, at least about 1% by weight, at least about 2% by weight, at least about 3% by weight, or at least about 4% by weight) of polyvinylpyrrolidone, by weight of the composition. In yet another example, the pharmaceutical composition comprises a glidant in an amount ranging from about 0.1% by weight to about 10% by weight (eg, from about 1% by weight to about 8% by weight. or from about 2% by weight to about 5% by weight) of polyvinylpyrrolidone, by weight of the composition.
[0282] Suitable diluents for the invention can add the necessary volume to a formulation to prepare tablets of the desired size and are generally compatible with the ingredients of the pharmaceutical composition, that is, they do not substantially reduce solubility, hardness, chemical stability, stability. physical, or biological activity of the pharmaceutical composition. Exemplary diluents include: sugars, eg, confectioner's sugar, compressible sugar, dextrates, dextrin, dextrose, lactose, mannitol, sorbitol, cellulose, and modified celluloses, eg, powdered cellulose, talc, calcium phosphate, starch, or any combination thereof.
[0284] Thus, in one embodiment, the pharmaceutical composition comprises a diluent in an amount of 40% by weight or less (for example, 35% by weight or less, 30% by weight or less, or 25% by weight or less, or 20% by weight or less, or 15% by weight or less, or 10% by weight or less) by weight of the composition. For example, the pharmaceutical composition comprises from about 40% by weight to about 1% by weight (for example, from about 35% by weight to about 5% by weight or from about 30% by weight to about 1% by weight). 7% by weight, from about 25% by weight to about 10% by weight, from about 20% by weight to about 15% by weight) of diluent, by weight of the composition. In another example, the pharmaceutical composition comprises 40% by weight or less (eg, 35% by weight or less, 25% by weight or less, or 15% by weight or less) of mannitol, by weight of the composition. In yet another example, the pharmaceutical composition comprises from about 35% by weight to about 1% by weight (eg, from about 30% by weight to about 5% by weight or from about 25% by weight to about 10% by weight) mannitol, by weight of the composition.
[0286] The glidants suitable for the invention improve the flow properties of the pharmaceutical composition and are compatible with the ingredients of the pharmaceutical composition, that is, they do not substantially reduce the solubility, hardness, chemical stability, physical stability or biological activity of the pharmaceutical composition. Exemplary glidants include colloidal silicon dioxide, talc, or a combination thereof.
[0288] Thus, in one embodiment, the pharmaceutical composition comprises a glidant in an amount of the 2% by weight or less (eg, 1.75% by weight, 1.25% by weight or less, or 1.00% by weight or less) by weight of the composition. For example, the pharmaceutical composition comprises from about 2% by weight to about 0.05% by weight (eg, from about 1.5% by weight to about 0.07% by weight or from about 1 0% by weight to about 0.09% by weight) of glidant, by weight of the composition. In another example, the pharmaceutical composition comprises 2% by weight or less (eg, 1.75% by weight, 1.25% by weight or less, or 1.00% by weight or less) of dioxide. of colloidal silicon, by weight of the composition. In yet another example, the pharmaceutical composition comprises from about 2% by weight to about 0.05% by weight (eg, from about 1.5% by weight to about 0.07% by weight or from about 1.0% by weight to about 0.09% by weight) of colloidal silicon dioxide, by weight of the composition.
[0290] In some embodiments, the pharmaceutical composition may include an oral solid pharmaceutical dosage form that may comprise a lubricant that may prevent adhesion of a mixture of granule beads to a surface (eg, a surface of a mixing bowl, a matrix compression and / or a punch). A lubricant can also reduce interparticle friction within the granulate and improve compression and ejection of compressed pharmaceutical compositions from a die press. The lubricant is also compatible with the ingredients of the pharmaceutical composition, that is, they do not substantially reduce the solubility, hardness, or biological activity of the pharmaceutical composition. Exemplary lubricants include magnesium stearate, calcium stearate, zinc stearate, sodium stearate, stearic acid, aluminum stearate, leucine, glyceryl behenate, hydrogenated vegetable oil, or any combination thereof. In one embodiment, the pharmaceutical composition comprises a lubricant in an amount of 5% by weight or less (for example, 4.75% by weight, 4.0% by weight or less, 3.00% by weight or less, or 2.0% by weight or less) by weight of the composition. For example, the pharmaceutical composition comprises from about 5% by weight to about 0.10% by weight (for example, from about 4.5% by weight to about 0.5% by weight or from about 3 % by weight to about 1% by weight) of lubricant, by weight of the composition. In another example, the pharmaceutical composition comprises 5% by weight or less (eg, 4.0% by weight or less, 3.0% by weight or less, 2.0% by weight or less, or 1.0% by weight or less) of magnesium stearate, by weight of the composition. In yet another example, the pharmaceutical composition comprises from about 5% by weight to about 0.10% by weight (eg, from about 4.5% by weight to about 0.15% by weight or from about 3.0% by weight to about 0.50% by weight) of magnesium stearate, by weight of the composition.
[0292] The pharmaceutical compositions of the invention may optionally comprise one or more colorants, flavors and / or fragrances to enhance the visual appeal, taste and / or aroma of the composition. Suitable colorants, flavors or fragrances are compatible with the ingredients of the pharmaceutical composition, that is, they do not substantially reduce the solubility, chemical stability, physical stability, hardness or biological activity of the pharmaceutical composition. In one embodiment, the pharmaceutical composition comprises a colorant, a flavor and / or a fragrance. In one embodiment, the pharmaceutical compositions provided by the invention are purple in color.
[0294] In some embodiments, the pharmaceutical composition includes or can be tableted and the tablets can be coated with a colorant and optionally labeled with a logo, other image, and / or text using a suitable ink. In still other embodiments, the pharmaceutical composition includes or can be tableted and the tablets can be dye coated, waxed, and optionally labeled with a logo, other image, and / or text using a suitable ink. Suitable colorants and inks are compatible with the ingredients of the pharmaceutical composition, that is, they do not substantially reduce the solubility, chemical stability, physical stability, hardness, or biological activity of the pharmaceutical composition. Suitable colorants and inks can be any color and are water or solvent based. In one embodiment, tablets made from the pharmaceutical composition are coated with a colorant and then labeled with a logo, other image, and / or text using a suitable ink. For example, tablets comprising a pharmaceutical composition as described herein may be coated with about 3% by weight (eg, less than about 6% by weight or less than about 4% by weight) of coating of film comprising a colorant. Colored tablets can be labeled with a logo and text indicating the concentration of the active ingredient in the tablet using a suitable ink. In another example, tablets comprising a pharmaceutical composition as described herein may be coated with about 3% by weight (eg, less than about 6% by weight or less than about 4% by weight) of a film coating comprising a colorant.
[0296] In another embodiment, tablets made from the pharmaceutical composition are coated with a colorant, waxed, and then labeled with a logo, other image, and / or text using a suitable ink. For example, tablets comprising a pharmaceutical composition as described herein may be coated with about 3% by weight (eg, less than about 6% by weight or less than about 4% by weight) of coating of film comprising a colorant. The colored tablets can be waxed with weighted powdered carnauba wax in an amount of approximately 0.01% w / w of the initial tablet core weight. Waxed tablets may be labeled with a logo and text indicating the concentration of the active ingredient in the tablet using a suitable ink. In another example, tablets comprising a pharmaceutical composition as described herein may be coated with about 3% by weight (eg, less than about 6% by weight or less than about 4% by weight) of a film coating comprising a colorant. The colored tablets can be waxed with weighted powdered carnauba wax in an amount of approximately 0.01% w / w of the initial tablet core weight. Waxed tablets can be labeled with a logo and text indicating the concentration of the active ingredient in the tablet using a pharmaceutical grade ink, such as black ink (for example, Opacode® S-1-17823, a solvent-based ink, commercially available from Colorcon, Inc. of West Point, PA.).
[0298] An exemplary pharmaceutical composition comprises from about 15% by weight to about 70% by weight (eg, from about 15% by weight to about 60% by weight, from about 15% by weight to about 50% by weight, or from about 20% by weight to about 70% by weight, or from about 30% by weight to about 70% by weight) of Form I of Compound 1, by weight of the composition; and from about 15% by weight to about 40% by weight (eg, about 20-35% by weight) of Compound 2 substantially amorphous by weight of the composition, and more typically, from 25% by weight to about 30% by weight of the substantially amorphous Compound 2 by weight of the composition. The aforementioned compositions can also include one or more pharmaceutically acceptable excipients, for example, from about 20% by weight to about 50% by weight of a filler; from about 1% by weight to about 5% by weight of a disintegrant; from about 2% by weight to about 0.3% by weight of a surfactant; and from about 0.1% by weight to about 5% by weight of a binder.
[0300] Another exemplary pharmaceutical composition comprises from about 15% by weight to about 70% by weight (eg, from about 15% by weight to about 60% by weight, from about 15% by weight to about 50% by weight, or from about 15% by weight to about 40% by weight, or from about 20% by weight to about 70% by weight, or from about 30% by weight to about 70% by weight , or from about 40% by weight to about 70% by weight, or from about 50% by weight to about 70% by weight) of Compound 1 Form I by weight of the composition, from about 15 % by weight to about 40% by weight (eg, about 20-35% by weight) of the substantially amorphous Compound 2 by weight of the composition, and more typically, from 25% by weight to about 30% by weight of Compound 2 substantially amorphous by weight of the composition, and one or more excipients, for example, from about 20% by weight to about 50% by weight of a filler; from about 1% by weight to about 5% by weight of a disintegrant; from about 2% by weight to about 0.3% by weight of a surfactant; from about 0.1% by weight to about 5% by weight of a binder; and from about 2% by weight to about 0.1% by weight of a lubricant.
[0302] Another exemplary pharmaceutical composition comprises from about 15% by weight to about 70% by weight (eg, from about 15% by weight to about 60% by weight, from about 15% by weight to about 50% by weight, or from about 15% by weight to about 40% by weight, or from about 20% by weight to about 70% by weight, or from about 30% by weight to about 70% by weight , or from about 40% by weight to about 70% by weight, or from about 50% by weight to about 70% by weight) of Compound 1 Form I by weight of the composition, from about 15 % by weight to about 40% by weight (eg, about 20-35% by weight) of the substantially amorphous Compound 2 by weight of the composition, and more typically, from 25% by weight to about 30% by weight of Compound 2 substantially amorphous by weight of the composition, and one or more excipients, for example, from about 20% by weight to about 50% by weight of a filler; from about 1% by weight to about 5% by weight of a disintegrant; from about 2% by weight to about 0.3% by weight of a surfactant; from about 0.1% by weight to about 5% by weight of a binder; from about 2% by weight to about 0.1% by weight of a lubricant; from about 2% by weight to about 4% by weight of colorant; and from about 0.005% by weight to about 0.015% by weight of wax.
[0304] In one embodiment, the invention is a granular pharmaceutical composition comprising:
[0306] to. about 43% by weight of Form I of Compound 1 by weight of the composition;
[0308] b. about 34% by weight of a solid dispersion comprising Compound 2 substantially amorphous by weight of the composition;
[0310] c. about 17% by weight microcrystalline cellulose by weight of the composition;
[0311] d. about 2% by weight croscarmellose sodium by weight of the composition;
[0312] and. about 1% by weight sodium lauryl sulfate by weight of the composition; Y
[0313] F. about 3% by weight of polyvinylpyrrolidone by weight of the composition.
[0314] In one embodiment, the invention is a tablet comprising:
[0315] to. about 35% by weight of Form I of Compound 1 by weight of the composition;
[0316] b. about 28% by weight of a solid dispersion comprising Compound 2 substantially amorphous by weight of the composition;
[0317] c. about 26% by weight of microcrystalline cellulose by weight of the composition;
[0318] d. about 6% by weight croscarmellose sodium by weight of the composition;
[0319] and. about 3% by weight of polyvinylpyrrolidone by weight of the composition;
[0320] F. about 1% by weight sodium lauryl sulfate by weight of the composition; Y
[0321] g. about 1% by weight of magnesium stearate by weight of the composition.
[0322] In one embodiment, the invention is a tablet comprising:
[0323] to. about 34% by weight of Form I of Compound 1 by weight of the composition;
[0324] b. about 27% by weight of a solid dispersion comprising Compound 2 substantially amorphous by weight of the composition;
[0325] c. about 26% by weight of microcrystalline cellulose by weight of the composition;
[0326] d. about 6% by weight croscarmellose sodium by weight of the composition;
[0327] and. about 2% by weight of polyvinylpyrrolidone by weight of the composition
[0328] F. about 1% by weight sodium lauryl sulfate by weight of the composition;
[0329] g. about 1% by weight of magnesium stearate by weight of the composition;
[0330] h. about 3% by weight of a colorant by weight of the composition; Y
[0331] i. about 0.010% by weight of a wax by weight of the composition.
[0332] Another tablet of the invention comprises:
[0333] to. about 150 to 250 mg of Compound 1 Form I;
[0334] b. about 100 to 150 mg of the substantially amorphous Compound 2;
[0335] c. about 125 to 175 mg of microcrystalline cellulose;
[0336] d. about 20 to 40 mg croscarmellose sodium;
[0337] and. about 10 to 20 mg of polyvinylpyrrolidone;
[0338] F. about 2 to 6 mg of sodium lauryl sulfate; Y
[0339] g. approximately 3 to 7 mg of magnesium stearate.
[0340] Another tablet of the invention comprises:
[0341] to. about 200 mg of Compound 1 Form I;
[0342] b. about 125 mg of the substantially amorphous Compound 2;
[0343] c. about 150 mg of microcrystalline cellulose;
[0344] d. approximately 34 mg croscarmellose sodium;
[0345] and. about 15 mg of polyvinylpyrrolidone;
[0346] F. about 4 mg of sodium lauryl sulfate; Y
[0347] g. approximately 6 mg of magnesium stearate.
[0348] Another tablet of the invention comprises:
[0349] to. about 200 mg of Compound 1 Form I;
[0350] b. about 125 mg of the substantially amorphous Compound 2;
[0351] c. about 150 mg of microcrystalline cellulose;
[0352] d. approximately 34 mg croscarmellose sodium;
[0353] and. about 15 mg of polyvinylpyrrolidone;
[0354] F. about 4 mg of sodium lauryl sulfate;
[0355] g. about 6 mg of magnesium stearate;
[0356] h. about 17 mg of a colorant; Y
[0357] i. approximately 0.06 mg of wax.
[0358] In one embodiment, the invention is a granular pharmaceutical composition comprising:
[0359] to. about 38% by weight of Form I of Compound 1 by weight of the composition;
[0360] b. about 40% by weight of a solid dispersion comprising Compound 2 substantially amorphous by weight of the composition;
[0361] c. about 16% by weight microcrystalline cellulose by weight of the composition;
[0362] d. about 2% by weight croscarmellose sodium by weight of the composition;
[0363] and. about 1% by weight sodium lauryl sulfate by weight of the composition; Y
[0364] F. about 3% by weight of polyvinylpyrrolidone by weight of the composition.
[0365] In one embodiment, the invention is a tablet comprising:
[0366] to. about 31% by weight of Form I of Compound 1 by weight of the composition;
[0367] b. about 32% by weight of a solid dispersion comprising Compound 2 substantially amorphous by weight of the composition;
[0368] c. about 26% by weight of microcrystalline cellulose by weight of the composition;
[0369] d. about 6% by weight croscarmellose sodium by weight of the composition;
[0370] and. about 3% by weight of polyvinylpyrrolidone by weight of the composition
[0371] F. about 1% by weight of the sodium lauryl sulfate by weight of the composition;
[0372] g. about 1% by weight of magnesium stearate by weight of the composition; Y
[0373] h. about 3% by weight of a colorant by weight of the composition.
[0374] Another tablet of the invention comprises:
[0375] to. about 100 to 200 mg of Compound 1 Form I;
[0376] b. about 100 to 150 mg of the substantially amorphous Compound 2;
[0377] c. about 100 to 150 mg of microcrystalline cellulose;
[0378] d. about 20 to 40 mg croscarmellose sodium;
[0379] and. about 10 to 20 mg of polyvinylpyrrolidone;
[0380] F. about 2 to 6 mg of sodium lauryl sulfate; Y
[0381] g. approximately 3 to 7 mg of magnesium stearate.
[0382] Another tablet of the invention comprises:
[0383] to. about 150 mg of Compound 1 Form I;
[0384] b. about 125 mg of the substantially amorphous Compound 2;
[0385] c. about 129 mg of microcrystalline cellulose;
[0386] d. approximately 29 mg croscarmellose sodium;
[0387] and. about 13 mg of polyvinylpyrrolidone;
[0388] F. about 4 mg of sodium lauryl sulfate;
[0389] g. about 5 mg of magnesium stearate; Y
[0390] h. about 15 mg of a colorant.
[0391] The pharmaceutical compositions of the invention can be processed into tablet form, capsule form, bag form, lozenge form, or other solid form that is suitable for oral administration. Thus, in some embodiments, the pharmaceutical compositions are in tablet form.
[0392] Another aspect of the invention provides a pharmaceutical formulation consisting of a tablet that includes Compound 1 Form I, a solid dispersion comprising substantially amorphous Compound 2 and excipients (e.g., a filler, a disintegrant, a surfactant, a binder. , a colorant, a lubricant, or any combination thereof), each of which is described above and in the Examples below, where the tablet has a dissolution of at least about 50% (for example, at least about 60%, at least about 70%, at least about 80%, at least about 90%, or at least about 99%) in about 30 minutes.
[0393] In one example, the pharmaceutical composition consists of a tablet that includes Compound 1 Form I in an amount ranging from 25 mg to 400 mg, for example, 25 mg, or 50 mg, or 75 mg, or 100 mg, or 150mg, 200mg, 250mg, 300mg or 400mg, Compound 2 substantially amorphous in an amount ranging from 25mg to 250mg, for example 25mg, or 50mg, or 75mg, or 100mg, or 150 mg, 200 mg, 250 mg, and one or more excipients (for example, a filler, a disintegrant, a surfactant, a binder, a colorant, a lubricant, or any combination thereof), each of which is described above and in the Examples below, wherein the tablet has a dissolution of from about 50% to about 100% (eg, from about 55% to about 95% or from about 60% to about 90% ) in approximately 30 minutes.
[0394] Dissolution can be measured with a standard USP Type II apparatus employing 0.1% CTAB dissolution medium dissolved in 900 ml deionized water, buffered to pH 6.8 with 50 mM monobasic potassium phosphate, shaking at approximately 50-75 rpm at a temperature of approximately 37 ° C. A single experimental tablet is tested in each test container of the apparatus. Dissolution can also be measured with a standard USP Type II apparatus employing 0.7% sodium lauryl sulfate dissolution medium dissolved in 900 ml of 50 mM sodium phosphate buffer (pH 6.8), with stirring. at about 65 rpm at a temperature of about 37 ° C. A single experimental tablet is tested in each test container of the apparatus. Dissolution can also be measured with a standard USP Type II apparatus employing 0.5% sodium lauryl sulfate dissolution medium dissolved in 900 ml of 50 mM sodium phosphate buffer (pH 6.8), with stirring. at about 65 rpm at a temperature of about 37 ° C. A single experimental tablet is tested in each test container of the apparatus.
[0395] METHODS FOR THE PREPARATION OF COMPOUND 1 FORM I AND A SOLID DISPERSION INCLUDING SUBSTANTIALLY AMORPHOUS COMPOUND 2
[0396] Compound 1
[0398] Compound 1 is used as a starting point for Compound 1 Form I and can be prepared by coupling an acid chloride moiety with an amine moiety according to Schemes 1-4.
[0403] Scheme 1 depicts the preparation of 1- (2,2-difluorobenzo [d] [1,3] dioxol-5-yl) cyclopropanecarbonyl chloride, which is used in Scheme 3 to make the amide bond of Compound 1.
[0405] The starting material, 2,2-Difluorobenzo [d] [1,3] dioxole-5-carboxylic acid, is commercially available from Saltigo (a subsidiary of Lanxess Corporation). Reduction of the carboxylic acid fraction in 2,2-difluorobenzo [d] [1,3] dioxole-5-carboxylic acid to the primary alcohol, followed by conversion to the corresponding chloride using thionyl chloride (SOCh), provides 5- (chloromethyl ) -2,2-difluorobenzo [d] [1,3] dioxole, which is subsequently converted to 2- (2,2-difluorobenzo [d] [1,3] dioxol-5-yl) acetonitrile using sodium cyanide. Treatment of 2- (2,2-difluorobenzo [d] [1,3] dioxol-5-yl) acetonitrile with base and 1-bromo-2-chloroethane provides 1- (2,2-difluorobenzo [d] [1 , 3] dioxol-5-yl) cyclopropanecarbonitrile. The nitrile fraction in 1- (2,2-difluorobenzo [d] [1,3] dioxol-5-yl) cyclopropanecarbonitrile is converted to a carboxylic acid using a base to give 1- (2,2-difluorobenzo [d ] [1,3] dioxol-5-yl) cyclopropanecarboxylic, which is converted to the desired acid chloride using thionyl chloride.
[0406] Scheme 2. Alternative synthesis of the acid chloride fraction
[0411] Scheme 2 represents an alternative synthesis of the required acid chloride. 5-Bromomethyl-2,2-difluoro-1,3-benzodioxole is coupled with ethyl cyanoacetate in the presence of a palladium catalyst to form the corresponding alpha cyanoethyl ester. Saponification of the ester moiety to the carboxylic acid gives the cyanoethyl compound. Alkylation of the cyanoethyl compound with 1-bromo-2-chloroethane in the presence of a base gives the cyanocyclopropyl compound. Treatment of the cyanocyclopropyl compound with a base gives the carboxylate salt, which is converted to carboxylic acid by acid treatment. Conversion of the carboxylic acid to acid chloride is then accomplished by using a chlorinating agent such as thionyl chloride or the like.
[0412] Scheme 3. Synthesis of the amine fraction.
[0414]
[0417] p e r o x i d o de u r e a - h i d r o g e n o italic anhydride
[0418]
[0423] Scheme 3 represents the preparation of the required tert-butyl 3- (6-amino-3-methylpyridin-2-yl) benzoate, which is coupled with 1- (2,2-difluorobenzo [d] [1,3 ] dioxol-5-yl) cyclopropanecarbonyl in Scheme 3 to give Compound 1. Palladium catalyzed coupling of 2-bromo-3-methylpyridine with 3- (tert-butoxycarbonyl) phenylboronic acid gives 3- (3-methylpyridin-2-yl ) tert-butyl benzoate, which is subsequently converted to the desired compound.
[0425] Scheme 4. Formation of a 3- (6- (1- (2,2-difluorobenzo [d] [1,3] dioxol-5-yl) cyclopropanecarboxamido) -methylpindin-2-yl) benzoic acid salt
[0430] Scheme 4 depicts the coupling of 1- (2,2-difluorobenzo [d] [1,3] dioxol-5-yl) cyclopropanecarbonyl chloride with 3- (6-amino-3-methylpyridin-2-yl) benzoate tert-butyl using triethylamine and 4-dimethylaminopyridine to initially provide the tert-butyl ester of Compound 1.
[0432] Compound 1 Form I
[0434] Compound 1 Form I is prepared by dispersing or dissolving a salt form, such as the HCl salt, of Compound 1 in an appropriate solvent for an effective amount of time. Treatment of the tert-butyl ester with an acid such as HCl gives the HCL salt of Compound 1, which is typically a crystalline solid. Compound 1 Form I can also be prepared directly from the t-butyl ester precursor by treatment with an appropriate acid, such as formic acid.
[0436] The HCl salt of 3- (6- (1- (2,2-difluorobenzo [d] [1,3] dioxol-5-yl) cyclopropanecarboxamido) -3-methylpyridin-2-yl) benzoic acid can be used to make Form I by dispersing or dissolving 3- (6- (1- (2,2-difluorobenzo [d] [1,3] dioxol-5-yl) cyclopropanecarboxamido) -3-methylpyridin-2-yl) benzoic acid salt in a suitable solvent for an effective period of time. Other salts of 3- (6- (1- (2,2-difluorobenzo [d] [1,3] dioxol-5-yl) cyclopropanecarboxamido) -3-methylpyridin-2-yl) benzoic acid can be used, for example , salts derived from other mineral or organic acids. The other salts result from acid-mediated hydrolysis of the t-butyl ester fraction. Salts derived from other acids can include, for example, nitric, sulfuric, phosphoric, boric, acetic, benzoic, and malonic. These 3- (6- (1- (2,2-difluorobenzo [d] [1,3] dioxol-5-yl) cyclopropanecarboxamido) -3-methylpyridin-2-yl) benzoic acid salt forms may be soluble or no, depending on the solvent used, but the lack of solubility does not prevent the formation of Compound 1 Form I. For example, in one embodiment, the appropriate solvent may be water or an alcohol / water mixture such as a methanol / 50% water, although the HCl salt form of 3- (6- (1- (2,2-difluorobenzo [d]) [1,3] dioxol-5-yl) cyclopropanecarboxamido) -3-methylpyridine- 2-yl) benzoic is poorly soluble in water. In one embodiment, the appropriate solvent is water.
[0438] The effective amount of time for the formation of Compound 1 Form I from the acid salt 3- (6- (1- (2,2-difluorobenzo [d] [1,3] dioxol-5-yl) Cyclopropanecarboxamido) -3-methylpyridine-2-yl) benzoic can be anytime between 2 and 24 hours or more. It is recognized that the amount of time required is inversely proportional to temperature. That is, the higher the temperature, the less time it takes to affect the dissociation of the acid to form Compound 1 Form I. When the solvent is water, stirring the dispersion for approximately 24 hours at room temperature provides the Compound 1 Form I in approximately 98% yield. If a solution of the 3- (6- (1- (2,2-difluorobenzo [d] [1,3] dioxol-5-yl) cyclopropanecarboxamido) -3-methylpyridin-2-yl) benzoic acid salt is desired for process purposes, an elevated temperature can be used. After stirring the solution for an effective amount of time at elevated temperature, recrystallization upon cooling provides substantially pure Compound 1 Form I. In one embodiment, "substantially pure" refers to a purity of greater than about 90%. In another embodiment, "substantially pure" refers to greater than about 95% purity. In another embodiment, "substantially pure" refers to a purity of greater than about 98%. In another embodiment, "substantially pure" refers to a purity of greater than about 99%. The temperature selected depends in part on the solvent used and is within the ability of one skilled in the art to determine. In one embodiment, the temperature is between room temperature and about 80 ° C. In another embodiment, the temperature is between room temperature and about 40 ° C. In another embodiment, the temperature is between about 40 ° C and about 60 ° C. C. In another embodiment, the temperature is between about 60 ° C and about 80 ° C.
[0440] Compound 1 Form I can also be formed directly from 3- (6- (1- (2,2-difluorobenzo [d] [1,3] dioxol-5-yl) cyclopropanecarboxamido) -3-methylpyridine-2- yl) -t-butylbenzoate (cf. Scheme 3), which is a precursor of the salt of Compound 1. Thus, 3- (6- (1- (2,2-difluorobenzo [d] [1,3 ] dioxol-5-yl) cyclopropanecarboxamido) -3-methylpyridin-2-yl) -t-butylbenzoate with an appropriate acid such as, for example, formic acid under appropriate reaction conditions to give Compound 1 Form I.
[0442] Compound 1 Form I can be further purified by recrystallization from an organic solvent. Examples of organic solvents include, but are not limited to, toluene, cumene, anisole, 1-butanol, isopropyl acetate, butyl acetate, isobutyl acetate, methyl t-butyl ether, methyl isobutyl ketone, and 1-propanol mixtures. -Water. The temperature can be as described above. For example, Form I of Compound 1 is dissolved in I-butanol at 75 ° C until completely dissolved. By cooling the solution to 10 ° C at a rate of 0.2 ° C / min crystals of Form I of Compound 1 are obtained which can be isolated by filtration.
[0444] In one embodiment, Form I of Compound 1 is characterized by one or more peaks at 15.2 to 15.6 degrees, 16.1 to 16.5 degrees, and 14.3 to 14.7 degrees in a diffraction X-ray powder obtained using Cu K alpha radiation. In another embodiment, Compound 1 Form I is characterized by one or more peaks at 15.4, 16.3, and 14.5 degrees. In another embodiment, Compound 1 Form I is further characterized by a peak at 14.6 to 15.0 degrees. In another embodiment, Compound 1 Form I is further characterized by a peak at 14.8 degrees. In another embodiment, Compound 1 Form I is further characterized by a peak at 17.6 to 18.0 degrees. In another embodiment, Compound 1 Form I is further characterized by a peak at 17.8 degrees. In another embodiment, Compound 1 Form I is further characterized by a peak at 16.4 to 16.8 degrees. In another embodiment, Form I of compound 1 is further characterized by a peak at 16.4 to 16.8 degrees. In another embodiment, Compound 1 Form I is further characterized by a peak at 16.6 degrees. In another embodiment, Form I of Compound 1 is further characterized by a peak at 7.6 to 8.0 degrees. In another embodiment, Compound 1 Form I is further characterized by a 7.8 degree peak. In another embodiment, Compound 1 Form I is further characterized by a peak at 25.8 to 26.2 degrees. In another embodiment, Compound 1 Form I is further characterized by a peak at 26.0 degrees. In another embodiment, Compound 1 Form I is further characterized by a peak at 21.4 to 21.8 degrees. In another embodiment, Form I of Compound 1 is further characterized by a peak at 21.6 degrees. In another embodiment, Form I of Compound 1 is further characterized by a peak at 23.1 to 23.5 degrees. In other In embodiment, Compound 1 Form I is further characterized by a peak at 23.3 degrees. In some embodiments, Form I of Compound 1 is characterized by a diffraction pattern substantially similar to that of Figure 1. In some embodiments, Form I of Compound 1 is characterized by a diffraction pattern substantially similar to that of Figure 2.
[0445] In some embodiments, the particle size distribution of D90 is about 82 µm or less for Form I of Compound 1. In some embodiments, the particle size distribution of D50 is about 30 µm or less for Form I of Compound 1.
[0446] Compound 2
[0447] Compound 2 is the starting point for the solid dispersion comprising substantially amorphous Compound 2 and can be prepared by coupling a 4-oxo-dihydroquinolinecarboxylic acid moiety with an amine moiety according to Schemes 5-7.
[0449]
[0450]
[0453] Starting from Compound 2, the amorphous form of Compound 2 can be prepared by spray drying methods. Spray drying is a process that converts a liquid feed into a dry particulate form. Optionally, a secondary drying process, such as fluidized bed drying or vacuum drying, can be used to reduce residual solvents to pharmaceutically acceptable levels. Typically, spray drying involves contacting a highly dispersed liquid suspension or solution and a sufficient volume of hot air to cause evaporation and drying of the liquid droplets. The preparation to be spray dried can be any solution, slurry, slurry, colloidal dispersion or paste that can be atomized using the selected spray drying apparatus. In a standard procedure, the preparation is sprayed into a stream of hot filtered air that evaporates the solvent and conveys the dried product to a collector (eg, a cyclone). The spent air is then blown out with the solvent or alternatively the spent air is sent to a condenser to capture and potentially recycle the solvent. Commercially available types of apparatus can be used to perform spray drying. For example, commercial spray dryers are manufactured by Buchi Ltd. and Niro (eg, the PSD line of spray dryers manufactured by Niro) (see, US 2004/0105820; US 2003/0144257).
[0455] Spray drying typically employs solid fillers of material of from about 3% to about 30% by weight (i.e., drug and excipients), for example about 4% to about 20% by weight, preferably at least about 10%. In general, the upper limit of solid loads is governed by the viscosity (eg, pumpability) of the resulting solution and the solubility of the components in the solution. Generally, the viscosity of the solution can determine the size of the particle in the resulting powdered product.
[0457] Techniques and methods for spray drying can be found in Perry's Chemical Engineering Handbook, 6th Ed., RH Perry, DW Green & JO Maloney, eds.), McGraw-Hill book co. (1984); and Marshall "Atomization and Spray-Drying" 50, Chem. Eng. Prog. Monogr. Series 2 (1954). In general, spray drying is carried out with an inlet temperature of from about 60 ° C to about 200 ° C, for example, from about 95 ° C to about 185 ° C, from about 110 ° C to about 182 ° C, from about 96 ° C to about 180 ° C, for example about 145 ° C. Spray drying is generally carried out with an outlet temperature of from about 30 ° C to about 90 ° C, for example from about 40 ° C to about 80 ° C, about 45 ° C to about 80 ° C, for example about 75 ° C. The atomization rate is generally about 4 kg / h to about 12 kg / h, for example about 4.3 kg / h to about 10, 5 kg / h, for example, about 6 kg / h or about 10.5 kg / h. The feed rate is generally about 3 kg / h to about 10 kg / h, for example about 3.5 kg / h to about 9.0 kg / h, for example about 8 kg / h or about 7.1 kg / h. The atomization ratio is generally about 0.3 to 1.7, for example, about 0.5 to 1.5, for example, about 0.8 or about 1.5.
[0458] Solvent removal may require a subsequent drying step, such as tray drying, fluidized bed drying (for example, from about room temperature to about 100 ° C), vacuum drying, microwave drying, rotary drum drying or biconical vacuum drying (eg, from about room temperature to about 200 ° C).
[0459] In one embodiment, the spray dried dispersion is fluidized bed dried.
[0460] In one process, the solvent includes a volatile solvent, for example a solvent
[0461] Preferred solvents are those in which Compound 2 has a solubility of at least about 10 mg / ml (eg, at least about 15 mg / ml, 20 mg / ml, 25 mg / ml, 30 mg / ml , 35mg / ml, 40mg / ml, 45mg / ml, 50mg / ml or more). The most preferred solvents include those in which Compound 2 has a solubility of at least about 20 mg / ml.
[0462] Exemplary solvents that could be tried include acetone, cyclohexane, dichloromethane, N, N-dimethylacetamide (DMA), N, N-dimethylformamide (DMF), 1,3-dimethyl-2-imidazolidinone (DMI), dimethylsulfoxide (DMSO), dioxane , ethyl acetate, ethyl ether, glacial acetic acid (HAc), methyl ethyl ketone (MEK), N-methyl-2-pyrrolidinone (NMP), methyl tert-butyl ether (MTBE), tetrahydrofuran (THF), pentane, acetonitrile, methanol , ethanol, isopropyl alcohol, isopropyl acetate, and toluene. Exemplary cosolvents include acetone / DMSO, acetone / DMF, acetone / water, MEK / water, THF / water, dioxane / water. In a two-solvent system, solvents can be present from about 0.1% to about 99.9%. In some preferred embodiments, the water is a cosolvent with acetone where the water is present from about 0.1% to about 15%, eg, from about 9% to about 11%, eg, about 10%. . In some preferred embodiments, the water is a MEK cosolvent where water is present from about 0.1% to about 15%, eg, from about 9% to about 11%, eg, about 10%. . In some embodiments, the solvent solution includes three solvents. For example, acetone and water can be mixed with a third solvent such as DMA, DMF, DMI, DMSO, or HAc. In cases where the substantially amorphous Compound 2 is a component of a solid dispersion, preferred solvents dissolve both Compound 2 and the polymer. Suitable solvents include those described above, for example MEK, acetone, water, methanol, and mixtures thereof.
[0463] The particle size and drying temperature range can be modified to prepare an optimal spray drying dispersion. As those skilled in the art will appreciate, a small particle size would lead to better solvent removal. However, Applicants have discovered that smaller particles can give rise to fluffy particles which, in some circumstances, do not provide optimal spray-dried dispersions for further processing, such as tableting. At higher temperatures, crystallization or chemical degradation of the substantially amorphous Compound 2 may occur. At lower temperatures, a sufficient amount of solvent may not be removed. The methods herein provide optimal particle size and optimal drying temperature.
[0464] In general, the particle size is such that D10 (| jm) is less than about 5, for example, less than about 4.5, less than about 4.0, or less than about 3.5, D50 (jm) is generally less than about 17, for example, less than about 16, less than about 15, less than about 14, less than about 13, and D90 (jm) is generally less than about 175, for example, less than about 170, less than about 170, less than about 150, less than about 125, less than about 100, less than about 90, less than about 80, less than about 70, less than about 60, or less than about 50. In general, the Bulk density of the spray-dried particles is from about 0.08 g / cc to about 0.20 g / cc, for example, from about 0.10 to about 0.15 g / cc, for example, from about 0.10 to about 0.10 g / cc. 11 g / cc or approx. about 0.14 g / cc. The hit density of the spray dried particles generally ranges from about 0.08 g / cc to about 0.20 g / cc, eg, about 0.10 to about 0.15 g / cc, eg, about 0.11 g / cc or about 0.14 g / cc, for 10 strokes; 0.10 g / cc to about 0.25 g / cc, for example, about 0.11 to about 0.21 g / cc, for example, about 0.15 g / cc, about 0.19 g / cc or about 0.21 g / cc for 500 strokes; 0.15 g / cc to about 0.27 g / cc, for example, about 0.18 to about 0.24 g / cc, for example, about 0.18 g / cc, about 0.19 g / cc, about 0.20 g / cc, about 0.24 g / cc for 1250 hits; and 0.15 g / cc to about 0.27 g / cc, for example, about 0.18 to about 0.24 g / cc, for example, about 0.18 g / cc, about 0.21 g / cc, about 0.23g / cc or about 0.24g / cc for 2500 hits.
[0465] Polymers
[0466] Also included herein are spray dried dispersions that include amorphous Compound 2 and a polymer (or solid state carrier). For example, Compound 2 is present as an amorphous compound as a component of a solid amorphous dispersion. The solid amorphous dispersion substantially includes the substantially amorphous Compound 2 and a polymer. Exemplary polymers include cellulosic polymers such as HPMC or HPMCAS and pyrrolidone-containing polymers such as PVP / VA. In some embodiments, the solid amorphous dispersion includes one or more additional excipients, such as a surfactant.
[0467] In one embodiment, a polymer can be dissolved in aqueous media. The solubility of the polymers can be independent of pH or dependent on pH. The latter include one or more enteric polymers. The term "enteric polymer" refers to a polymer that is preferably soluble in the less acidic environment of the intestine relative to the more acidic environment of the stomach, for example, a polymer that is insoluble in acidic aqueous media but soluble when the pH is below above 5-6. A suitable polymer should be chemically and biologically inert. To improve the physical stability of spray-dried dispersions, the glass transition temperature (Tg) of the polymer should be as high as possible. For example, preferred polymers have a glass transition temperature at least equal to or greater than the glass transition temperature of the drug (ie, Compound 2). Other preferred polymers have a glass transition temperature that is within about 10 to about 15 ° C of the drug (ie, Compound 2). Examples of suitable glass transition temperatures of polymers include at least about 90 ° C, at least about 95 ° C, at least about ^{10 0} ° C, at least about 105 ° C, at least about 110 ° C. C, at least about 115 ° C, at least about 120 ° C, at least about 125 ° C, at least about 130 ° C, at least about 135 ° C, at least about 140 ° C, at least about 145 ° C, at least about 150 ° C, at least about 155 ° C, at least about 160 ° C, at least about 165 ° C, at least about 170 ° C, or by at least about 175 ° C (measured under dry conditions). Without wishing to be bound by theory, it is believed that the underlying mechanism is that a polymer with a higher Tg generally has a lower molecular mobility at room temperature, which can be a crucial factor in stabilizing the physical stability of the dispersion. spray dried amorphous.
[0468] Furthermore, the hygroscopicity of the polymers should be as low, for example, less than about 10%. For the purpose of comparison in this application, the hygroscopicity of a polymer or composition is characterized at about 60% relative humidity. In some preferred embodiments, the polymer has less than about ¹⁰ % water absorption, eg, less than about 9%, less than about ⁸ %, less than about 7%, less than about ⁶ %. , less than about 5%, less than about about 4%, less than about 3%, or less than about 2% water absorption. Hygroscopicity can also affect the physical stability of spray-dried dispersions. Generally, moisture adsorbed on polymers can greatly reduce the Tg of the polymers as well as the resulting spray-dried dispersions, which will further reduce the physical stability of the spray-dried dispersions as described above.
[0469] In one embodiment, the polymer is one or more water soluble polymers or partially water soluble polymers. Water soluble or partially water soluble polymers include, but are not limited to, cellulose derivatives (eg, hydroxypropylmethylcellulose (HPMC), hydroxypropylcellulose (HPC)) or ethylcellulose; polyvinylpyrrolidones (PVP); polyethylene glycols (PEG); polyvinyl alcohols (PVA); acrylates such as polymethacrylate (eg Eudragit® E); cyclodextrins (eg, p-cyclodestin) and copolymers and derivatives thereof, including eg PVP-VA (polyvinylpyrrolidone-vinyl acetate).
[0470] In some embodiments, the polymer is hydroxypropylmethylcellulose (HPMC), such as HPMCAS, HPMC E50, HPMCE15, or HPMC60SH50).
[0471] As discussed herein, the polymer can be a pH dependent enteric polymer. Such pH-dependent enteric polymers include, but are not limited to, cellulose derivatives (e.g., acetate phthalate cellulose (CAP)), hydroxypropylmethylcellulose phthalates (HPMCP), hydroxypropylmethylcellulose acetate succinate (HPMCAS), carboxymethylcellulose (CMC) or a salt thereof (for example, a sodium salt such as (CMC-Na)); Cellulose acetate trimellitate (CAT), hydroxypropyl cellulose acetate phthalate (HPCAP), hydroxypropylmethylcellulose acetate phthalate (HPMCAP) and methyl cellulose acetate phthalate (MCAP), or polymethacrylates (for example, Eudragit® S). In some embodiments, the polymer is hydroxypropylmethylcellulose acetate succinate (HPMCAS). In some embodiments, the polymer is hydroxypropylmethylcellulose acetate succinate quality H ^g (HPMCAS-HG).
[0472] In yet another embodiment, the polymer is a polyvinylpyrrolidone copolymer, for example, a vinylpyrrolidone / vinyl acetate (PVP / VA) copolymer.
[0473] In embodiments where Compound 2 forms a spray-dried dispersion with a polymer, for example with an HPMC, HPMCAS or PVP / VA polymer, the amount of polymer relative to the total weight of the spray-dried dispersion ranges from about 0.1% to 99% by weight. Unless otherwise specified, the percentages of disclosed drug, polymer, and other excipients within a dispersion are given in percentages by weight. The amount of polymer is typically at least about 20%, and preferably at least about 30%, for example, at least about 35%, at least about 40%, at least of about 45% or about 50% (eg, 49.5%). The amount is typically about 99% or less, and preferably about 80% or less, for example about 75% or less, about 70% or less, about 65% or less, of about 60% or less, or about 55% or less. In one embodiment, the polymer is in an amount of to about 50% of the total weight of the dispersion (and even more specifically, between about 40% to 50%, such as about 49%, about 49.5% or about 50%). HPMC and HPMCAs are available in a variety of grades from ShinEtsu, for example, HPMCAS is available in a number of varieties, including AS-LF, AS-MF, AS-HF, AS-LG, AS-MG, AS-HG . Each of these qualities varies with the percentage of substitution of acetate and succinate.
[0474] In some embodiments, the substantially amorphous Compound 2 and the polymer are present in approximately equal amounts, for example, each polymer and drug make up approximately one half of the weight percent of the dispersion. For example, the polymer is about 49.5% present and the drug is about 50% present.
[0475] In some embodiments, the combined substantially amorphous Compound 2 and polymer represent ¹ % to ²⁰ % w / w total solids content of the non-spray dried dispersion prior to spray drying. In some embodiments, the ^{combined substantially amorphous Compound 2} and polymer represent 5% to 15% w / w of the total solids content of the non-spray dried dispersion prior to spray drying. In some embodiments, the combined substantially amorphous Compound 2 and polymer represent approximately ¹¹ % w / w of the total solids content of the non-spray dried dispersion prior to spray drying.
[0476] In some embodiments, the dispersion also includes other minor ingredients, such as a surfactant (eg, SLS). In some embodiments, the surfactant is present in less than about 10% of the dispersion, for example, less than about 9%, less than about ⁸ %, less than about 7%, less than about ⁶ %, less than about 5%, less than about 4%, less than about 3%, less than about 2%, about 1%, or about 0.5%.
[0477] In embodiments that include a polymer, the polymer should be present in an amount effective to stabilize the spray-dried dispersion. Stabilizing includes inhibiting or preventing crystallization of the substantially amorphous Compound 2. Such stabilization would inhibit the conversion of Compound 2 from amorphous to crystalline. For example, the polymer would prevent at least a portion (e.g., about 5%, about ¹⁰ %, about 15%, about ²⁰ %, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75% or more) of Compound 2 becomes from an amorphous to a crystalline shape. Stabilization can be measured, for example, by measuring the glass transition temperature of the spray-dried dispersion, measuring the relaxation rate of the amorphous material, or measuring the solubility or bioavailability of Compound 2.
[0478] Polymers suitable for use in combination with Compound 2, for example to form a spray dried dispersion such as an amorphous spray dried dispersion, should have one or more of the following properties:
[0479] The glass transition temperature of the polymer should have a temperature of not less than about 10-15 ° C lower than the glass transition temperature of the substantially amorphous Compound 2. Preferably; the glass transition temperature of the polymer is greater than the glass transition temperature of the substantially amorphous Compound 2 and generally at least 50 ° C higher than the desired storage temperature of the drug product. For example, at least about 100 ° C, at least about 105 ° C, at least about 105 ° C, at least about 110 ° C, at least about 120 ° C, at least about 130 ° C , at least about 140 ° C, at least about 150 ° C, at least about 160 ° C, at least about 160 ° C or more.
[0480] The polymer should be relatively non-hygroscopic. For example, the polymer should, when stored under standard conditions, absorb less than about ¹⁰ % water, for example, less than about 9%, less than about ⁸ %, less than about 7%, less of about ⁶ % or less. about 5%, less than about 4%, or less than about 3% water. Preferably, the polymer, when stored under standard conditions, will be substantially free of absorbed water.
[0481] The polymer should have similar or better solubility in solvents suitable for spray drying processes as Compound 2. In preferred embodiments, the polymer will dissolve in one or more of the same solvents or solvent systems as Compound 2 It is preferred that the polymer be soluble in at least one non-hydroxy solvent such as methylene chloride, acetone, or a combination thereof.
[0482] The polymer, when combined with the substantially amorphous Compound 2, for example in a spray-dried dispersion or in a liquid suspension, should increase the solubility of Compound 2 in aqueous media and physiologically relative, either with respect to the solubility of the Compound. 2 in the absence of polymer or with respect to the solubility of Compound 2 when combined with a reference polymer. For example, the polymer could increase the solubility of amorphous Compound 2 by reducing the amount of amorphous Compound 2 that becomes crystalline Compound 2, either from a solid amorphous dispersion or from a liquid suspension.
[0483] The polymer should slow down the relaxation rate of the amorphous substance.
[0484] The polymer should increase the physical and / or chemical stability of the substantially amorphous Compound 2. The polymer should enhance the machinability of the substantially amorphous Compound 2.
[0485] The polymer should enhance one or more of the substantially amorphous Compound 2 handling, delivery or storage properties.
[0486] The polymer must not interact adversely with other pharmaceutical components, eg excipients.
[0487] The suitability of a candidate polymer (or other component) can be tested using the spray drying methods (or other methods) described herein to form an amorphous composition. The candidate composition can be compared in terms of stability, resistance to crystal formation or other properties, and compared to a reference preparation, for example, a preparation of pure amorphous Compound 2 or crystalline Compound 2. For example, a candidate composition could be tested to determine if it inhibits the time to onset of solvent-mediated crystallization, or the percent conversion at a given time under controlled conditions, by at least 50%, 75%, 100 % or 110%, as well as the reference preparation, or a candidate composition could be tested to determine if it has improved bioavailability or solubility over crystalline Compound 2.
[0488] Surfactants
[0489] The spray dried dispersion can include a surfactant. A surfactant or a mixture of surfactants would generally lower the interfacial tension between the spray-dried dispersion and an aqueous medium. A suitable surfactant or mixture of surfactants can also improve the aqueous solubility and bioavailability of Compound 2 from a spray dried dispersion. Surfactants for use in connection with the present invention include, but are not limited to, sorbitan fatty acid esters (eg, Spans®), polyoxyethylene sorbitan fatty acid esters (eg, Tweens®), sodium lauryl sulfate (SLS), sodium dodecylbenzene sulfonate (SDBS) dioctyl sodium sulfosuccinate (docusate), dioxycholic acid sodium salt (DOSS), sorbitan monostearate, sorbitan tristearate, hexadecyltrimethylammonium bromide (HTAB), sodium N-lauroylsarcosate sodium, sodium stearate, sodium palmitate, Gelucire 44/14, ethylenediaminetetraacetic acid (EDTA), vitamin E d-alpha tocopheryl polyethylene glycol 1000 succinate (TPGS), lecithin, MW677-692, glutanic acid monosodium monohydrate, Labrasol, glycerides Caprylic / Capric from PEG ⁸ , Transcutol, Ether Diethylene glycol monoethyl, Solutol HS-15, polyethylene glycol / hydroxystearate, taurocholic acid, Pluronic F ^{6 8} , Pluronic F108 and Pluronic F127 (or any other polyoxyethylene-polyoxypropylene copolymer (Pluronics®) or saturated polyglycolized glycerides®). Specific examples of such surfactants that can be used in connection with this invention include, but are not limited to, Span 65, Span 25, Tween 20, Capryol 90, Pluronic F108, Sodium Lauryl Sulfate (SLS), Vitamin E TPGS, Pluronics, and copolymers. SLS is generally preferred.
[0490] The amount of surfactant (eg SLS) with respect to the total weight of the spray-dried dispersion can be between 0.1-15%. Preferably, it is from about 0.5% to about 10%, more preferably from about 0.5 to about 5%, for example, from about 0.5 to 4%, from about 0.5 to 3%, about 0.5 to 2%, about 0.5 to 1%, or about 0.5%.
[0491] In certain embodiments, the amount of surfactant based on the total weight of the spray-dried dispersion is at least about 0.1%, preferably about 0.5%. In these embodiments, the surfactant would be present in an amount of no more than about 15%, and preferably no more than about ¹² %, about ¹¹ %, about ¹⁰ %, about 9%, about 10%. ⁸ %, about 7%, about ⁶ %, about 5%, about 4%, about 3%, about 2%, or about 1%. An embodiment in which the surfactant is in an amount of about 0.5% by weight is preferred.
[0492] Candidate surfactants (or other components) can be tested for suitability for use in the invention in a manner similar to that described for testing polymers.
[0493] METHODS FOR PREPARING THE PHARMACEUTICAL COMPOSITIONS
[0494] The pharmaceutical compositions of the invention can be produced by wet granulation, compaction or compression of a mixture or composition, eg, a powder or granules, under pressure to form a stable three-dimensional shape (eg, a tablet). As used herein, "tablet" includes compressed pharmaceutical dosage unit forms of all shapes and sizes, whether coated or uncoated.
[0495] The term "tablet", as used herein, refers to a physically discrete unit of agent appropriate to the patient to be treated. In general, a compacted mix has a higher density than the mix before compaction. A dosage tablet of the invention can have almost any shape, including concave and / or convex faces, rounded or angled corners, and a rounded to rectilinear shape. In some embodiments, the compressed tablets of the invention comprise a rounded tablet having flat faces. Tablets of the invention can be prepared by any compaction and compression method known to those skilled in the art of forming compressed solid pharmaceutical dosage forms. In particular embodiments, the formulations provided herein can be prepared using conventional methods known to those of skill in the field of pharmaceutical formulation, as described, for example, in relevant textbooks. See, for example, Remington: The Science and Practice of Pharmacy, 21st Ed., Lippincott Williams & Wilkins, Baltimore, Md. (2003); Ansel et al., Pharmaceutical Dosage Forms And Drug Delivery Systems, 7th Edition, Lippincott Williams & Wilkins, (1999); The Handbook of Pharmaceutical Excipients, 4th ed., Rowe et al., Eds., American Pharmaceuticals Association (2003); Gibson, Pharmaceutical Preformulation And Formulation, CRC Press (2001), these references are incorporated herein by reference in their entirety.
[0496] Granulation and compression
[0497] In some embodiments, the ingredients are weighed according to the formula determined herein. Then all the intragranular ingredients are sifted and mixed well. The ingredients can be lubricated with a suitable lubricant, for example magnesium stearate. The next step may comprise compacting / crushing the powder mix and sizing ingredients. The compacted or crushed mixtures are then ground into granules and sieved to the desired size. The granules can then be further lubricated with, for example, magnesium stearate. The granular composition of the invention can then be compressed into suitable punches in various pharmaceutical formulations according to the invention. Optionally, the tablets can be coated with a film, dye, or other coating.
[0498] Another aspect of the invention provides a method of producing a pharmaceutical composition comprising providing a mixture of a composition comprising Compound 1 Form I, a solid dispersion comprising substantially amorphous Compound 2 and one or more excipients selected from: a filler , a diluent, a binder, a surfactant, a lubricant, a disintegrant, and compressing the composition into a tablet having a dissolution of at least about 50% in about 30 minutes.
[0499] In another embodiment, a wet granulation process is performed to produce the pharmaceutical formulation of the invention from a mixture of powdered and liquid ingredients. For example, a pharmaceutical composition comprising a mixture of a composition comprising Compound 1 Form I, a solid dispersion comprising substantially amorphous Compound 2, and one or more excipients selected from: a filler, a binder, a surfactant, is weighed. or a disintegrant according to the formula determined herein. Then all intragranular ingredients are screened and mixed in a high shear or low shear granulator using water or water with a surfactant or water with a binder or water with a surfactant and a binder to granulate the powder mixture. A fluid other than water with or without surfactant and / or binder can also be used to granulate the powder mixture. The wet granules can then optionally be ground using a suitable grinder. The water can then optionally be removed from the mixture by drying the ingredients in any suitable manner. The dry granules can then optionally be ground to the required size. Then, extragranular excipients can be added by mixing (eg, a filler, a diluent, and a disintegrant). The sized granules can then be further lubricated with magnesium stearate and a disintegrant, for example croscarmellose sodium. The granular composition of the invention can then be sieved for a sufficient time to obtain the correct size and then compressed into suitable punches in various pharmaceutical formulations according to the invention. Optionally, the tablets can be coated with a film, dye, or other coating. Surprisingly, wet granulation can be carried out without substantial loss of the solid state forms of Compound 1 Form I or substantially amorphous Compound 2.
[0501] In a particularly favored embodiment, the pharmaceutical compositions of the present invention are prepared by a continuous twin screw wet granulation (TSWG) process. Continuous manufacturing offers a high quality and highly consistent product with online monitoring and control. Continuous manufacturing also facilitates quality through design development with a "data rich" design space and an easier to understand impact of upstream variables on downstream process and end product quality. Furthermore, the pharmaceutical compositions of the present invention can be finalized earlier in commercial-scale equipment that avoids the risks of upscaling and formulation changes late in development. Lastly, continuous manufacturing has business manufacturing advantages such as improved process control, reduced product handling, and real-time release efficiencies. The overall result is a more robust, controllable, and scalable process that has fewer process controls resulting in increased product quality and therefore greater patient safety. These advantages address the concerns of Janet Woodcock (director of the Center for Drug Evaluation and Research (CDER)) that chemistry, manufacturing and controls (CMC) will not be able to keep up with the rapid clinical development of highly effective therapies ( “What we are seeing is that often the step that limits speed will be manufacturing," July 24, 2013 Friends of Cancer hosted the congress briefing "Responding to a pressing need: Expediting life-saving treatments for patients "to discuss the Food and Drug Administration's breakthrough therapy designation).
[0503] For example, high shear granulation (HSG), a common granulation technique, is well known for the risk of overgranulation and poor process control. Scaling up this process is very challenging and involves significant risk. The change from an HSG process to a continuous TSWG process allows for scalability using the same equipment to produce different batch sizes, running longer. This eliminates the risk of scaling up commonly found with other granulation processes. Furthermore, the TSWg process was found to be more robust, being less sensitive to overgranulation. As can be seen in Figure 3 for a Compound 1 tablet, the HSG process showed a significant dissolution slowdown with increasing water content, while the TSWG process did not show a change for a similar range of water addition. Surprisingly, no performance changes were found with the tablet formulations comprising Compound 1 between 45 and 55 weight percent and the tablet formulations comprising Compound 1 between 60 and 70 weight percent using the twin screw wet granulation process. This was not the case with the HSG process. Additionally, this ongoing, increased product quality process addresses a common FDA complaint regarding the unavailability of drugs to patients in need.
[0505] In one embodiment, the continuous process begins with the feeding of individual excipients, Compound 1 and Compound 2, into a continuous in-line mixer via weight loss feeding. From this mixer, the material is continuously conveyed and processed through twin screw wet granulation, drying, milling, addition of extra-granular excipients, mixing, compression and film coating.
[0507] For example, in one embodiment, a tablet comprising Compound 1 and Compound 2 can be continuously prepared according to the following flow chart.
[0509] Each of the ingredients in this exemplary blend is described above and in the Examples that follow. Furthermore, the mixture may comprise optional additives such as one or more colorants, one or more flavors and / or one or more fragrances as described above and in the Examples below. In some embodiments, the relative concentrations (eg, weight%) of each of these ingredients (and any optional additives) in the mixture are also presented above and in the Examples below. The ingredients that make up the mixture can be provided sequentially or in any combination of additions; and the ingredients or combination of ingredients can be provided in any order. In one embodiment, the lubricant is the last component added to the mix.
[0510] In another embodiment, the mixture comprises a composition of Compound 1 Form I, a substantially amorphous solid dispersion of Compound 2 and any one or more of the excipients; a binder, a surfactant, a diluent, a lubricant, a disintegrant, and a filler, where each of these ingredients is provided in the form of a powder (for example, as particles having a mean or average diameter, measured by light scattering , 250 pm or less (for example, 150 pm or less, 100 pm or less, 50 pm or less, 45 pm or less, 40 pm or less, or 35 pm or less)).
[0511] In another embodiment, compression of the mixture into a tablet is achieved by filling a shape (for example, a mold) with the mixture and applying pressure to the mixture. This can be accomplished using a die press or other similar apparatus. In some embodiments, the mixture of Compound 1 Form I, a solid dispersion comprising substantially amorphous Compound 2, and the excipients may first be processed in granular form. The granules can then be sized and compressed into tablets or formulated for encapsulation according to methods known in the pharmaceutical art. It is also noted that applying pressure to the mixture in the form can be repeated using the same pressure during each compression or using different pressures during compressions. In another example, the mixture of powdered ingredients or granules can be compressed using a die press that applies enough pressure to form a tablet that has a dissolution of about 50% or more in about 30 minutes (for example, about 55% or more in about 30 minutes or about 60% or more in about 30 minutes). For example, the mixture is compressed using a die press to produce a tablet hardness of at least about 5 kP (at least about 5.5 kP, at least about ⁶ kP, at least about 7 kP, by at least about ¹⁰ kP, or at least about 15 kP). In some cases, the mixture is compressed to produce a tablet hardness of between about 5 and 20 kP.
[0513] In some embodiments, tablets comprising a pharmaceutical composition as described herein may be coated with about 3.0% by weight of a film coating comprising a colorant by weight of the tablet. In certain cases, the dye suspension or solution used to coat the tablets comprises about ²⁰ % w / w solids by weight of the dye suspension or solution. In still other cases, the coated tablets may be labeled with a logo, another image, or text.
[0515] In another embodiment, the method of producing a pharmaceutical composition comprises providing a mixture of solid forms, for example, a mixture of powdered and / or liquid ingredients, the mixture comprising Form I of Compound 1, a solid dispersion comprising Compound 2 substantially amorphous, and one or more excipients selected from: a binder, a diluent, a surfactant, a lubricant, a disintegrant, and a filler; mixing the mixture until the mixture is substantially homogeneous, and compressing or compacting the mixture into granular form. The granular composition comprising Compound 1 Form I and a solid dispersion comprising substantially amorphous Compound 2 can then be compressed into tablets or formulated into capsules as described above or in the Examples below. Alternatively, methods of producing a pharmaceutical composition comprise providing a mixture of Compound 1 Form I, a solid dispersion comprising substantially amorphous Compound 2 and one or more excipients, eg, a binder, diluent, surfactant, a lubricant, a disintegrant and a filler .; mixing the mixture until substantially homogeneous, and compressing / compacting the mixture into a granular form using a high shear wet granule compaction process as set forth in the Examples below. Pharmaceutical formulations, for example a tablet as described herein, can be made using granules prepared by incorporating Compound 1 Form I and a solid dispersion comprising substantially amorphous Compound 2 in addition to the selected excipients described herein.
[0517] In some embodiments, the mixture is mixed by shaking, mixing, shaking, or the like using hand mixing, a blender, a mixer, any combination thereof, or the like. When ingredients or ingredient combinations are added sequentially, mixing can occur between successive additions, continuously throughout ingredient addition, after addition of all ingredients or ingredient combinations, or any combination thereof. The mixture is mixed until it has a substantially homogeneous composition.
[0519] In another embodiment, the present invention comprises jet milling a pharmaceutical composition comprising Compound 1 Form I and a solid dispersion comprising substantially amorphous Compound 2 in a suitable conventional milling apparatus using a suitable air pressure to produce particles which they have a significant particle size fraction between 0.1 microns and 50 microns. In another embodiment, the particle size is between 0.1 microns and 20 microns. In another embodiment, the size of the particles is between 0.1 microns and 10 microns. In another embodiment, the particle size is between 1.0 microns and 5 microns. In yet another embodiment, the pharmaceutical composition has a D50 particle size of 2.0 microns.
[0521] The formulations of the present invention provide a fixed dosage of two APIs for the effective treatment of cystic fibrosis, a combination that has received one of only two innovative therapy designations from the FDA, and does so with surprising stability as measured by the small loss of solid amorphous form of Compound 2. Figure 4 represents the small amount of crystallinity of Compound 2 over time in PC-XVII at 50 ° C after pre-equilibrium at 60% relative humidity. Even after about ^{10 0 0} hours under these conditions, less than 5% by weight of Compound ² has crystallized. Figure 5 shows for PC-XVII that even at the highest temperature of 60 ° C after pre-equilibration at 60% relative humidity, about 1000 hours under these conditions, less than 10% by weight of Compound 2 has crystallized. Figures ⁶ and 7 show similar results for PC-XIX. The present formulations therefore provide the convenience of a fixed dosage of two innovative APIs in one surprisingly good pharmaceutical composition. stable. Such formulations increase patient compliance, which is directly related to effective disease management.
[0522] Dosage forms prepared as above may be subjected to in vitro dissolution evaluations in accordance with Test 711 "Dissolution" in the United States Pharmacopeia 29, United States Pharmacopeial Convention, Inc., Rockville, Md., 2005 ("USP "), to determine the rate at which the active substance is released from the dosage forms. Active substance content and impurity levels are conveniently measured by techniques such as high performance liquid chromatography (HPLC).
[0523] In some embodiments, the invention includes the use of packaging materials such as high-density polyethylene (HDPE), low-density polyethylene (LDPE) and / or polypropylene and / or glass containers and closures, aluminum bags. and blister packs or strips composed of aluminum or high density polyvinyl chloride (PVC), optionally including a desiccant, polyethylene (PE), polyvinylidene dichloride (PVDC), PVC / PE / PVDC and the like. These packaging materials can be used to store the various pharmaceutical compositions and formulations in a sterile manner after proper sterilization of the package and its contents using chemical or physical sterilization techniques commonly employed in pharmaceutical arts.
[0524] METHODS FOR ADMINISTERING PHARMACEUTICAL COMPOSITIONS
[0525] In one aspect, the pharmaceutical compositions of the invention can be administered to a patient once a day or about every twenty-four hours. Alternatively, the pharmaceutical compositions of the invention can be administered to a patient twice daily. Alternatively, the pharmaceutical composition of the invention can be administered approximately every twelve hours. These pharmaceutical compositions are administered as oral formulations containing about 25 mg, 50 mg, 100 mg, 125 mg, 150 mg, 200 mg, 250 mg, 300 mg, or 400 mg of Form I of Compound 1; and about 25 mg, 50 mg, 100 mg, 125 mg, 150 mg, 200 mg, or 250 mg of the substantially amorphous Compound 2. In this regard, in addition to Compound 1 Form I and the substantially amorphous Compound 2, the pharmaceutical compositions comprise a filler, a disintegrant; a surfactant; a binder and a lubricant (depending on whether the pharmaceutical composition is a granule or a tablet). For example, a 400 mg dose of Compound 1 Form I may comprise two tablets of the invention each containing 200 mg of Compound Form I 1. A 250 mg dose of substantially amorphous ^{Compound 2 may comprise} two tablets of the invention each containing 125 mg of the substantially amorphous Compound 2.
[0526] It will also be appreciated that the compound and the pharmaceutically acceptable compositions and formulations of the invention can be employed in combination therapies; that is, Form I of Compound 1 and a solid dispersion of Compound 2 substantially amorphous and pharmaceutically acceptable compositions thereof may be administered concurrently with, before, or after, one or more other desired medical or therapeutic procedures.
[0527] In one embodiment, the additional therapeutic agent is selected from a mucolytic agent, bronchodilator, an antibiotic, an anti-infective agent, an anti-inflammatory agent, a compound that induces CFTR activity other than Form I of Compound 1, and the substantially amorphous Compound 2, or a nutritional agent.
[0528] In one embodiment, the additional agent is (R) -1- (2,2-difluorobenzo [d] [1,3] dioxol-5-yl) -N- (1- (2,3-dihydroxypropyl) -6- fluoro-2- (1-hydroxy-2-methylpropan-2-yl) -1H-indol-5-yl) cyclopropanecarboxamide. In another embodiment, the additional agent is 4- (3- (1- (2,2-difluorobenzo [d] [1,3] dioxol-5-yl) cyclopropanecarboxamido) isoquinolin-1-yl) benzoic acid. In another embodiment, the additional agent is selected from Table 1:
[0529] Table 1.
[0534] In another embodiment, the additional agent is any combination of the above agents. For example, the combination may comprise a pharmaceutical composition or tablet of the present invention comprising Compound 1 Form I and a substantially amorphous solid dispersion of Compound 2, and the additional therapeutic agent is (R) -1- (2,2-Difluorobenzo [d] [1,3] dioxol-5-yl) -N- (1- (2,3-dihydroxypropyl) -6-fluoro-2- (1-hydroxy- 2-methylpropan-2-yl) -1H-indol-5-yl) acidpropanecarboxamide. In another example, the combination may comprise a pharmaceutical composition or tablet of the present invention comprising Form I of Compound 1 and a substantially amorphous solid dispersion of Compound 2, and the additional therapeutic agent is 4- (3- (1- (2,2-Difluorobenzo [d] [1,3] dioxol-5-yl) cyclopropanecarboxamido) isoquinolin-1-yl) benzoic. In another example, the combination may comprise a pharmaceutical composition or tablet of the present invention comprising Form I of Compound 1 and a solid dispersion of Compound 2 substantially amorphous, and the additional therapeutic agent is any of the compounds in Table 1, ie compounds 1 to 14 of Table 1, or any combination thereof.
[0536] In another embodiment, the additional agent is selected from Table 1:
[0541] In another embodiment, the additional agent is selected from Table 2:
[0543] In one embodiment, the additional therapeutic agent is an antibiotic. Exemplary antibiotics useful herein include tobramycin, including inhaled powdered tobramycin (TIP), azithromycin, cayston, aztreonam, including the aerosolized form of aztreonam, amikacin, including liposomal formulations thereof, ciprofloxacin, including formulations thereof. suitable for administration by inhalation, levoflaxacin, including aerosolized formulations thereof, and combinations of two antibiotics, eg, fosfomycin and tobramycin.
[0544] In another embodiment, the additional agent is a mucolith. Exemplary mucoliths useful herein include Pulmozyme®.
[0545] In another embodiment, the additional agent is a bronchodilator. Exemplary bronchodiators include albuterol, metaprotenerol sulfate, pirbuterol acetate, salmeterol, or tetrabulin sulfate.
[0546] In another embodiment, the additional agent is effective in restoring fluid to the surface of the airways of the lung. Such agents enhance the movement of salt in and out of cells, allowing mucus in the lung airways to be more hydrated and thus more easily cleared. Examples of such agents include hypertonic saline, tetrasodium denufosol ([[(3S, 5R) -5- (4-amino-2-oxopyrimidin-1-yl) -3-hydroxyoxolan-2-yl] methoxy-hydroxyphosphoryl] [[ [(2R, 3S, 4R, 5R) -5- (2,4-dioxopyrimidin-1-yl) -3,4-dihydroxyxolan- ^2- yl] methoxy-hydroxyphosphoryl] oxy-hydroxyphosphoryl] hydrogen phosphate) or bronchitol (inhaled formulation mannitol).
[0547] In another embodiment, the additional agent is an anti-inflammatory agent, that is, an agent that can reduce inflammation in the lungs. Examples of such agents useful in the present invention include ibuprofen, docosahexaenoic acid (DHA), sildenafil, inhaled glutathione, pioglitazone, hydroxychloroquine, or simavastatin.
[0548] In another embodiment, the additional agent is a compound that increases or induces CFTR activity other than Form I of Compound 1 or a solid dispersion comprising substantially amorphous Compound 2, i.e., an agent that has the effect of inducing or increase CFTR activity. Examples of such agents include ataluren ("PTC 124®"; 3- [5- (2-fluorophenyl) -1,2,4-oxadiazol-3-yl] benzoic acid), sinapultide, lancovutide, Pelestat (a recombinant human neutrophil elastase inhibitor) and cobiprostone (7 - {(2R, 4aR, 5R, 7aR) -2 - [(3S) -1,1-difluoro-3-metNpentN] -2 acid -hydroxy-6-oxooctahydroddopenta [b] pyran-5-N} heptanoic).
[0549] In another embodiment, the additional agent is a nutritional agent. Exemplary nutritional people include pancrelipase (pancreatic enzyme replacement), including Pancrease®, Pancreacarb®, Ultrase® or Creon®, Liprotomase® (formerly Trizytek®), Aquadeks®, or glutathione inhalation. In one embodiment, the additional nutritional agent is pancrelipase.
[0550] In another embodiment, the additional agent is a compound selected from gentamicin, curcumin, cyclophosphamide, 4-phenylbutyrate, miglustat, felodipine, nimodipine, phyloxin B, geniestein, apigenin, cAMP / cGMP enhancers or inducers such as rolipram, sildenafil, milrinone, tadalafil , amrinone, isoproterenol, albuterol and almeterol, deoxyspergualin, HSP 90 inhibitors, HSP 70 inhibitors, proteasome inhibitors like epoxomycin, lactacystin, etc.
[0551] In another embodiment, the additional agent is a compound selected from 3-amino-6- (4-fluoro-phenyl) -5-trifluoromethyl acid (3,3,3-trifluoro-2-hydroxy-2-methylpropyl) -amide -pyridine-2-carboxylic; 5-Amino-6'-methyl-3-trifluoromethyl- [2,3] bipyridinyl-6-carboxylic acid (3,3,3-trifluoro-2-hydroxy-2-methyl-propyl) amide; 3-amino-6-cyclopropyl-N- (3,3,3-trifluoro-2-hydroxy-2-methylpropyl) -5- (trifluoromethyl) picolinamide; 3-amino-6-methoxy-N- (3,3,3-trifluoro-2-hydroxy-2- (trifluoromethyl) propyl) -5- (trifluoromethyl) picolinamide; 3-amino-6- (4-fluoro-phenyl) -5-trifluoromethyl-pyridine-2-carboxylic acid ((S) -3,3,3-trifluoro-2-hydroxy-2-methyl-propyl) -amide ; ((S-3,3,3-trifluoro-2-hydroxy-2-methyl-propyl) -amide of 3-amino-6-methoxy-5-trifluoromethyl-pyridine-2-carboxylic acid; ((R) -3 3-Amino-6-methoxy-5-trifluoromethyl-pyridine-2-carboxylic acid, 3,3-trifluoro-2-hydroxy-2-methyl-propyl) -amide; ((S) -3,3,3- 3-amino-6- (2,4-dichloro-phenyl) -5-trifluoromethyl-pyridine-2-carboxylic acid trifluoro-2-hydroxy-2-methyl-propyl) -amide; ((R) -3,3 3-Amino-6- (2,4-dichloro-phenyl) -5-trifluoromethyl-pyridine-2-carboxylic acid, 3-trifluoro-2-hydroxy-2-methyl-propyl) -amide; (2-hydroxy- 3-Amino-6- (4-fluoro-phenyl) -5-trifluoromethyl-pyridine-2-carboxylic acid 2-methyl-propyl) -amide; ((S) -3,3,3-trifluoro-2-hydroxy 3-Amino-5,6-bis-trifluoromethyl-pyridine-2-carboxylic acid -2-methyl-propyl) -amide; ((R) -3,3,3-trifluoro-2-hydroxy-2-methyl- 3-Amino-5,6-bis-trifluoromethyl-pyridine-2-carboxylic acid propyl) -amide; (S) -3-amino-6-ethoxy-N- (3,3,3-trifluoro-2-hydroxy -2-methylpropyl) -5- (trifluoromethyl) picolinamide; ((S) -3,3,3-trifluoro-2-hydroxy-2-methyl-propyl) - 3-Amino-6-methoxy-5-trifluoromethyl-pyridine-2-carboxylic acid amide; 3-amino-6-methoxy-5-trifluoromethyl-pyridine-2-carboxylic acid ((R) -3,3,3-trifluoro-2-hydroxy-2-methyl-propyl) -amide; 3-Amino-6- (4-fluoro-phenyl) -5-trifluoromethyl-pyridine-2-carboxylic acid (3,3,3-trifluoro-2-hydroxy-2-methyl-propyl) -amide; 3-amino-5,6-bis-trifluoromethyl-pyridine-2-carboxylic acid ((S) -3,3,3-trifluoro -2-hydroxy-2-methyl-propyl) -amide; 3-amino-5,6-bis-trifluoromethyl-pyridine-2-carboxylic acid ((R) -3,3,3-trifluoro-2-hydroxy-2-methyl-propyl) -amide, or pharmaceutically acceptable salts of the same. In another embodiment, the additional agent is a compound disclosed in US Patent No. 8,247,436 and PCTWO International Publication 2011113894, incorporated herein in their entirety by reference.
[0552] In another embodiment, the additional agent may be an epithelial sodium channel (ENac) modulator disclosed in PCT publications WO2012035158, WO2009074575, WO2011028740, WO2009150137, WO2011079087 or WO2008135557, incorporated herein in their entirety by reference.
[0553] In other embodiments, the additional agent is a compound disclosed in WO 2004028480, WO 2004110352, WO 2005094374, WO 2005120497, or WO 2006101740, incorporated herein in their entirety by reference. In another embodiment, the additional agent is a benzo [c] quinolizinium derivative that exhibits CFTR-inducing or increasing activity or a benzopyran derivative that exhibits CFTR-inducing or increasing activity. In another embodiment, the additional agent is a compound disclosed in US Patent No. 7,202,262, 6,992,096, US20060148864, US20060148863, US20060035943, US20050164973, WO2006110483, WO2006044456, WO2006044682, WO2006044505, WO200604491502, WO200604491502, or incorporated WO200604491502 herein in its entirety for reference. In another embodiment, the additional agent is a compound disclosed in WO2004080972, WO2004111014, WO2005035514, WO2005049018, WO2006099256, WO2006127588, or WO2007044560, incorporated herein in their entirety by reference.
[0554] In one embodiment, 400 mg of Compound 1 Form I and 250 mg of the substantially amorphous Compound 2 can be administered to a subject in need thereof. In these embodiments, dosage amounts can be achieved by administering one or more tablets of the invention. For example, administration of 400 mg of Form I of Compound 1 and 250 mg of substantially amorphous Compound 2 can be achieved by the administration of two tablets each containing 200 mg of Form I of Compound 1 and 125 mg of Compound 2. substantially amorphous. The duration of administration can continue until improvement of the disease is achieved or until indicated by the subject's physician, for example, the duration of administration can be less than one week, 1 week, 2 weeks, 3 weeks. , four weeks (28 days), or a month or more. ^{In one embodiment, two tablets each comprising 20} mg of Form I of Compound ¹ , and 125 mg of substantially amorphous ^{Compound 2} , may be administered to the patient per day. In a further embodiment, the two tablets can be administered at the same time or at different times during the day. In a further embodiment, one tablet is administered every 12 hours.
[0555] In one embodiment, 400 mg of Compound 1 Form I and 500 mg of Compound can be administered. 2 substantially amorphous to a subject in need thereof. In these embodiments, dosage amounts can be achieved by administering two tablets each containing 200 mg of Compound 1 Form I and 250 mg of substantially amorphous Compound 2. In one embodiment, a tablet is administered once every 12 hours. In another embodiment, the dosage amount can also be achieved by administering two tablets, each containing 100 mg of Compound 1 Form I and 125 mg of substantially amorphous Compound 2, every 12 hours. In another embodiment, dosage amounts can also be achieved by administering Compound 1 Form I and substantially amorphous Compound 2 in separate tablets. For example, dosage amounts can be achieved by administering two tablets containing ^{20 0} mg of Compound 1 Form I and four tablets containing 125 mg of substantially amorphous Compound 2 or two tablets containing 150 mg of substantially amorphous Compound 2 and two tablets containing 100 mg of the substantially amorphous Compound 2. The duration of administration can continue until improvement of the disease is achieved or until indicated by the subject's physician, for example, the duration of administration can be less than a week, 1 week, 2 weeks, 3 weeks. , four weeks (28 days), or a month or more. In one embodiment, two tablets comprising 200 mg of Compound 1 Form I and four tablets comprising 125 mg of substantially amorphous Compound 2 may be administered to the patient per day. In one embodiment, two tablets comprising 200 mg of Compound 1 Form I may be administered to the patient per day, and two tablets comprising 150 mg and 100 mg of substantially amorphous Compound 2 may be administered to the patient twice per day. In a further embodiment, the two tablets can be administered at the same time or at different times during the day. In a further embodiment, one tablet comprising 200 mg of Compound 1 is administered every 12 hours, and two tablets comprising 150 mg and 100 mg of substantially amorphous Compound 2 are administered every 12 hours.
[0557] In one embodiment, 300 mg of Compound 1 Form I and 250 mg of the substantially amorphous Compound 2 can be administered to a subject in need thereof. In these embodiments, dosage amounts can be achieved by administering one or more tablets of the invention. For example, administration of 300 mg of Form I of Compound 1 and 250 mg of substantially amorphous Compound 2 can be achieved by administration of two tablets each containing 150 mg of Form I of Compound 1 and 125 mg of Compound 2. substantially amorphous. The duration of administration can continue until improvement of the disease is achieved or until indicated by the subject's physician, for example, the duration of administration can be less than one week, 1 week, 2 weeks, 3 weeks. , four weeks (28 days), or a month or more. In one embodiment, two tablets each comprising 150 mg of Form I of Compound 1, and 125 mg of substantially amorphous Compound 2, may be administered to the patient per day. In a further embodiment, the two tablets can be administered at the same time or at different times during the day. In a further embodiment, one tablet is administered every ¹² hours.
[0559] In one embodiment, 600 mg of Compound 1 Form I and 500 mg of the substantially amorphous Compound 2 can be administered to a subject in need thereof. In these embodiments, dosage amounts can be achieved by administering one or more tablets of the invention. For example, administration of 600 mg of Compound 1 Form I and 500 mg of substantially amorphous Compound 2 can be achieved by the administration of two tablets, each containing 150 mg of Compound 1 Form I and 125 mg of the substantially amorphous Compound 2, every 12 hours. The duration of administration can continue until improvement of the disease is achieved or until indicated by the subject's physician, for example, the duration of administration can be less than one week, 1 week, 2 weeks, 3 weeks. , four weeks (28 days), or a month or more. In one embodiment, four tablets each comprising 150 mg of Compound 1 Form I and 125 mg of substantially amorphous Compound 2 may be administered to the patient per day. In a further embodiment, all four tablets can be administered at the same time or at different times during the day. In a further embodiment, two tablets are administered every ¹² hours.
[0561] In one embodiment, 800 mg of Compound 1 Form I and 500 mg of the substantially amorphous Compound 2 can be administered to a subject in need thereof. In these embodiments, dosage amounts can be achieved by administering one or more tablets of the invention. For example, administration of 800 mg of Form I of Compound 1 and 500 mg of substantially amorphous Compound 2 can be achieved by administration of four tablets each containing 200 mg of Form I of Compound 1 and 125 mg of Compound 2. substantially amorphous. The duration of administration can continue until improvement of the disease is achieved or until indicated by the subject's physician, for example, the duration of administration can be less than a week, 1 week, 2 weeks, 3 weeks. , four weeks (28 days), or a month or more. In one embodiment, four tablets each comprising 200 mg of Compound 1 Form I and 125 mg of substantially amorphous Compound 2 may be administered to the patient per day. In a further embodiment, all four tablets can be administered at the same time or at different times during the day. In a further embodiment, two tablets are administered per dosing occasion, and there are two dosing occasions per day. In a further embodiment, 800 mg of Compound 1 and 500 mg of Compound 2 are administered to the patient by administering two tablets each comprising 200 mg of Compound 1 and 125 mg of Compound 2 twice daily (BID). In a further embodiment, 800 mg of Compound 1 and 500 mg of Compound 2 are administered to the patient by administering two tablets each comprising 200 mg of the Compound 1 and 125 mg of Compound 2 every 12 hours (q12 h).
[0563] In one embodiment, 600 mg of Compound 1 Form I and 250 mg of the substantially amorphous Compound 2 can be administered to a subject in need thereof. In these embodiments, dosage amounts can be achieved by administering one or more tablets of the invention. For example, administration of 600 mg of Compound 1 Form I and 250 mg of the substantially amorphous Compound 2 can be accomplished by administering three tablets each containing 200 mg of Compound 1 Form I and 83.3 mg of the Compound 2 substantially amorphous. The duration of administration can continue until improvement of the disease is achieved or until indicated by the subject's physician, for example, the duration of administration can be less than one week, 1 week, 2 weeks, 3 weeks. , four weeks (28 days), or a month or more. In one embodiment, three tablets each comprising 200 mg of Compound 1 Form I and 83.3 mg of substantially amorphous Compound 2 may be administered to the patient per day. In a further embodiment, all three tablets can be administered at the same time or at different times during the day. In a further embodiment, three tablets are administered at the same time.
[0565] In one embodiment, 600 mg of Compound 1 Form I and 500 mg of the substantially amorphous Compound 2 can be administered to a subject in need thereof. In these embodiments, dosage amounts can be achieved by administering one or more tablets of the invention. For example, administration of 600 mg of Compound 1 Form I and 500 mg of substantially amorphous Compound 2 can be accomplished by administering three tablets each containing 200 mg of Compound 1 Form I and substantially 83.3 mg of Compound 2. amorphous, followed by two additional tablets each comprising 125 mg of Compound 2. The duration of administration may continue until improvement of the disease is achieved or until indicated by the subject's physician, for example, the duration of administration can be less than a week, 1 week, 2 weeks, 3 weeks, four weeks (28 days), or a month or more. In one embodiment, 600 mg of Compound 1 can be administered daily (qd) and 250 mg of Compound 2 administered twice daily (bid) by administering three tablets each comprising 200 mg of Compound 1 Form I and 83.3 mg of Compound 2 substantially amorphous per day (qd) and two tablets each comprising 125 mg of Compound 2 every 12 hours (q12h). In one embodiment, 600 mg of Compound 1 can be administered daily (qd) and 250 mg of Compound 2 administered every 12 hours (q12h) by administering three tablets each comprising 200 mg of Compound 1 Form I and 83.3 mg of Compound 2 substantially amorphous per day (qd) and two tablets each comprising 125 mg of Compound 2 every 12 hours (q12h).
[0567] These combinations are useful for treating the diseases described herein, including cystic fibrosis. These combinations are also useful in the kits described herein. In another aspect, the present invention features a kit comprising a pharmaceutical composition or tablet of the present invention comprising Compound 1 Form I and a solid dispersion comprising substantially amorphous Compound 2, and a separate additional therapeutic agent or pharmaceutical composition. of the same. In another embodiment, the pharmaceutical composition or tablet of the present invention, the separate additional therapeutic agent, or the pharmaceutical composition thereof are in separate containers. In another embodiment, the separate containers are bottles. In another embodiment, the separate containers are vials. In another embodiment, the separate containers are blister packs.
[0569] The amount of additional therapeutic agent present in the compositions of this invention will not be greater than the amount that would normally be administered in a composition comprising that therapeutic agent as the only active agent. Preferably, the amount of additional therapeutic agent in presently disclosed compositions will range from about 50% to 100% of the amount normally present in a composition comprising that agent as the only therapeutically active agent.
[0571] THERAPEUTIC USES OF THE COMPOSITION
[0573] In one aspect, the invention also provides a method of treating, lessening the severity, or symptomatically treating a disease in a patient, the method comprising administering an effective amount of the pharmaceutical composition or tablet of the invention to the patient, preferably a mammal, in where the disease is selected from cystic fibrosis, asthma, smoke-induced COPD, chronic bronchitis, rhinosinusitis, constipation, pancreatitis, pancreatic insufficiency, male infertility caused by bilateral congenital absence of the vas deferens (CBAVD), mild lung disease, idiopathic pancreatitis, Allergic bronchopulmonary aspergillosis (ABPA), liver disease, hereditary emphysema, hereditary hemochromatosis, coagulation-fibrinolysis deficiencies, such as protein C deficiency, hereditary angioedema type 1, deficiencies in lipid processing such as familial hypercholesterolemia, chylomicroneproteinemia type ¹ , abetalipoproteinemia type 1 sick Lysosomal storage disorders such as I cell disease / pseudo-Hurler, mucopolysaccharidosis, Sandhof / Tay-Sachs, Crigler-Najjar type II, poliendocrinopathy / hyperinsulemia, diabetes mellitus, Laron's dwarfism, mylooperoxidase deficiency, primary hypoparathyroidism, melanoma, CDG type glucanosis 1, congenital hyperthyroidism, osteogenesis imperfecta, hereditary hypofibrinogenemia, ACT deficiency, diabetes insipidus (DI), neurophyseal DI, neprogenic DI, Charcot-Marie Tooth syndrome, PerlizaeusMerdegenecher, neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, progressive supranuclear palsy, Pick's disease, various polyglutamine neurological disorders such as Huntington's, spinocerebullar ataxia type I, spinal and bulbar muscular atrophy, dentatorubal and myotrophic pallidoluysian dystrophy, dentatorubal-myotonic dystrophy such as spongiform encephalopathies such as inherited Creutzfeldt-Jakob disease (due to a prion protein processing defect), Fabry disease, Straussler-Scheinker syndrome, COPD, dry eye disease, or Sjogren's disease, osteoporosis, osteopenia, healing bone and bone growth (including bone repair, bone regeneration, reduced bone resorption and increased bone deposition), Gorham syndrome, chloride channelopathies such as myotonia congenita (Thomson and Becker forms), Bartter syndrome type III , Dent's disease, hypereplexia, epilepsy, enf Lysosomal storage disease, Angelman syndrome and primary ciliary dyskinesia (PCD), a term for inherited disorders of the structure and / or function of the cilia, including dCp with situs inversus (also known as Kartagener syndrome), PCD without situs inversus and ciliary aplasia.
[0575] In one aspect, the invention also provides a method of treating, lessening the severity of, or symptomatically treating a disease in a patient comprising administering an effective amount of the pharmaceutical composition or tablet of the invention to the patient, preferably a mammal, wherein disease is selected from generalized epilepsy with febrile seizures plus (GEFS +), general epilepsy with febrile and afebrile seizures, myotonia, paramyotonia congenita, myotonia aggravated by potassium, hyperkalemic periodic paralysis, LQTS, LQTS / Brugada syndrome, autosomal dominant LQTS with deafness , Autosomal recessive LQTS, LQTS with dysmorphic features, congenital and acquired LQTS, Timothy syndrome, persistent hyperinsulinemic hypolglycemia of childhood, dilated cardiomyopathy, autosomal dominant LQTS, Dent's disease, osteopetrosis, Bartter syndrome type III, central nucleus disease, malignant hyperthermia and polymorphic tachycardia c atecholaminergic.
[0577] In one aspect, the present invention is directed to a method of treating, lessening the severity of, or symptomatically treating cystic fibrosis in a patient which comprises administering an effective amount of the pharmaceutical composition or tablet of the invention to the patient, preferably a mammal. , where the patient has the CFTR N1303K, AI507 or R560T genetic mutation.
[0579] In one aspect, the present invention is directed to a method of treating, lessening the severity of, or symptomatically treating cystic fibrosis in a patient which comprises administering an effective amount of the pharmaceutical composition or tablet of the invention to the patient, preferably a mammal. , where the patient has the CFTR G551D genetic mutation. In another embodiment, the patient is homozygous at G551D. In another embodiment, the patient is heterozygous at G551D where the other CFTR gene mutation is any of AF508, G542X, N1303K, W1282X, R117H, R553X, 1717-1G-> A, 621 1G-> T, 2789 + 5G- > A, 3849 + 10kbC-> T, R1162X, G85E, 3120 + 1G-> A, AI507, 1898 + 1G-> A, 3659delC, R347P, R560T, R334W, A455E, 2184delA, or 711 1G-> T.
[0581] In one aspect, the present invention is directed to a method of treating, lessening the severity of, or symptomatically treating cystic fibrosis in a patient which comprises administering an effective amount of the pharmaceutical composition or tablet of the invention to the patient, preferably a mammal. , where the patient has the CFTR AF508 genetic mutation. In another embodiment, the patient is homozygous at AF508. In another embodiment, the patient is heterozygous at AF508 where the other CFTR gene mutation is any of G551D, G542X, N1303K, W1282X, R117H, R553X, 1717-1G-> A, 621 1G-> T, 2789 + 5G-> A, 3849 + 10kbC-> T, R1162X, G85E, 3120 + 1G-> A, AI507, 1898 + 1G-> A, 3659delC, R347P, R560T, R334W, A455E, 2184delA, or 711 1G-> T.
[0583] In one aspect, the present invention is directed to a method of treating, lessening the severity of, or symptomatically treating cystic fibrosis in a patient which comprises administering an effective amount of the pharmaceutical composition or tablet of the invention to the patient, preferably a mammal. , where the patient has the selected CFTR genetic mutation of G178R, G551S, G970R, G1244E, S1255P, G1349D, S549N, S549R, S1251N, E193K, F1052V, G1069R, R117C, D110H, R347H, R35267Q, E , A455E, D579G, S1235R, S945L, R1070W, F1074L, D110E, D1270N, D1152H, 1717-1G-> A, 621 1G-> T, 3120 + 1G-> A, 1898 + 1G-> A, 711 1G-> T, 2622 + 1G-> A, 405 + 1G-> A, 406-1G-> A, 4005 + 1G-> A, 1812-1G-> A, 1525-1G-> A, 712-1G-> T , 1248 + 1G-> A, 1341 1G-> A, 3121-1G-> A, 4374 + 1G-> T, 3850-1G-> A, 2789 + 5G-> A, 3849 + 10kbC-> T, 3272 -26A-> G, 711 + 5G-> A, 3120G-> A, 1811 1.6kbA-> G, 711 + 3A-> G, 1898 + 3A-> G, 1717-8G-> A, 1342-2A- > C, 405 + 3A-> C, 1716G / A, 1811 1G-> C, 1898 + 5G-> T, 3850-3T-> G, IVS14b + 5G-> A, 1898 + 1G-> T, 4 005 + 2T-> C and 621 + 3A-> G.
[0585] In one aspect, the present invention is directed to a method of treating, lessening the severity of, or symptomatically treating cystic fibrosis in a patient which comprises administering an effective amount of the pharmaceutical composition or tablet of the invention to the patient, preferably a mammal. , wherein the patient has the CFTR gene mutation selected from G178R, G551S, G970R, G1244E, S1255P, G1349D, S549N, S549R, S1251N, E193K, F1052V and G1069R. In one embodiment of this aspect, the invention provides a method of treating CFTR which comprises administering Compound 1 to a patient possessing a human CFTR mutation selected from G178R, G551S, G970R, G1244E, S1255P, G1349D, S549N, S549R and S1251N.
[0586] In one aspect, the present invention is directed to a method of treating, lessening the severity of, or symptomatically treating cystic fibrosis in a patient which comprises administering an effective amount of the pharmaceutical composition or tablet of the invention to the patient, preferably a mammal. , wherein the patient has the CFTR gene mutation selected from E193K, F1052V and G1069R. In some embodiments of this aspect, the method produces a greater than ^10- fold increase in chloride transport over reference chloride transport.
[0588] In one aspect, the present invention is directed to a method of treating, lessening the severity of, or symptomatically treating cystic fibrosis in a patient which comprises administering an effective amount of the pharmaceutical composition or tablet of the invention to the patient, preferably a mammal. , where the patient has the CFTR gene mutation selected from R117C, D110H, R347H, R352Q, E56K, P67L, L206W, A455E, D579G, S1235R, S945L, R1070W, F1074L, D110E, D1270N and D1152H. In one embodiment of this aspect, the method produces an increase in chloride transport that is greater than or equal to ¹⁰ % above the reference chloride transport.
[0590] In one aspect, the present invention is directed to a method of treating, lessening the severity of, or symptomatically treating cystic fibrosis in a patient which comprises administering an effective amount of the pharmaceutical composition or tablet of the invention to the patient, preferably a mammal. , where the patient has the selected CFTR genetic mutation of 1717-1G-> A, 621 1G-> T, 3120 + 1G-> A, 1898 + 1G-> A, 711 1G-> T, 2622 + 1G- > A, 405 + 1G-> A, 406-1G-> A, 4005 + 1G-> A, 1812-1G-> A, 1525-1G-> A, 712-1G-> T, 1248 + 1G-> A, 1341 1G-> A, 3121-1G-> A, 4374 + 1G-> T, 3850-1G-> A, 2789 + 5G-> A, 3849 + 10kbC-> T, 3272-26A-> G, 711 + 5G-> A, 3120G-> A, 1811 1.6kbA-> G, 711 + 3A-> G, 1898 + 3A-> G, 1717-8G-> A, 1342-2A-> C, 405 + 3A -> C, 1716G / A, 1811 1G-> C, 1898 + 5G-> T, 3850-3T-> G, IVS14b + 5G-> A, 1898 + 1G-> T, 4005 + 2T-> C and 621 + 3A-> G. In one aspect, the present invention is directed to a method of treating, lessening the severity of, or symptomatically treating cystic fibrosis in a patient which comprises administering an effective amount of the pharmaceutical composition or tablet of the invention to the patient, preferably a mammal. , where the patient has the selected CFTR genetic mutation of 1717-1G-> A, 1811 1.6kbA-> G, 2789 + 5G-> A, 3272-26A-> G and 3849 + 10kbC-> T. In one aspect, the present invention is directed to a method of treating, lessening the severity of, or symptomatically treating cystic fibrosis in a patient which comprises administering an effective amount of the pharmaceutical composition or tablet of the invention to the patient, preferably a mammal. , where the patient has the selected CFTR genetic mutation of 2789 + 5G-> A and 3272-26A-> G.
[0592] In one aspect, the present invention is directed to a method of treating, lessening the severity of, or symptomatically treating cystic fibrosis in a patient which comprises administering an effective amount of the pharmaceutical composition or tablet of the invention to the patient, preferably a mammal. , where the patient has the selected CFTR genetic mutation of G178R, G551S, G970R, G1244E, S1255P, G1349D, S549N, S549R, S1251N, E193K, F1052V, G1069R, R117C, D110H, R347H, R35267Q, E , A455E, D579G, S1235R, S945L, R1070W, F1074L, D110E, D1270N, D1152H, 1717-1G-> A, 621 1G-> T, 3120 + 1G-> A, 1898 + 1G-> A, 711 1G-> T, 2622 + 1G-> A, 405 + 1G-> A, 406-1G-> A, 4005 + 1G-> A, 1812-1G-> A, 1525-1G-> A, 712-1G-> T , 1248 + 1G-> A, 1341 1G-> A, 3121-1G-> A, 4374 + 1G-> T, 3850-1G-> A, 2789 + 5G-> A, 3849 + 10kbC-> T, 3272 -26A-> G, 711 + 5G-> A, 3120G-> A, 1811 1.6kbA-> G, 711 + 3A-> G, 1898 + 3A-> G, 1717-8G-> A, 1342-2A- > C, 405 + 3A-> C, 1716G / A, 1811 + 1G-> C, 1898 + 5G-> T, 3850-3T-> G, IVS14b + 5G-> A, 1898 + 1G-> T, 40 05 + 2T-> C and 621 + 3A-> G, and a human CFTR mutation selected from AF508, R117H and G551D.
[0594] In one aspect, the present invention is directed to a method of treating, lessening the severity of, or symptomatically treating cystic fibrosis in a patient which comprises administering an effective amount of the pharmaceutical composition or tablet of the invention to the patient, preferably a mammal. , where the patient has the selected CFTR gene mutation from G178R, G551S, G970R, G1244E, S1255P, G1349D, S549N, S549R, S1251N, E193K, F1052V and G1069R, and a selected human CFTR mutation from AF508, R1DH and G55 . In one aspect, the present invention is directed to a method of treating, lessening the severity of, or symptomatically treating cystic fibrosis in a patient which comprises administering an effective amount of the pharmaceutical composition or tablet of the invention to the patient, preferably a mammal. , wherein the patient has the CFTR gene mutation selected from G178R, G551S, G970R, G1244E, S1255P, G1349D, S549N, S549R and S1251N, and a human CFTR mutation selected from AF508, R117H and G551D. In one aspect, the present invention is directed to a method of treating, lessening the severity of, or symptomatically treating cystic fibrosis in a patient which comprises administering an effective amount of the pharmaceutical composition or tablet of the invention to the patient, preferably a mammal. , wherein the patient possesses the CFTR gene mutation selected from E193K, F1052V and G1069R, and a human CFTR mutation selected from AF508, R117H and G551D. In some embodiments of this aspect, the method produces a greater than ^10- fold increase in chloride transport over reference chloride transport.
[0596] In one aspect, the present invention is directed to a method of treating, lessening the severity of, or symptomatically treating cystic fibrosis in a patient which comprises administering an effective amount of the pharmaceutical composition or tablet of the invention to the patient, preferably a mammal. , where the patient has the CFTR gene mutation selected from R117C, D110H, R347H, R352Q, E56K, P67L, L206W, A455E, D579G, S1235R, S945L, R1070W, F1074L, D110E, D1270N, and D1152H, and a human CFTR mutation selected from AF508, R117H, and G551D. In one embodiment of this aspect, the method produces an increase in chloride transport that is greater than or equal to ¹⁰ % above the reference chloride transport.
[0598] In one aspect, the present invention is directed to a method of treating, lessening the severity of, or symptomatically treating cystic fibrosis in a patient which comprises administering an effective amount of the pharmaceutical composition or tablet of the invention to the patient, preferably a mammal. , where the patient has the selected CFTR genetic mutation of 1717-1G-> A, 621 1G-> T, 3120 + 1G-> A, 1898 + 1G-> A, 711 1G-> T, 2622 + 1G- > A, 405 + 1G-> A, 406-1G-> A, 4005 + 1G-> A, 1812-1G-> A, 1525-1G-> A, 712-1G-> T, 1248 + 1G-> A, 1341 1G-> A, 3121-1G-> A, 4374 + 1G-> T, 3850-1G-> A, 2789 + 5G-> A, 3849 + 10kbC-> T, 3272-26A-> G, 711 + 5G-> A, 3120G-> A, 1811 1.6kbA-> G, 711 + 3A-> G, 1898 + 3A-> G, 1717-8G-> A, 1342-2A-> C, 405 + 3A -> C, 1716G / A, 1811 + 1G-> C, 1898 + 5G-> T, 3850-3T-> G, IVS14b + 5G-> A, 1898 + 1G-> T, 4005 + 2T-> C and 621 + 3A-> G, and a human CFTR mutation selected from AF508, R117H, and G551D. In one aspect, the present invention is directed to a method of treating, lessening the severity of, or symptomatically treating cystic fibrosis in a patient which comprises administering an effective amount of the pharmaceutical composition or tablet of the invention to the patient, preferably a mammal. , where the patient has the selected CFTR genetic mutation of 1717-1G-> A, 1811 1.6kbA-> G, 2789 + 5G-> A, 3272-26A-> G and 3849 + 10kbC-> T and a mutation human CFTR selected from AF508, R117H, G551D. In one aspect, the present invention is directed to a method of treating, lessening the severity or symptomatically treating cystic fibrosis in a patient which comprises administering an effective amount of the pharmaceutical composition or tablet of the invention to the patient, preferably a mammal, n where the patient has the CFTR gene mutation selected from 2789 + 5G-> A and 3272-26A-> G, and a human CFTR mutation selected from AF508, R117H.
[0600] In one aspect, the present invention is directed to a method of treating, lessening the severity of, or symptomatically treating cystic fibrosis in a patient which comprises administering an effective amount of the pharmaceutical composition or tablet of the invention to the patient, preferably a mammal. , where the patient has the selected CFTR genetic mutation of G178R, G551S, G970R, G1244E, S1255P, G1349D, S549N, S549R, S1251N, E193K, F1052V, G1069R, R117C, D110H, R347H, R35267Q, E , A455E, D579G, S1235R, S945L, R1070W, F1074L, D110E, D1270N, D1152H, 1717-1G-> A, 621 1G-> T, 3120 + 1G-> A, 1898 + 1G-> A, 711 1G-> T, 2622 + 1G-> A, 405 + 1G-> A, 406-1G-> A, 4005 + 1G-> A, 1812-1G-> A, 1525-1G-> A, 712-1G-> T , 1248 + 1G-> A, 1341 1G-> A, 3121-1G-> A, 4374 + 1G-> T, 3850-1G-> A, 2789 + 5G-> A, 3849 + 10kbC-> T, 3272 -26A-> G, 711 + 5G-> A, 3120G-> A, 1811 1.6kbA-> G, 711 + 3A-> G, 1898 + 3A-> G, 1717-8G-> A, 1342-2A- > C, 405 + 3A-> C, 1716G / A, 1811 + 1G-> C, 1898 + 5G-> T, 3850-3T-> G, IVS14b + 5G-> A, 1898 + 1G-> T, 40 05 + 2T-> C and 621 + 3A-> G, and a human CFTR mutation selected from AF508, R117H and G551D.
[0602] In one aspect, the present invention is directed to a method of treating, lessening the severity of, or symptomatically treating cystic fibrosis in a patient which comprises administering an effective amount of the pharmaceutical composition or tablet of the invention to the patient, preferably a mammal. , wherein the patient has the CFTR gene mutation selected from G178R, G551S, G970R, G1244E, S1255P, G1349D, S549N, S549R, S1251N, E193K, F1052V and G1069R. In one aspect, the present invention is directed to a method of treating, lessening the severity of, or symptomatically treating cystic fibrosis in a patient which comprises administering an effective amount of the pharmaceutical composition or tablet of the invention to the patient, preferably a mammal. , wherein the patient has the CFTR gene mutation selected from G178R, G551S, G970R, G1244E, S1255P, G1349D, S549N, S549R and S1251N. In one aspect, the present invention is directed to a method of treating, lessening the severity of, or symptomatically treating cystic fibrosis in a patient which comprises administering an effective amount of the pharmaceutical composition or tablet of the invention to the patient, preferably a mammal. , wherein the patient has the CFTR gene mutation selected from E193K, F1052V and G1069R. In some embodiments of this aspect, the method produces a greater than ^10- fold increase in chloride transport over reference chloride transport.
[0604] In one aspect, the present invention is directed to a method of treating, lessening the severity of, or symptomatically treating cystic fibrosis in a patient which comprises administering an effective amount of the pharmaceutical composition or tablet of the invention to the patient, preferably a mammal. , where the patient has the CFTR gene mutation selected from R117C, D110H, R347H, R352Q, E56K, P67L, L206W, A455E, D579G, S1235R, S945L, R1070W, F1074L, D110E, D1270N and D1152H. In one embodiment of this aspect, the method produces an increase in chloride transport that is greater than or equal to ¹⁰ % above the reference chloride transport.
[0606] In one aspect, the present invention is directed to a method of treating, lessening the severity of, or symptomatically treating cystic fibrosis in a patient which comprises administering an effective amount of the pharmaceutical composition or tablet of the invention to the patient, preferably a mammal. , where the patient has the selected CFTR genetic mutation of 1717-1G-> A, 621 1G-> T, 3120 + 1G-> A, 1898 + 1G-> A, 711 1G-> T, 2622 + 1G- > A, 405 + 1G-> A, 406-1G-> A, 4005 + 1G-> A, 1812-1G-> A, 1525-1G-> A, 712-1G-> T, 1248 + 1G-> A, 1341 1G-> A, 3121-1G-> A, 4374 + 1G-> T, 3850-1G-> A, 2789 + 5G-> A, 3849 + 10kbC-> T, 3272-26A-> G, 711 + 5G-> A, 3120G-> A, 1811 1.6kbA-> G, 711 + 3A-> G, 1898 + 3A-> G, 1717-8G-> A, 1342-2A-> C, 405 + 3A -> C, 1716G / A, 1811 1G-> C, 1898 + 5G-> T, 3850-3T-> G, IVS14b + 5G-> A, 1898 + 1G-> T, 4005 + 2T-> C and 621 + 3A-> G. In one aspect, the present invention is directed to a method of treating, lessening the severity of, or symptomatically treating cystic fibrosis in a patient which comprises administering an effective amount of the pharmaceutical composition or tablet of the invention to the patient, preferably a mammal. , where the patient has the selected CFTR genetic mutation of 1717-1G-> A, 1811 1.6kbA-> G, 2789 + 5G-> A, 3272-26A-> G and 3849 + 10kbC-> T. In one aspect, the present invention is directed to a method of treating, lessening the severity of, or symptomatically treating cystic fibrosis in a patient which comprises administering an effective amount of the pharmaceutical composition or tablet of the invention to the patient, preferably a mammal. , where the patient has the selected CFTR genetic mutation of 2789 + 5G-> A and 3272-26A-> G.
[0608] In one aspect, the present invention is directed to a method of treating, lessening the severity of, or symptomatically treating cystic fibrosis in a patient which comprises administering an effective amount of the pharmaceutical composition or tablet of the invention to the patient, preferably a mammal. , where the patient has the selected CFTR genetic mutation of G178R, G551S, G970R, G1244E, S1255P, G1349D, S549N, S549R, S1251N, E193K, F1052V, G1069R, R117C, D110H, R347H, R35267Q, E , A455E, D579G, S1235R, S945L, R1070W, F1074L, D110E, D1270N, D1152H, 1717-1G-> A, 621 1G-> T, 3120 + 1G-> A, 1898 + 1 G-> A, 711 1G- > T, 2622 + 1G-> A, 405 + 1G-> A, 406-1G-> A, 4005 + 1G-> A, 1812-1G-> A, 1525-1G-> A, 712-1G-> T, 1248 + 1G-> A, 1341 1G-> A, 3121-1G-> A, 4374 + 1G-> T, 3850-1G-> A, 2789 + 5G-> A, 3849 + 10kbC-> T, 3272-26A-> G, 711 + 5G-> A, 3120G-> A, 1811 1.6kbA-> G, 711 + 3A-> G, 1898 + 3A-> G, 1717-8G-> A, 1342-2A -> C, 405 + 3A-> C, 1716G / A, 1811 + 1G-> C, 1898 + 5G-> T, 3850-3T-> G, IVS14b + 5G-> A, 1898 + 1G-> T, 4 005 + 2T-> C and 621 + 3A-> G, and a human CFTR mutation selected from AF508, R117H and G551D, and one or more human CFTR mutations selected from AF508, R117H and G551D.
[0610] In one aspect, the present invention is directed to a method of treating, lessening the severity of, or symptomatically treating cystic fibrosis in a patient which comprises administering an effective amount of the pharmaceutical composition or tablet of the invention to the patient, preferably a mammal. , wherein the patient has the selected CFTR gene mutation from G178R, G551S, G970R, G1244E, S1255P, G1349D, S549N, S549R, S1251N, E193K, F1052V and G1069R, and one or more selected human CFTR mutations from AF508, R117H , and G551D. In one aspect, the present invention is directed to a method of treating, lessening the severity of, or symptomatically treating cystic fibrosis in a patient which comprises administering an effective amount of the pharmaceutical composition or tablet of the invention to the patient, preferably a mammal. , wherein the patient possesses the CFTR gene mutation selected from G178R, G551S, G970R, G1244E, S1255P, G1349D, S549N, S549R and S1251N, and one or more human CFTR mutations selected from AF508, R117H and G551D. In one aspect, the present invention is directed to a method of treating, lessening the severity of, or symptomatically treating cystic fibrosis in a patient which comprises administering an effective amount of the pharmaceutical composition or tablet of the invention to the patient, preferably a mammal. , wherein the patient possesses the selected CFTR gene mutation from E193K, F1052V and G1069R, and one or more human CFTR mutations selected from AF508, R117H and G551D. In some embodiments of this aspect, the method produces a greater than ^10- fold increase in chloride transport over reference chloride transport.
[0612] In one aspect, the present invention is directed to a method of treating, lessening the severity of, or symptomatically treating cystic fibrosis in a patient which comprises administering an effective amount of the pharmaceutical composition or tablet of the invention to the patient, preferably a mammal. , where the patient has the CFTR gene mutation selected from R117C, D110H, R347H, R352Q, E56K, P67L, L206W, A455E, D579G, S1235R, S945L, R1070W, F1074L, D110E, D1270N and D1152H, and one or more mutations human selected from AF508, R117H and G551D. In one embodiment of this aspect, the method produces an increase in chloride transport that is greater than or equal to ¹⁰ % above the reference chloride transport.
[0614] In one aspect, the present invention is directed to a method of treating, lessening the severity of, or symptomatically treating cystic fibrosis in a patient which comprises administering an effective amount of the pharmaceutical composition or tablet of the invention to the patient, preferably a mammal. , where the patient has the selected CFTR genetic mutation of 1717-1G-> A, 621 1G-> T, 3120 + 1G-> A, 1898 + 1G-> A, 711 1G-> T, 2622 + 1G- > A, 405 + 1G-> A, 406-1G-> A, 4005 + 1G-> A, 1812-1G-> A, 1525-1G-> A, 712-1G-> T, 1248 + 1G-> A, 1341 1G-> A, 3121-1G-> A, 4374 + 1G-> T, 3850-1G-> A, 2789 + 5G-> A, 3849 + 10kbC-> T, 3272-26A-> G, 711 + 5G-> A, 3120G-> A, 1811 1.6kbA-> G, 711 + 3A-> G, 1898 + 3A-> G, 1717-8G-> A, 1342-2A-> C, 405 + 3A -> C, 1716G / A, 1811 1G-> C, 1898 + 5G-> T, 3850-3T-> G, IVS14b + 5G-> A, 1898 + 1G-> T, 4005 + 2T-> C y621 + 3A-> G, and one or more human CFTR mutations selected from AF508, R117H, and G551D. In one aspect, the present invention is directed to a method of treating, lessening the severity of, or symptomatically treating cystic fibrosis in a patient which comprises administering an effective amount of the pharmaceutical composition or tablet of the invention to the patient, preferably a mammal. , where the patient has the selected CFTR genetic mutation of 1717-1G-> A, 1811 1.6kbA-> G, 2789 + 5G-> A, 3272-26A-> G and 3849 + 10kbC-> T, and a or more human CFTR mutations selected from AF508, R117H and G551D. In one aspect, the present invention is directed to a method of treating, lessening the severity of, or symptomatically treating cystic fibrosis in a patient comprising administering an effective amount of the pharmaceutical composition or tablet of the invention to the patient, preferably a mammal, wherein the patient possesses the CFTR gene mutation selected from 2789 + 5G-> A and 3272-26A-> G, and one or more human CFTR mutations selected from AF508, R117H and G551D.
[0615] In certain embodiments, the pharmaceutically acceptable composition or tablet of the present invention comprising Compound 1 Form I and a substantially amorphous solid dispersion of Compound 2 are useful for treating, lessening the severity of, or symptomatically treating cystic fibrosis in patients who show residual CFTR activity in the apical membrane of respiratory and non-respiratory epithelia. The presence of residual CFTR activity on the epithelial surface can be readily detected using methods known in the art, eg, standard electrophysiological, biochemical, or histochemical techniques. Such methods identify CFTR activity using in vivo or ex vivo electrophysiological techniques, measurement of sweat or salivary Cl concentrations, or ex vivo biochemical or histochemical techniques to monitor cell surface density. Using such methods, residual CFTR activity can be easily detected in patients heterozygous or homozygous for a variety of different mutations, including patients homozygous or heterozygous for the most common mutation, AF508, as well as other mutations such as the G551D mutation or the R117 ^{h mutation.} . In certain embodiments, pharmaceutically acceptable compositions or tablets comprising Compound 1 Form I and a solid dispersion comprising substantially amorphous Compound 2 are useful for treating, lessening the severity of, or symptomatically treating cystic fibrosis in patients with poor or no residual CFTR activity. In certain embodiments, pharmaceutically acceptable compositions or tablets comprising Compound 1 Form I and a solid dispersion comprising substantially amorphous Compound 2 are useful for treating, lessening the severity of, or symptomatically treating cystic fibrosis in patients with poor or no residual CFTR activity in the apical membrane of the respiratory epithelium.
[0616] In another embodiment, the compounds and compositions of the present invention are useful for treating or lessening the severity of cystic fibrosis in patients who have induced or increased residual CFTR activity using pharmacological methods. In another embodiment, the compounds and compositions of the present invention are useful for treating or lessening the severity of cystic fibrosis in patients who have induced or increased residual CFTR activity using gene therapy. Such methods increase the amount of CFTR present on the cell surface, thereby inducing a hitherto absent CFTR activity in a patient or increasing the existing level of residual CFTR activity in a patient.
[0617] In one embodiment, the pharmaceutical compositions and tablets of the present invention comprising Compound 1 Form I and a solid dispersion comprising substantially amorphous Compound 2, as described herein, are useful for treating or lessening the severity of the disease. cystic fibrosis in patients within certain genotypes that show residual CFTR activity, for example, Class I mutations (not synthesized), Class II mutations (misfolding), Class III mutations (altered regulation), Class IV mutations ( altered conductance) or class V mutations (reduced synthesis).
[0618] In one embodiment, the pharmaceutical compositions and tablets of the present invention comprising Compound 1 Form I and a solid dispersion comprising substantially amorphous Compound 2, as described herein, are useful for treating, lessening the severity of , or symptomatically treat cystic fibrosis in patients within certain clinical phenotypes, eg, a moderate to mild clinical phenotype that typically correlates with the amount of residual CFTR activity in the apical membrane of the epithelium. Such phenotypes include patients with pancreatic sufficiency.
[0619] In one embodiment, the pharmaceutical compositions and tablets of the present invention comprising Compound 1 Form I and a solid dispersion comprising substantially amorphous Compound 2, as described herein, are useful for treating, lessening the severity of, or treat symptomatically patients diagnosed with pancreatic sufficiency, idiopathic pancreatitis, and congenital bilateral absence of the vas deferens, or mild lung disease in which the patient shows residual CFTR activity.
[0620] In one embodiment, the pharmaceutical compositions and tablets of the present invention comprising Compound 1 Form I and a solid dispersion comprising substantially amorphous Compound 2, as described herein, are useful for treating, lessening the severity of, or treat symptomatically patients diagnosed with pancreatic sufficiency, idiopathic pancreatitis, and congenital bilateral absence of the vas deferens, or mild lung disease where the patient has wild-type CFTR.
[0621] In addition to cystic fibrosis, modulation of CFTR activity may be beneficial for other diseases not directly caused by mutations in CFTR, such as secretory diseases and other CFTR-mediated protein folding diseases. These include, but are not limited to, chronic obstructive pulmonary disease (COPD), dry eye disease, and Sjogren's syndrome. COPD is characterized by airflow limitation that is progressive and not completely reversible. Airflow limitation is due to mucus hypersecretion, emphysema, and bronchiolitis. Wild-type or mutant CFTR activators offer a potential treatment for mucus hypersecretion and impaired mucociliary clearance that is common in the COPD. Specifically, increased anion secretion through CFTR can facilitate fluid transport into airway surface fluid to hydrate mucus and optimize periciliary fluid viscosity. This would lead to improved mucociliary clearance and a reduction in symptoms associated with COPD. Dry eye disease is characterized by decreased tear water production and abnormal lipid, protein, and mucin profiles of the tear film. There are many causes of dry eye, some of which include age, Lasik eye surgery, arthritis, medications, chemical / thermal burns, allergies, and diseases such as cystic fibrosis and Sjogrens syndrome. Increased anion secretion through CFTR would enhance fluid transport from corneal endothelial cells and secretory glands surrounding the eye to increase corneal hydration. This would help alleviate the symptoms associated with dry eye disease. Sjogrens syndrome is an autoimmune disease in which the immune system attacks moisture-producing glands throughout the body, including the eyes, mouth, skin, respiratory tissue, liver, vagina, and intestine. Symptoms include dry eye, mouth, and vagina, as well as lung disease. The disease is also associated with rheumatoid arthritis, systemic lupus, systemic sclerosis, and polymyposis / dermatomyositis. Defective protein trafficking is believed to cause disease, so treatment options are limited. Enhancers or inducers of CFTR activity can hydrate the various organs affected by the disease and help elevate associated symptoms.
[0622] In one embodiment, the invention relates to a method of increasing or inducing the activity of the anion channel in vitro or in vivo, which comprises contacting the channel with any of the pharmaceutical compositions PC-I to PC-XXV . In another embodiment, the anion channel is a chloride channel or a bicarbonate channel. In another embodiment, the anion channel is a chloride channel.
[0623] The exact amount required will vary from subject to subject, depending on the species, age and general condition of the subject, the severity of the infection, the particular agent, its mode of administration, and the like. The compounds of the invention are preferably formulated in dosage unit form for ease of administration and uniformity of dosage. The term "dosage unit form" as used herein refers to a physically discrete unit of agent appropriate for the patient to be treated. However, it will be understood that the treating physician will decide the total daily use of the compounds and compositions of the invention within the scope of sound medical judgment. The specific effective dose level for any particular patient or organism will depend on a variety of factors including the disorder being treated and the severity of the disorder; the activity of the specific compound employed; the specific composition used; the age, body weight, general health, sex, and diet of the patient; the time of administration, the route of administration and the rate of excretion of the specific compound employed; the duration of the treatment; drugs used in combination or coincident with the specific compound employed, and similar factors well known in the medical art. The term "patient", as used herein, means an animal, preferably a mammal, and most preferably a human.
[0624] Anywhere in the present application where the name of a compound does not correctly describe the structure of the compound, the structure supersedes the name and will prevail.
[0625] EXAMPLES XRPD (X-ray powder diffraction)
[0626] X-ray diffraction (XRD) data for Compound 1 Form I was collected on a Bruker D ⁸ DISCOVER powder diffractometer with two-dimensional HI-STAR detector and a flat graphite monochromator. A sealed Cu tube with Ka radiation at 40 kV, 35 mA was used. The samples were placed on zero background silicon wafers at 25 ° C. For each sample, two data frames were collected at 120 seconds each at 2 different ^{02 angles: 8} ° and 26 °. Data were integrated with GADDS software and merged with DIFFRACTplusEVA Software. The uncertainties for the reported peak positions are ± ^0.2 degrees.
[0627] Differential Scanning Calorimetry (DSC)
[0628] Differential Scanning Calorimetry (DSC) data for Form I of Compound 1 was collected using a DSC Q100 V9.6 Build 290 (TA Instruments, New Castle, DE). The temperature was calibrated with indium and the heat capacity was calibrated with sapphire. Samples of 3-6 mg were weighed into aluminum containers which were sealed using 1 pin hole lids. Samples were scanned from 25 ° C to 350 ° C at a heating rate of 1.0 ° C / min and with a nitrogen gas purge of 50 ml / min. Data were collected using Thermal Advantage Q Series ™ software version 2.2.0.248 and analyzed using Universal Analysis software version 4.1D (TA Instruments, New Castle, DE). Reported numbers represent individual analyzes.
[0629] Determination of the monocrystalline structure of Form I of Compound 1
[0630] Diffraction data was acquired on a Bruker Apex II diffractometer equipped with a Cu source. Kalfa sealed tube and an Apex II CCD detector. The structure was solved and refined using the SHELX program (Sheldrick, GM, Acta Cryst., (2008) A64, 112-122). Based on the systemic statistics of absences and intensities, the structure in the space group P2l / n was solved and refined.
[0631] Vitride® (sodium bis (2-methoxyethoxy) aluminum hydride [or NaAlH ² (OCH ² CH ² OCH ³ ) ² ], 65% by weight solution in toluene) was purchased from Aldrich Chemicals.
[0632] 2,2-Difluoro-1,3-benzodioxole-5-carboxylic acid was purchased from Saltigo (a subsidiary of Lanxess Corporation).
[0633] Preparation of compound 1
[0634] Preparation of (2,2-Difluoro-1,3-benzodioxol-5-yl) -methanol
[0638] Commercially available 2,2-Difluoro-1,3-benzodioxole-5-carboxylic acid (1.0 eq) was suspended in toluene (10 vol). Vitride® (2 eq) was added via an addition funnel at a rate to maintain the temperature at 15-25 ° C. At the end of the addition, the temperature was increased to 40 ° C for 2 hours (h), then 10% (w / w) aqueous NaOH (aq.) (4.0 eq) was carefully added via an addition funnel, maintaining the temperature at 40-50 ° C. After stirring for an additional 30 minutes (min), it was allowed the layers to separate at 40 ° C. The organic phase was cooled to 20 ° C, then washed with water (2 x 1.5 vol), dried (Na ² SO ⁴ ), filtered, and concentrated to provide the crude (2,2-difluoro-1,3-benzodioxol-5-yl) -methanol which was used directly in the next step.
[0639] Preparation of 5-chloromethyl-2,2-difluoro-1,3-benzodioxole.
[0644] (2,2-Difluoro-1,3-benzodioxol-5-yl) -methanol (1.0 eq) was dissolved in MTBE (5 vol). A catalytic amount of 4- (N, N-dimethyl) aminopyridine (DMAP) (1 mol%) was added and SOCl (1.2 eq) was added via an addition funnel. The SOCh was added at a rate to maintain the temperature in the reactor at 15-25 ° C. The temperature was increased to 30 ° C for 1 h, and then cooled to 20 ° C. Water (4 vol) was added by an addition funnel while maintaining the temperature below 30 ° C. After stirring for an additional 30 min, the layers were allowed to separate. The organic layer was stirred and aq NaOH was added. 10% (w / v) (4.4 vol). After stirring for 15-20 min, the layers were allowed to separate. The organic phase was then dried (Na ² SO ⁴ ), filtered and concentrated to yield crude 5-chloromethyl-2,2-difluoro-1,3-benzodioxole which was used directly in the next step.
[0645] Preparation of (2,2-Difluoro-1,3-benzodioxol-5-yl) -acetonitrile
[0649] A solution of 5-chloromethyl-2,2-difluoro-1,3-benzodioxole (1 eq) in DMSO (1.25 vol) was added to a suspension of NaCN (1.4 eq) in DMSO (3 vol), while maintaining the temperature between 30-40 ° C. The mixture is stirred for 1h, then water ⁽⁶ vol) was added, followed by methyl tert-butyl ether (MTBE) (4 vol). After stirring for 30 min, the layers were separated. The aqueous layer was extracted with MTBE (1.8 vol). The combined organic layers were washed with water ^{(1, 8} vol), dried (Na ² SO ^4), filtered and concentrated to afford ^{(2, 2} - difluoro-1,3-benzodioxol-5-yl) -acetonitrile crude (95%) that was used directly in the next step.
[0651] Synthesis of (2,2-Difluoro-1,3-benzodioxol-5-yl) -1-acetatedeethyl-acetonitrile
[0656] A reactor was purged with nitrogen and charged with 900 ml of toluene. The solvent was degassed by nitrogen sparging for not less than 16 h. Then Na3PO4 (155.7 g, 949.5 mmol) was charged to the reactor, followed by bis (dibenzylideneacetone palladium (0) (7.28 g, 12.66 mmol). A 10% w / w solution was charged of tert-butylphosphine in hexanes (51.23 g, 25.32 mmol) over 10 min from a nitrogen purged addition funnel at 23 ° C. The mixture was allowed to stir for 50 min, at which time 5-bromo- 2,2-Difluoro-1,3-benzodioxole (75 g, 316.5 mmol) for 1 min After stirring for an additional 50 min, the mixture was charged with ethyl cyanoacetate (71.6 g, 633.0 mmol ) for 5 min followed by water (4.5 ml) in one portion The mixture was heated to 70 ° C for 40 min and analyzed by HPLC every 1-2 h to determine the percent conversion of the reagent to the product. Once complete conversion was observed (typically 100% conversion after 5-8 h), the mixture was cooled to 20-25 ° C and filtered through a pad of celite. The pad of celite was rinsed. with toluene (2 x 450 ml) and the Combined organic extracts were concentrated to 300 ml in vacuo at 60-65 ° C. The concentrate was charged with 225 ml of DMSO and concentrated in vacuo at 70-80 ° C. until active solvent distillation ceased. The solution was cooled to 20-25 ° C and diluted to 900 ml with DMSO in preparation for Step 2. 1H NMR (500 MHz, CDCla) ⁸ 7.16 - 7.10 (m, 2H), 7.03 (d, J = 8.2 Hz, 1H), 4.63 (s, 1H), 4.19 (m, 2H), 1.23 (t, J = 7.1 Hz, 3H).
[0658] Synthesis of (2,2-Difluoro-1,3-benzodioxol-5-yl) -acetonitrile
[0663] The DMSO solution of (2,2-difluoro-1,3-benzodioxol-5-yl) -1-ethyl acetate-acetonitrile from above was charged with 3N HCl (617.3 mL, 1.85 mol) for 20 min while it maintained an internal temperature at <40 ° C. The mixture was then heated to 75 ° C for 1 hour and analyzed by HPLC every 1-2 hours to determine% conversion. When> 99% conversion was observed (typically after 5-6 h), the reaction was cooled to 20-25 ° C and extracted with MTBE (2 X 525 mL), with enough time to allow complete phase separation. during extractions. The combined organic extracts were washed with 5% NaCl (2 X 375 ml). The solution was then transferred to appropriate equipment for 1.5-2.5 Torr vacuum distillation that was equipped with a cooled receiving flask. The solution was concentrated in vacuo at <60 ° C to remove solvents. Then (2,2-Difluoro-1,3-benzodioxol-5-yl) -acetonitrile was distilled as the resulting oil at 125-130 ° C (oven temperature) and 1.5 2.0 Torr. Was isolated (2,2-difluoro-1,3-benzodioxol-5-yl) -acetonitrile as a clear oil yield ^{6% 6} from 5-bromo-2,2-difluoro-1,3-benzodioxole (2 steps) and with an HPLC purity of 91.5% AUC (corresponds to a 95% w / w assay). 1H NMR (500 MHz, DMSO) ⁸ 7.44 (br s, 1H), 7.43 (d, J = 8.4 Hz, 1H), 7.22 (dd, J = 8.2, 1.8 Hz, 1H), 4.07 (s, 2H).
[0665] Preparation of (2,2-Difluoro-1,3-benzodioxol-5-yl) -cyclopropanecarbonitrile
[0670] A mixture of (2,2-difluoro-1,3-benzodioxol-5-yl) -acetonitrile (1.0 eq), 50% by weight aqueous KOH (5.0 eq) 1-bromo-2- chloroethane (1.5 eq) and Oct ⁴ NBr (0.02 eq) at 70 ° C for 1 h. The reaction mixture is cooled and then treated with MTBE and water. The organic phase was washed with water and brine. The solvent was removed to yield (2,2-Difluoro-1,3-benzodioxol-5-yl) -cyclopropanecarbonitrile.
[0671] Preparation of 1- (2,2-Difluoro-1,3-benzodioxol-5-yl) -cyclopropanecarboxylic acid
[0672] 6 M N to O H (8 equiv)
[0673] E tO H (5 vol), 80 degrees C
[0676]
[0678] citric acid ac. 10% (8 vol)
[0679] 69% yield
[0680] Hydrolysis is (2,2-difluoro-1,3-benzodioxol-5-yl) -cyclopropanecarbonitrile using ⁶ M ⁽⁸ equiv.) In ethanol (5 vol) at 80 ° C overnight NaOH. The mixture was cooled to room temperature and the ethanol was evaporated in vacuo. The residue was taken up in water and MTBE was added, 1M HCl was added and the layers were separated. The MTBE layer was then treated with dicyclohexylamine (DCHA) (0.97 equiv.). The slurry was cooled to 0 ° C, filtered and washed with heptane to give the corresponding DCHA salt. The salt was taken up in MTBE and 10% citric acid and stirred until all solids dissolved. The layers were separated and the MTBE layer was washed with water and brine. A change of solvent to heptane followed by filtration gave 1- (2,2-difluoro-1,3-benzodioxol-5-yl) -cyclopropanecarboxylic acid after drying in a vacuum oven at 50 ° C overnight.
[0681] Preparation of 1- (2,2-Difluoro-1,3-benzodioxol-5-yl) -cyclopropanecarbonyl chloride
[0685] 1- (2,2-Difluoro-1,3-benzodioxol-5-yl) -cyclopropanecarboxylic acid (1.2 eq) was suspended in toluene (2.5 vol) and the mixture was heated to 60 ° C. SOCh (1.4 eq) was added via addition funnel. Toluene and SOCh were distilled from the reaction mixture after 30 minutes. Additional toluene (2.5 vol) was added and the resulting mixture distilled again, leaving the acid chloride product as an oil, which was used without further purification.
[0686] Preparation of tert-butyl-3- (3-methylpyridin-2-yl) benzoate
[0690] 2-Bromo-3-methylpyridine (1.0 eq) was dissolved in toluene (12 vol). K ² CO ³ (4.8 eq) was added, followed by water (3.5 vol). The resulting mixture was heated at 65 ° C under a stream of N ² for 1 hour. Then 3- (t-butoxycarbonyl) phenylboronic acid (1.05 eq) and Pd (dppf) Cl ² -CH ² Ch (0.015 eq.) Were added and the mixture was heated to 80 ° C. After 2 hours, the heating, water (3.5 vol) was added and the layers were allowed to separate. The organic phase was then washed with water (3.5 vol) and extracted with 10% aqueous methanesulfonic acid (2 eq MsOH, 7.7 vol). The aqueous phase was made basic with 50% aqueous NaOH (2 eq) and extracted with EtOAc ⁽⁸ vol). The organic layer was concentrated to yield crude tert-butyl-3- (3-methylpyridin-2-yl) benzoate (82%) which was used directly in the next step.
[0691] Preparation of 2- (3- (tert-butoxycarbonyl) phenyl) -3-methylpyridine-1-oxide
[0694] Tert-Butyl-3- (3-methylpyridin-2-yl) benzoate (1.0 eq) was dissolved in EtOAc ⁽⁶ vol). Water (0.3 vol) was added, followed by urea-hydrogen peroxide (3 eq). Italic anhydride (3 eq) was then added portionwise to the mixture as a solid at a rate to keep the temperature in the reactor below 45 ° C. After completion of the addition of Italic anhydride, the mixture was heated to 45 ° C. C. After stirring for a further 4 hours, the heat was turned off. Aqueous 10% w / w Na ² SO ³ (1.5 eq) was added via addition funnel. After the addition of Na ² SO ^{3 was complete} , the mixture was stirred for an additional 30 min and the layers were separated. The organic layer was stirred and ^{10% w / w aqueous Na 2} CO ³ (2 eq.) Was added. After stirring for 30 minutes, the layers were allowed to separate. The organic phase was washed with 13% w / v aqueous NaCl. The organic phase was then filtered and concentrated to provide crude 2- (3- (tert-butoxycarbonyl) phenyl) -3-methylpyridine-1-oxide (95%) which was used directly in the next step.
[0696] Preparation of tert-butyl-3- (6-amino-3-methylpyridin-2-yl) benzoate
[0701] A solution of 2- (3- (tert-butoxycarbonyl) phenyl) -3-methylpyridine-1-oxide (1 eq) and pyridine (4 eq) in acetonitrile ⁽⁸ vol) was heated to 70 ° C. A solution was added of methanesulfonic anhydride (1.5 eq) in MeCN (2 vol) for 50 min via addition funnel while maintaining the temperature below 75 ° C. The mixture was stirred for an additional 0.5 hours after completion of the addition . Then the mixture was allowed to cool to room temperature. Ethanolamine (10 eq.) Was added via addition funnel. After stirring for 2 hours, water ⁽⁶ vol) was added and the mixture was cooled to 10 ° C. After stirring for 3 hours, the solid was collected by filtration and washed with water (3 vol), acetonitrile / water 2: 1 (3 vol) and acetonitrile (2 x 1.5 vol). The solid was dried to constant weight (<1% difference) in a vacuum oven at 50 ° C with a slight amount of N ² purge to provide tert-butyl-3- (6-amino-3-methylpyridin-2 -yl) benzoate as a red-yellow solid (53% yield).
[0702] Preparation of 3- (6- (1- (2,2-Difluorobenzo [d] [1,3] dioxole-5-M) -cyclopropanecarboxamido) -3-metNpyridm-2-N) -tbutylbenzoate
[0707] The crude acid chloride described above was dissolved in toluene (2.5 vol based on acid chloride) and added via addition funnel to a mixture of tert-butyl-3- (6-amino-3-methylpyridine-2 -yl) benzoate (1 eq.), DMAP, (0.02 eq) and triethylamine (3.0 eq) in toluene (4 vol based on tert-butyl-3- (6-amino-3-methylpyridin-2 -yl) benzoate). After 2 hours, water (4 volumes based on tert-butyl-3- (6-amino-3-methylpyridin-2-yl) benzoate) was added to the reaction mixture. After stirring for 30 minutes, the layers were separated. The organic phase was then filtered and concentrated to provide a thick oil of 3- (6- (1- (2,2-difluorobenzo [d] [1,3] dioxol-5-yl) cyclopropanecarboxamido) -3-methylpyridine -2-yl) -t-butylbenzoate (quantitative crude yield). Acetonitrile (3 vol based on crude product) was added and distilled until crystallization occurred. Water (2 vol based on crude product) and the mixture was stirred for 2 h. The solid was collected by filtration, washed with 1: 1 (by volume) acetonitrile / water (2 x 1 volumes based on crude product) and partially dried on the filter under vacuum. The solid was dried to constant weight (<1% difference) in a 60 ° C vacuum oven with a slight N ² purge to provide 3- (6- (1- (2,2-difluorobenzo [d] [1,3] dioxol-5-yl) cyclopropanecarboxamido) -3-methylpyridin-2-yl) -t-butylbenzoate as a brown solid.
[0708] Preparation of 3- (6- (1- (2,2-difluorobenzo [d] [1,3] dioxol-5-M) cyclopropanecarboxamido) -3-methylpyridin-2-yl) benzoic acid • HCL salt
[0712] To a slurry of 3- (6- (1- (2,2-difluorobenzo [d] [1,3] dioxol-5-yl) cyclopropanecarboxamido) -3-methylpyridin-2-yl) -t-butylbenzoate (1, 0 eq.) In MeCN (3.0 vol) water (0.83 vol) was added followed by concentrated aqueous HCl (0.83 vol). The mixture was heated to 45 ± 5 ° C. After stirring for 24 to 48 h, the reaction was complete and the mixture was allowed to cool to room temperature. Water (1.33 vol) was added and the mixture stirred. The solid was collected by filtration, washed with water (2 x 0.3 vol) and partially dried on the filter under vacuum. The solid was dried to constant weight (<1% difference) in a 60 ° C vacuum oven with a slight N ² purge to provide 3- (6- (1- (2,2-difluorobenzo [d ] [1,3] dioxol-5-yl) cyclopropanecarboxamido) -3-methylpyridin-2-yl) benzoic • HCl as an off-white solid.
[0713] A ^{1HNMR spectrum of Compound 1 is shown in Figure 8} and Figure 9 represents a 1HNMR spectrum of Compound 1 as an HCl salt.
[0714] Table 2 below lists the 1HNMR data for Compound 1.
[0715] Table 2.
[0717]
[0719] Preparation of Compound 1 Form I
[0720] Preparation of Compound 1 Form I, Method A
[0723] A slurry of 3- (6- (1- (2,2-difluorobenzo [d] [1,3] dioxol-5-yl) cyclopropanecarboxamido) -3-methylpyridin-2-yl) benzoic acid • HCl (1 eq) in water (10 vol) at room temperature. A sample was taken after stirring for 24 h. The sample was filtered and the solid was washed with water (2 times). The solid sample was sent for DSC analysis. When DSC analysis indicated complete conversion to Form I, the solid was collected by filtration, washed with water (2 x 1.0 vol), and partially dried on a vacuum filter. The solid was then dried to constant weight (<1% difference) in a 60 ° C vacuum oven with a slight N ² purge to provide Compound 1 Form I as an off-white solid (98% yield). 1H NMR (400 MHz, DMSO-d ⁶⁾ 9.14 (s, 1H), 7.99 7.93 (m, 3H), 7.80-7.78 (m, ^1H), 7.74-7.72 (m, 1H), 7.60-7.55 (m , 2H), 7.41-7.33 (m, 2H), 2.24 (s, 3H), 1.53-1.51 (m, 2H), 1.19-1.17 (m, 2H).
[0725] Preparation of Compound 1 Form I, Method B
[0730] A solution of 3- (6- (1- (2,2-difluorobenzo [d] [1,3] dioxol-5-yl) cyclopropanecarboxamido) -3-methylpyridin-2-yl) -t-butylbenzoate (1 , 0 eq) in formic acid (3.0 vol) with stirring at 70 ± 10 ° C, for ⁸ h. The reaction was considered complete when no more than 1.0% of the AUC remained by chromatographic methods of 3- (6- (1- (2,2-difluorobenzo [d] [1,3] dioxol-5-yl) cyclopropanecarboxamido ) -3-methylpyridine-2-yl) -t-butylbenzoate). The mixture was allowed to cool to room temperature. The solution was added to water ⁽⁶ vol), heated to 50 ° C, and the mixture stirred. Then, the mixture was heated to 70 ± 10 ° C until the level of 3- (6- (1- (2,2-difluorobenzo [d] [1,3] dioxol-5-yl) cyclopropanecarboxamido) -3- methylpyridin-2-yl) -t-butylbenzoate was not higher than 0.8% (AUC). The solid was collected by filtration, washed with water (2x3 vol), and partially dried on the filter under vacuum. The solid was dried to constant weight (<1% difference) in a 60 ° C vacuum oven with a slight N ² purge to produce Compound 1 Form I as an off-white solid.
[0732] Figure 10 shows the DSC trace of Form I of Compound 1. 10. The fusion of Form I of Compound 1 occurs at approximately 204 ° C.
[0733] An X-ray diffraction pattern was calculated from a monocrystalline structure of Compound 1 Form I and is shown in Figure 1. Table 3 lists the calculated peaks for Figure 1.
[0734] Table 3.
[0739] An actual X-ray powder diffraction pattern of Compound 1 Form I is shown in Figure 2. Table 4 lists the actual peaks for Figure 2.
[0741] Table 4.
[0745] Colorless crystals of Form I of Compound 1 were obtained by cooling a concentrated solution of 1-butanol from 75 ° C to 10 ° C at a rate of 0.2 ° C / min. A glass with dimensions of 0.50 x 0.08 x 0.03 mm was selected, cleaned with mineral oil, mounted on a MicroMount and centered on a Bruker APEX II system. Three batches of 40 frames separated in reciprocal space were obtained to provide an orientation matrix and initial cell parameters. The final parameters of the cell were obtained and refined based on the complete data set.
[0746] A reciprocal space diffraction data set was obtained at 0.82 A resolution using 0.5 ° steps using a 30 s exposure for each frame. Data were collected at ^{10 0} ( ² ) K. Integration of intensities and refinement of cellular parameters were accomplished using APEXII software. Observation of the crystal after data collection showed no signs of decomposition.
[0747] A conformational image of Compound 1 Form I based on monocrystalline X-ray analysis is shown in Figure 11. Form I of compound 1 is monoclinic, P ²¹ / n, with the following unit cell dimensions: a = 4.9626 (7) A, b = 12.299 (2) A, c = 33.075 (4) A, P = 93.938 ( 9) °, V = 2014.0 A3, Z = 4. The density of Compound 1 Form I calculated from structural data is 1.492 g / cm ³ at 100 K.
[0748] Preparation of compound 2
[0750] Synthesis of 4-oxo-1,4-dihydroquinoline-3-carboxylic acid (26)
[0755] Process for the preparation of ethyl 4-oxo-1,4-dihydroquinoline-3-carboxylate (25)
[0760] Compound 23 (4.77 g, 47.7 mmol) was added dropwise to compound 22 (10 g, 46.3 mmol) with ^{subsurface N 2} flow to drive ethanol below 30 ° C for 0, 5 hours. The solution was then heated to ^{10 0-1 1 0} ° C and stirred for 2.5 hours. After cooling the mixture below 60 ° C, diphenyl ether was added. The resulting solution was added dropwise to diphenyl ether which had been heated at 228-232 ° C for 1.5 hours with ^{subsurface N 2} flow to drive off the ethanol. The mixture was stirred at 228-232 ° C for another 2 hours, cooled below 100 ° C and then heptane was added to precipitate the product. The resulting slurry was stirred at 30 ° C for 0.5 hours. The solids were then filtered off and the cake was washed with heptane and dried in vacuo to give compound 25 as a brown solid. 1H NMR (DMSO-d ⁶ ; 400 MHz) ⁸ 12.25 (s), ⁸ 8.49 (d), 68.10 (m), ⁸ 7.64 (m), ⁸ 7.55 (m), ⁸ 7.34 (m), ⁸ 4.16 (q ), ⁸ 1.23 (t).
[0762] Process for the preparation of 4-oxo-1,4-dihydroquinoline-3-carboxylic acid (26)
[0765] Method 1
[0767] Compound 25 (1.0 eq) was suspended in a solution of HCl (10.0 eq) and H ² O (11.6 vol). The slurry was heated to 85-90 ° C, although alternative temperatures are also suitable for this hydrolysis step. For example, the hydrolysis can alternatively be carried out at a temperature of about 75 to about 100 ° C. In some cases, the hydrolysis is carried out at a temperature of about 80 to about 95 ° C. In others, the hydrolysis step is carried out at a temperature of about 82 to about 93 ° C (eg, about 82.5 to about 92.5 ° C or about ⁸⁶ to about 89 ° C). After stirring at 85-90 ° C for approximately 6.5 hours, the reaction was sampled to complete the reaction. Stirring can be carried out at any of the temperatures suitable for hydrolysis. The solution was then cooled to 20-25 ° C and filtered. The reactor / cake was rinsed with H ² O (2 vol x 2). Then the cake was washed with 2 vol H ² O until pH> 3.0. Then the cake was dried under vacuum at 60 ° C to give compound 26 .
[0769] Method 2
[0771] Compound 25 (11.3 g, 52 mmol) was added to a mixture of 10% NaOH (aqueous) (10 ml) and ethanol (100 ml). The solution was refluxed for 16 hours, cooled to 20-25 ° C and then the pH was adjusted to 2-3 with ⁸ % HCl. Then the mixture was stirred for 0.5 hour and filtered. The cake was washed with water (50 ml) and then dried in vacuo to give compound 26 as a brown solid. 1H NMR (DMSO-d ⁶ ; 400 MHz) ⁸ 15.33 (s), ⁸ 13.39 (s), ⁸ 8.87 (s), ⁸ 8.26 (m), ⁸ 7.87 (m), ⁸ 7.80 (m), ⁸ 7.56 ( m).
[0773] Total synthesis of N- (2,4-di-tert-butyl-5-hydroxyphenyl) -4-oxo-1,4-dihydroquinoline-3-carboxamide (Compound 2)
[0778] Process for the preparation of 2,4-di-tert-butylphenyl methyl carbonate (30)
[0781] Method 1
[0783] To a solution of 2,4-di-tert-butyl phenol, 29 , (10 g, 48.5 mmol) in diethyl ether (100 ml) and triethylamine (10.1 ml, 72.8 mmol), was added Methyl chloroformate (7.46 ml, 97 mmol) dropwise at 0 ° C. The mixture was then allowed to warm to room temperature and stirred for an additional 2 hours. Then, an additional 5 ml of triethylamine and 3.7 ml of methyl chloroformate were added and the reaction was stirred overnight. The reaction was then filtered, the filtrate was cooled to 0 ° C and then an additional 5 ml of triethylamine and 3.7 ml of methyl chloroformate were added and the reaction was allowed to warm to room temperature and then stirred for an additional 1 hour. At this stage, the reaction was almost complete and treated by filtration, then washing with water ^(2x), followed by brine. The solution was then concentrated to produce a yellow oil and purified using column chromatography to give compound 30 . ¹ H NMR (400 MHz, DMSO-d ⁶ ) ⁸ 7.35 (d, J = 2.4 Hz, 1H), 7.29 (dd, J = 8.4, 2.4 Hz, 1H), 7.06 (d, J = 8.4 Hz, 1H) , 3.85 (s, 3H), 1.30 (s, 9H), 1.29 (s, 9H).
[0785] Method 2
[0787] To a reactor vessel charged with 4-dimethylaminopyridine (DMAP, 3.16 g, 25.7 mmol) and 2,4-di-tert-butyl phenol (compound 29 , 103.5 g, 501.6 mmol) was added chloride of methylene (415 g, 313 mL) and the solution was stirred until all solids dissolved. Then, triethylamine (76 g, 751 mmol) was added and the solution was cooled to 0.5 ° C. Then, methyl chloroformate (52 g, 550.3 mmol) was added dropwise over 2.5-4 hours, keeping the solution temperature between 0-5 ° C. The reaction mixture was then slowly heated to 23-28 ° C and stirred for 20 hours. Then the reaction was cooled to 10-15 ° C and charged with 150 ml of water. The mixture was stirred at 15-20 ° C for 35-45 minutes and then the aqueous layer was separated and extracted with 150 ml of methylene chloride. The organic layers were combined and neutralized with 2.5% HCl (aq) at 5-20 ° C to give a final pH of 5-6. Then the organic layer was washed with water and concentrated in vacuo at a temperature below 20 ° C to 150 ml to give compound 30 in methylene chloride.
[0789] Process for the preparation of 5-nitro-2,4-di-tert-butylphenyl methyl carbonate (31)
[0794] Method 1
[0796] To a stirred solution of compound 30 (6.77 g, 25.6 mmol) was added dropwise ⁶ ml of a 1: 1 mixture of sulfuric acid and nitric acid at 0 ° C. The mixture was allowed to warm to temperature room and stirred for 1 hour. The product was purified using liquid chromatography (iSCO, 120g, 0-7% EtOAc / Hexanes, 38 min) yielding approximately an 8: 1-10: 1 mixture of regioisomers of compound 31 as a white solid. ^1H NMR (400 MHz, DMSO-d ^{6) 8} 7.63 (s, 1H), 7.56 (s, 1H), 3.87 (s, 3H), 1.36 (s, 9H), 1.32 (s, 9H). HPLC time ret.
[0797] 3.92 min 10-99% CH ³ CN, 5 min run; ESI-MS 310 m / z (MH) +.
[0798] Method 2
[0800] To compound 30 (100g, 378mmol) was added DCM (540g, 408ml). The mixture was stirred until all solids dissolved and then cooled to -5-0 ° C. Concentrated sulfuric acid (163 g) was then added dropwise, while maintaining the initial reaction temperature, and the mixture stirred for 4.5 hours. Then, nitric acid (62 g) was added dropwise over 2-4 hours while maintaining the initial reaction temperature, and then stirred at this temperature for an additional 4.5 hours. Then, the reaction mixture was slowly added to cold water, keeping a temperature below 5 ° C. Then, the quenched reaction was heated to 25 ° C and the aqueous layer was removed and extracted with methylene chloride. The combined organic layers were washed with water, dried using Na ² SO ⁴ and concentrated to 124-155 ml. Hexane (48 g) was added and the resulting mixture was again concentrated to 124-155 ml. Later more hexane (160 g) was added to the mixture. Then the mixture was stirred at 23-27 ° C for 15.5 hours and then filtered. Hexane (115 g) was added to the filter cake, the resulting mixture was heated under reflux and stirred for 2-2.5 hours. The mixture was then cooled to 3-7 ° C, stirred for an additional 1-1.5 hours, and filtered to give compound 31 as a pale yellow solid.
[0802] Process for the preparation of 5-amino-2,4-di-tert-butylphenyl methyl carbonate (32)
[0807] 2,4-di-tert-butyl-5-nitrophenyl methyl carbonate (1.00 eq) was charged into a suitable hydrogenation reactor, followed by 5% Pd / C (2.50% by weight on dry basis, Johnson-Matthey Type 37). MeOH (15.0 vol) was charged to the reactor and the system was closed. The system was purged with N ² (g) and then pressurized to 2.0 bar with H ² (g). The reaction was carried out at a reaction temperature of 25 ° C / -5 ° C. When complete, the reaction was filtered and the reactor / cake was washed with MeOH (4.00 vol). The resulting filtrate was vacuum distilled at no more than 50 ° C to 8.00 vol. Water (2.00 vol) was added at 45 ° C / -5 ° C. The resulting slurry was cooled to 0 ° C / -5. The slurry was kept at 0 ° C / -5 ° C for not less than 1 hour and leaked. The cake was washed once with 0 ° C / -5 ° C MeOH / H ² O (8: 2) (2.00 vol). The cake was dried under vacuum (-0.90 bar and -0.86 bar) at 35 ° C - 40 ° C to give compound 32. 1H NMR (400 MHz, DMSO-d ⁶ ) ⁸ 7.05 (s, 1H ), 6.39 (s, 1H), 4.80 (s, 2H), 3.82 (s, 3H), 1.33 (s, 9H), 1.23 (s, 9H).
[0809] After the reaction was complete, the resulting mixture was diluted with about 5 to 10 volumes of MeOH (e.g., about ⁶ to about 9 volumes of MeOH, about 7 to about 8.5 volumes of MeOH, of about 7.5 to about ⁸ volumes of MeOH, or about 7.7 volumes of MeOH), heated to a temperature of about 35 ± 5 ° C, filtered, washed and dried, as described above.
[0811] Preparation of N- (2,4-di-tert-butyl-5-hydroxyphenyl) -4-oxo-1,4-dihydroquinoline-3-carboxamide (Compound 2)
[0814] 4-Oxo-1,4-dihydroquinoline-3-carboxylic acid, 26, (1.0 eq) and 5-amino-2,4-di-tert-butylphenyl methyl carbonate, 32, (1.1 eq ). 2-MeTHF (4.0 vol, based on acid) was added followed by a 50% solution of T3P® in 2-MeTHF (1.7 eq). The container loaded with T3P was washed with 2-MeTHF (0.6 vol). Pyridine (2.0 eq) was then added and the resulting suspension was heated to 47.5 / - 5.0 ° C and kept at this temperature for ⁸ hours. A sample was taken and its completion verified by HPLC. Upon completion, the resulting mixture was cooled to 25.0 ° C / -2.5 ° C. 2-MeTHF (12.5 vol) was added to dilute the mixture. The reaction mixture was washed with water (10.0 vol) 2 times. 2-MeTHF was added to bring the total reaction volume to 40.0 vol (~ 16.5 loaded vol). NaOMe / MeOH (1.7 equiv.) Was added to this solution to perform methanolysis. The reaction was stirred for not less than 1.0 hour and was checked for completion by HPLC. Upon completion, the reaction was quenched with 1N HCl (10.0 vol) and washed with 0.1N HCl (10.0 vol). The organic solution was filtered to polish to remove any particles and placed in a second reactor. The filtered solution was concentrated at no more than 35 ° C (jacket temperature) and not less than 8.0 ° C (internal reaction temperature) under reduced pressure at 20 vol. CH ³ CN was added at 40 vol and the solution was concentrated to no more than 35 ° C (jacket temperature) and not less than 8.0 ° C (internal reaction temperature) at 20 vol. The addition of CH ³ CN and the concentration cycle were repeated 2 more times for a total of 3 additions of CH ³ CN and 4 concentrations at 20 vol. After final concentration at 20 vol, 16.0 vol of CH ³ CN was added followed by 4.0 vol of H ² O to make a final concentration of 40 vol of H ² O / CH ³ CN at 10% with respect to the acid of departure. This slurry was heated to 78.0 ° C, / - 5.0 ° C (reflux). Then the slurry was stirred for not less than 5 hours. The slurry was cooled to 0.0 ° C / -5 ° C for 5 hours and filtered. The cake was washed with 0.0 ° C / -5.0 ° C CH ³ CN (5 vol) 4 times. The resulting solid (Compound 2) was dried in a vacuum oven at 50.0 ° C / - 5.0 ° C. 1H NMR (400 MHz, DMSO-d 6) ⁸ 12.8 (s, 1H), 11.8 (s , 1H), 9.2 (s, 1H), 8.9 (s, 1H), 8.3 (s, 1H), 7.2 (s, 1H), 7.9 (t, 1H), 7.8 (d, 1H), 7.5 (t, 1H), 7.1 (s, 1H), 1.4 (s, 9H), 1.4 (s, 9H).
[0816] Alternative preparation of N- (2,4-di-tert-butyl-5-hydroxyphenyl) -4-oxo-1,4-dihydroquinoline-3-carboxamide (Compound 2)
[0819] Compound 2
[0821] 4-Oxo-1,4-dihydroquinoline-3-carboxylic acid, 26, (1.0 eq) and 5-amino-2,4-di-tert-butylphenyl methyl carbonate, 32, (1.1 eq ). 2-MeTHF (4.0 vol, based on acid) was added followed by a 50% solution of T3P® in 2-MeTHF (1.7 eq). The container loaded with T3P was washed with 2-MeTHF (0.6 vol). Pyridine (2.0 eq) was then added and the resulting suspension was heated to 47.5 / - 5.0 ° C and kept at this temperature for 8 hours. A sample was taken and its completion verified by HPLC. Upon completion, the resulting mixture was cooled to -20 ° C / -5 ° C. 2-MeTHF (12.5 vol) was added to dilute the mixture. The reaction mixture was washed with water (10.0 vol) 2 times and 2-MeTHF (16.5 vol) was charged to the reactor. This solution was charged with NaOMe / MeOH 30% w / w (1.7 equiv.) To perform the methanolysis. The reaction was stirred at 25.0 ° C / -5.0 ° C for not less than 1.0 hour, and its completion was verified by HPLC. Upon completion, the reaction was quenched with ^{1.2N HCl / H 2} O (10.0 vol), and washed with ^{0.1N HCl / H 2} O (10.0 vol). The organic solution was filtered to polish to remove any particles and placed in a second reactor.
[0823] The filtered solution was concentrated at no more than 35 ° C (jacket temperature) and not less than 8.0 ° C (internal reaction temperature) under reduced pressure at 20 vol. CH ³ CN was added at 40 vol and the solution was concentrated to no more than 35 ° C (jacket temperature) and not less than 8.0 ° C (internal reaction temperature) at 20 vol. The addition of CH ³ CN and the concentration cycle were repeated 2 more times for a total of 3 additions of CH ³ CN and 4 concentrations at 20 vol. After the final concentration at 20 vol, 16.0 vol of CH ³ CN were charged followed by 4.0 vol of H ² O to make a final concentration of 40 vol of H ² O / CH ³ CN at 10% with respect to to the starting acid. This slurry was heated to 78.0 ° C, / - 5.0 ° C (reflux). Then the slurry was stirred for not less than 5 hours. The slurry was cooled to 20-25 ° C for 5 hours and filtered. The cake was washed with CH ³ CN (5 vol) heated from 20 to 25 ° C 4 times. The resulting solid (Compound 2) was dried in a vacuum oven at 50.0 ° C / -. 5.0 ° C. 1H NMR (400 MHz, DMSO-de) 812.8 (s, 1H), 11.8 (s, 1H), 9.2 (s, 1H), 8.9 (s, 1H), 8.3 (s, 1H) , 7.2 (s, 1H), 7.9 (t, 1H), 7.8 (d, 1H), 7.5 (t, 1H), 7.1 (s, 1H), 1.4 (s, 9H), 1.4 (s, 9H).
[0825] Procedure for recrystallization of N- (2,4-di-tert-butN-5-hydroxypheml) -4-oxo-1,4-dihydroqumolm-3-carboxamide (Compound 2)
[0828] Compound 2 (1.0 eq.) Was charged into a reactor. 2-MeTHF (20.0 vol) was added followed by 0.1N HCl (5.0 vol). The biphasic solution was stirred and separated and the upper organic phase was washed two more times with 0.1N HCl (5.0 vol). The organic solution was filtered to polish to remove any particles and placed in a second reactor. The filtered solution was concentrated at no more than 35 ° C (jacket temperature) and no more than 8.0 ° C (internal reaction temperature) under reduced pressure at 10 vol. Isopropyl acetate (IPAc) (10 vol) was added and the solution was concentrated to no more than 35 ° C (jacket temperature) and no more than 8.0 ° C (internal reaction temperature) at 10 vol. The IPAc addition and concentration was repeated 2 more times for a total of 3 IPAc additions and 4 concentrations at 10 vol. After final concentration, 10 vol of IPAc was charged and the suspension was heated to reflux and kept at this temperature for 5 hours. The suspension was cooled to 0.0 ° C / -5 ° C for 5 hours and filtered. The cake was washed once with IPAc (5 vol). The resulting solid was dried in a vacuum oven at 50.0 ° C / -5.0 ° C.
[0829] Preparation of a solid dispersion comprising Compound 2 substantially amorphous
[0830] A solvent system of MEK and DI water, formulated according to the ratio 90% by weight of MEK / 10% by weight of DI water, was heated to a temperature of 20-30 ° C in a reactor, equipped with a magnetic stirrer. and thermal circuit. In this solvent system, polymer of hypromellose acetate succinate (HPMCAS) (grade HG), SLS and Compound 2 were added according to the ratio of 19.5% by weight of hypromellose acetate succinate / 0.5 % by weight of SLS / 80% by weight of Compound 2. The resulting mixture contained 10.5% by weight of solids. The actual amounts of ingredients and solvents used to generate this mixture are listed in Table 5, below:
[0831] Table 5 : Solid Spray Dispersion Ingredients for Product
[0832] intermediate F.
[0836] The temperature of the mixture was adjusted to a range of 20-45 ° C and mixed until it was substantially homogeneous and all components had substantially dissolved.
[0837] A spray dryer, Niro PSD4 Commercial Spray Dryer, equipped with a pressure nozzle (Spray Systems Maximum Passage SK-MFP series with 54/21 orifice / core size) equipped with an anti-scuff cap, was used in the mode normal spray drying, following the spray process parameters listed in Table 6, below.
[0838] Table 6 : Dry spray process parameters used to generate
[0839] Intermediate Product F
[0842] A high-efficiency cyclone separated the wet product from the spray gas and solvent vapors. The wet product contained 8.5-9.7% MEK and 0.56-0.83% water and had a mean particle size of 17 19 um and a bulk density of 0.27-0.33 g / DC. The wet product was transferred to a 4000 L stainless steel double cone vacuum drier for drying to reduce residual solvents to a level of less than about 5000 ppm and generate a dry spray dried dispersion of amorphous Compound 2, containing <0.03% M ^and K and 0.3% water.
[0843] Tableting from a fully continuous wet granulation process Equipment / Process
[0844] Team
[0845] Fully Continuous Development and Launch Device (DLR) or similar type of equipment.
[0846] Screening
[0847] Compound 1 Form I, the solid dispersion comprising substantially amorphous Compound 2 and excipients can be dispensed into separate intermediate container (IBC) containers. These materials can be screened using a "container to container" screening operation. Appropriate mesh sizes are 20 mesh, 40 mesh or 60 mesh.
[0848] Mixed
[0849] IBCs containing screened Compound 1 Form I, the solid dispersion comprising substantially amorphous Compound 2, and excipients can be coupled to a feeder system, which can feed the materials in a controlled manner, for example, using volumetric or gravimetric loss. in weigh feeders, in a continuous mixer. The feed rate of the individual components is defined by the composition of the formulation and the overall rate of the line. The rate of the line can be from 8kg / h to 30kg / h. The continuous mixer can have different blade configurations to allow proper mixing and the rotational speed of these blades can be between 80 RPM and 300 RPM.
[0850] Wet granulation
[0851] A granulation solution can be prepared by dissolving 48 g of sodium lauryl sulfate and 159 g of polyvinylpyrrolidone in 1626 g of water in a stainless steel container, using an overhead stirrer with a stirring speed of 700 RPM. The granulation solution can be placed in a container from which the solution can be pumped into the twin screw granulator using a peristaltic pump with a mass flow meter and control, using a flow rate that is appropriate for the process. The mixture can be granulated using a twin screw granulator such as the granulator that is part of the DLR. The mixture can be added to the twin screw granulator using a loss-in-weight feeder, such as the K-Tron feeder on the DLR, with a feed rate of 8 kg / hr to 24 kg / hr. The twin screw granulator can work with a barrel temperature of 25 degrees Celsius and a screw speed of 200 to 950 RPM. The granulation process can take three minutes for small batch sizes or several hours for large batch sizes.
[0852] Drying
[0853] The wet granules can be fed directly into a fluid bed dryer, such as the segmented fluid bed dryer in the DLR. The end point of drying can be chosen at a product temperature during discharge ranging from 40 to 55 degrees Celsius, at which point the water content of the granules can be 2.1% w / w ("Loss on drying , LOD ") or less. Drying time can be 12 minutes, or shorter or longer, to reach the desired end point of drying.
[0854] Grinding
[0855] The dried granules can be ground to reduce the size of the granules. For this, a cone mill such as the integrated Quadro U 10 CoMil can be used.
[0856] Mixed
[0857] The granules can be mixed with extragranular excipients as fillers and lubricants using weight loss feeders and a continuous mixer. Mixing speed can be 80 - 300 RPM. Compression
[0858] The compression blend can be compressed into tablets using a single station or a rotary tablet press, such as the Courtoy Modul P press, which is part of the DLR system, using appropriately sized tools. The weight of tablets for a dose of 200 mg of Form I Compound 1 and 125 mg of the substantially amorphous Compound 2 may be about 500 or 600 mg. Film coating
[0859] Tablets can be film coated using the innovative Omega film coater, which is part of the DLR system. This coater allows rapid film coating of sub-batches from 1 to 4 kg to allow continuous manufacturing.
[0860] Print
[0861] Film-coated tablets can be monogrammed on one or both sides of the tablet with, for example, an Ackley ramp printer.
[0862] The continuous process described above in one embodiment is enhanced by PAT techniques as described in Table 7. There are 6 PAT positions, each of which includes a manual sampling port. Process samples can be obtained for research purposes, as required, and also for maintenance, transfer, and validation of the PAT model. PAT systems can be used for real-time release testing (RTRT) and can also be used for process controls (IPC) and feedback / advance control.
[0863] Table 7
[0866] The RTRT can meet specifications as described in Table 8.
[0867] Table 8.
[0869]
[0872] There is a high probability of detecting non-conforming material. For example, if the model's sort criteria is set to a minimum of 95% confidence and 800 tablets are tested during batch manufacturing, running 40 hours with a sample rate of 1 tablet every 3 minutes equals 800 tablets. So, the probability of approving a non-conforming lot is extremely low: <(0.05) n-, where n = No. of samples, therefore, the probability is <1.5 * ¹⁰ -1041. The probability of not detecting non-conforming tablets as a result of a short-term event (> 3 minutes) is as follows: 1 tablet (3-minute event) ^ <0.05 (probability of detection>0.95); 2 tablets (6 minute event) ^ <0.0025 (probability of detection> 0.9975).
[0873] PAT measurements can serve as surrogates for conventional final tests directly by combining measurements to express attributes in a conventional manner (ie, as assay, CU, dissolution, etc.). Validation can be done using ICH Q2 as a guide. The development of sequential offline to online methods enables CQA assessment in a material saving manner. Ultimately, RTRT will ensure product quality to a higher level of confidence than conventional testing.
[0874] Tableting from Twin Screw Wet Granulation Process Equipment / Process
[0875] Team
[0876] Twin screw wet granulators: ConsiGma-1, ConsiGma-25 or Leistritz nano.
[0877] Screening / Weighing
[0878] Compound 1 Form I, the solid dispersion comprising substantially amorphous Compound 2 and excipients can be screened before or after weighing. Appropriate mesh sizes are 20 mesh, 40 mesh, or 60 mesh. Compound 1 Form I and / or the solid dispersion comprising substantially amorphous Compound 2 may be premixed with one or more of the excipients to simplify screening.
[0879] Mixed
[0880] Compound 1 Form I, the solid dispersion comprising substantially amorphous Compound 2 and the excipients can be added to the mixer in a different order. Mixing can be done in a Turbula mixer, v-shell mixer, or container mixer. The components can be mixed for 10 minutes.
[0881] Wet granulation
[0882] A granulation solution can be prepared by dissolving 48 g of sodium lauryl sulfate and 159 g of polyvinylpyrrolidone in 1626 g of water in a stainless steel container, using an overhead stirrer with a stirring speed of 700 RPM. The mixture can be granulated using a twin screw granulator such as ConsiGma-1. The granulation solution can be added to the twin screw granulator using a peristaltic pump, such as the ConsiGma-1 pump, with a feed rate of 67 g / min. The mixture can be added to the twin screw granulator using a loss-in-weight feeder, such as the Brabender feeder on the ConsiGma-1, with a feed rate of 10 kg / hr. The twin screw granulator can be operated with a barrel temperature of 25 degrees Celsius and a screw speed of 400 RPM. The granulation process can be carried out for four minutes. The granulation process can be carried out for shorter or longer periods of time to produce a smaller or larger quantity of wet granules.
[0883] Drying
[0884] The wet granules can be fed directly into a fluid bed dryer, such as the drying chamber of the ConsiGma-1 or the segmented fluid bed dryer of the CTL-25. The end point of drying can be chosen at a product temperature of 43 degrees Celsius, at which point the water content of the granules can be 1.6% w / w ("Loss on drying, LOD"). Drying time can be 12 minutes, or shorter or longer, to reach the desired end point of drying. Drying can be done with an air flow of 59 m3 / min and an inlet temperature of 60 degrees Celsius. Alternatively, the wet granules coming from the twin screw granulator can be collected in a container or container for a certain period of time after which the wet granules are transferred to a separate fluidized bed dryer, such as the Vector Multi 15.
[0885] Grinding
[0886] The dried granules can be ground to reduce the size of the granules. For this, a cone mill such as the Quadro 194 CoMil can be used.
[0887] Mixed
[0888] The granules can be mixed with extragranular excipients as fillers and lubricants using a shell mixer or a container mixer. Mixing time can be 5, 3 or 1 minute. Compression
[0889] The compression blend can be compressed into tablets using a single station or a rotary tablet press, such as the Courtoy Modul P press, using 0.55 'x 0.33' oval shaped tools. The weight of the tablets for a dose of 200 mg of Form I of Compound 1 and 125 mg of substantially amorphous Compound 2 may be about 500 or 600 mg.
[0890] Film coating
[0891] Tablets can be film coated using a tray coater such as a coater from Thomas Engineering Compu-Lab. A trace amount of Carnauba wax can be added to improve tablet appearance and processability.
[0892] Print
[0893] Film-coated tablets can be monogrammed on one or both sides of the tablet with, for example, a Hartnett Delta printer.
[0894] Tableting from Continuous Double Thyme Wet Granulation Process Equipment / Process
[0895] Team
[0896] Granulator: ConsiGma or Leistritz or Thermo Fisher double thyme granulator.
[0897] Screening / Weighing
[0898] Compound 1 and excipients can be screened before or after weighing. Possible mesh sizes are 20 mesh, 40 mesh or 60 mesh. Compound 1 can be premixed with one or more of the excipients to simplify screening.
[0899] Mixed
[0900] Compound 1 and excipients can be added to the mixer in a different order. Mixing can be done in a Turbula mixer, a v-shell mixer, a container mixer, or a continuous mixer. The components can be mixed for 10 minutes for batch mixers or continuously for a continuous mixer.
[0901] Granulation operation
[0902] Granulation Fluid - SLS and binder are added to purified water and mixed until dissolved. A suitable ratio is 2.5% w / w SLS and 10.0% w / w PVP K30 in water.
[0903] Granulation - the mixture containing Compound 1 and excipients can be dosed into the twin screw granulator using a loss-in-weight feeder at a rate of 10 kg / hr. The granulation fluid can be added using a peristaltic pump at a speed of 3.5 kg / h. The granulator can run at a speed of 400 RPM. A notable advantage of the present twin screw wet granulation process is the use of a granulation fluid comprising both a surfactant and the binder for better granulation through increased wettability. In one embodiment, the surfactant is SLS. Another notable advantage is that because the process is continuous and at any one time only a limited amount of material is processed, the process can be well controlled and results in a high quality product.
[0904] Grinding
[0905] The granules can be reduced in size using a screen mill or a cone mill, either before drying or after drying, or both.
[0906] Drying
[0907] The granules can be dried using a vacuum oven, tray dryer, biconical dryer, or fluid bed dryer.
[0908] Mixed
[0909] The granules can be mixed with extragranular excipients. The granules have been mixed using a 300 liter container mixer for 60 revolutions.
[0910] Compression
[0911] The compression mix has been compressed into tablets using a Courtoy Modul P rotary press.
[0912] Film coating
[0913] Tablets can be film coated using a tray coater, such as an O'Hara Labcoat.
[0914] Print
[0915] Film-coated tablets can be monogrammed on one or both sides of the tablet with, for example, a Hartnett Delta printer.
[0916] TESTS PROTOCOL 1
[0917] Assays to Detect and Measure AF508-CFTR Enhancing Properties of Compounds Optical Membrane Potential Methods to Evaluate AF508-CFTR Modulation Properties of Compounds
[0918] The assay uses fluorescent voltage detection dyes to measure changes in membrane potential using a fluorescent plate reader (e.g., FLIPR III, Molecular Devices, Inc.) as a readout for the increase in functional AF508-CFTR in NIH 3T3 cells. . The driving force behind the response is the creation of a chloride ion gradient along with channel activation by a single fluid addition step after cells have been pretreated with compounds and subsequently loaded with a detection dye dye. voltage.
[0919] Identification of enhancing compounds
[0920] To identify AF508-CFTR enhancers, a double-spiked HTS assay format was developed. This HTS assay uses fluorescent voltage detector dyes to measure changes in membrane potential in FLIPR III as a measure for up-regulation (conductance) of AF508 CFTR in NIH 3T3 cells with temperature-corrected AF508 CFTR. The driving force of the response is a Cl- ion gradient along with channel activation with forskolin in a single liquid addition step using a fluorescent plate reader such as FLIPR III after cells have been pretreated with enhancer compounds. (or DMSO vehicle control) and subsequently loaded with a redistributing dye.
[0921] Solutions
[0922] Bath solution # 1: (in mM) NaCl 160, KCl 4.5, CaCh2, MgCh 1, HEPES 10, pH 7.4 with NaOH.
[0923] Chloride-Free Bath Solution: The chloride salts in Bath Solution No. 1 (above) are replaced by gluconate salts.
[0924] Cell culture
[0925] Mouse NIH3T3 fibroblasts stably expressing AF508-CFTR are used for optical measurements of membrane potential. The cells were kept at 37 ° C in 5% CO ² and 90% humidity in Dulbecco's modified Eagle's medium supplemented with 2 mM glutamine, 10% fetal calf serum, 1 X NEAA, p-ME, 1 X pen. / strep, and 25 mM HEPES in 175 cm2 culture flasks. For all optical assays, cells were seeded at ~ 20,000 / well in 384-well matrigel coated plates and cultured for 2 hours at 37 ° C before culturing at 27 ° C for 24 hours. for the enhancer assay. For correction assays, cells are cultured at 27 ° C or 37 ° C with and without compounds for 16-24 hours.
[0926] Electrophysiological Assays to Evaluate AF508-CFTR Modulation Properties of Compounds. Ussing chamber test
[0927] Chamber of Ussing experiments were performed on polarized airway epithelial cells expressing AF508-CFTR to further characterize the enhancers or inducers of AF508-CFTR identified in the optical assays. Airway epithelia without CF and with CF were isolated from bronchial tissue, cultured as previously described (Galietta, LJV, Lantero, S., Gazzolo, A., Sacco, O., Romano, L., Rossi, GA , & Zegarra-Moran, O. (1998) In Vitro Cell. Dev. Biol. 34, 478-481), and plated on Costar® Snapwell ™ filters that were pre-coated with NIH3T3 conditioned media. After four days, the apical medium was removed and cells were cultured in an air-liquid interface for> 14 days before use. This resulted in a monolayer of fully differentiated columnar cells that were ciliated, characteristics that are characteristic of airway epithelia. HBE without CF were isolated from nonsmokers who did not have any known lung disease. CF-HBE were isolated from patients homozygous for AF508.
[0928] HBE cultured in Costar® Snapwell ™ cell culture inserts were mounted in a Ussing chamber (Physiologic Instruments, Inc., San Diego, CA.), and transepithelial short-circuit and resistance current were measured in the presence of a Cl- gradient. basolateral to apical (I ^sc ) using a voltage clamp system (Department of Bioengineering, University of Iowa, Iowa). Briefly, HBE were examined under voltage clamp recording conditions (Vhold = 0 mV) at 37 ° C. The basolateral solution contained (in mM) 145 NaCl, 0.83 K ² HPO ⁴ , 3.3 KH ² PO ⁴ , 1.2 MgCl ² , 1.2 CaCl ² , 10 glucose, 10 HEPES (pH adjusted to 7.35 with NaoH) and the apical solution contained (in mM) 145 NaGluconate, 1.2 MgCh, 1.2 CaCh , 10 glucose, 10 HEPES (pH adjusted to 7.35 with NaoH).
[0929] Identification of enhancing compounds
[0930] The typical protocol used a basolateral to apical membrane Cl' concentration gradient. For To establish this gradient, normal signals were used on the basolateral membrane, while the apical NaCl was replaced by equimolar sodium gluconate (titrated to pH 7.4 with NaOH) to give a large Cl-concentration gradient across the epithelium. Forskolin (10 µM) and all test compounds were added to the apical side of the cell culture inserts. The efficacy of the putative F508-CFTR enhancers was compared with that of the known enhancer, genistein.
[0932] Patch-Clamp Registers
[0934] The total current of Cl- in the AF508-NIH3T3 cells was monitored using the perforated patch recording setup as previously described (Rae, J., Cooper, K., Gates, P. & Watsky, M. (1991) J. Neurosci. Methods 37, 15-26). Voltage clamp recordings were made at 22 ° C using an Axopatch 200B patchclamp amplifier (Axon Instruments Inc., Foster City, CA). The pipette solution contained (in mM) 150 N-methyl-D-glucamine (NMDG) -Cl, 2 MgCh, 2 CaCh, 10 EGTA, 10 HEpES and 240 pg / ml of amphotericin-B (pH adjusted to 7.35 with HC1). The extracellular medium contained (in mM) 150 NMDG-Cl, 2 MgCh, 2 CaCh, 10 HEPES (pH adjusted to 7.35 with HCl). Pulse generation, data acquisition, and analysis were performed using a PC equipped with a Digidata 1320 A / D interface in conjunction with Clampex 8 (Axon Instruments Inc.). To activate AF508-CFTR, 10 µM forskolin and 20 µM genistein were added to the bath and the current-voltage ratio was monitored every 30 seconds.
[0936] Identification of enhancing compounds
[0938] The ability of AF508-CFTR enhancers to increase the macroscopic current of AF508-CFTR CI '(I ^af50s ) in NIH3T3 cells stably expressing AF508-CFTR was also investigated using perforated patch recording techniques. The enhancers identified from the optical assays elicited a dose-dependent increase in IA ^f508 with similar potency and efficacy seen in the optical assays. In all cells examined, the reversal potential before and during enhancer application was approximately -30 mV, which is the ^{calculated E ci} (-28 mV).
[0940] Cell culture
[0942] NIH3T3 mouse fibroblasts stably expressing AF508-CFTR are used for whole cell recordings. Cells are kept at 37 ° C in 5% CO ² and 90% humidity in Dulbecco's Modified Eagle's Medium supplemented with 2 mM glutamine, 10% fetal calf serum, 1 x NEAA, p-ME, 1 x pen / strep, and 25 mM HEPES in 175 cm2 culture flasks. For whole cell recordings, 2,500-5,000 cells were seeded on poly-L-lysine coated glass coverslips and cultured for 24-48 hours at 27 ° C prior to use to test the activity of enhancers; and incubated with or without the correction compound at 37 ° C to measure the activity of the correctors.
[0944] Single channel records
[0946] Temperature-corrected wt-CFTR and AF508-CFTR regulatory activity expressed in NIH3T3 cells was observed using inside-out membrane patch logs excised as previously described (Dalemans, W., Barbry, P., Champigny, G., Jallat, S., Dott, K., Dreyer, D., Crystal, RG, Pavirani, A., Lecocq, JP., Lazdunski, M. (1991) Nature 354, 526-528) using an amplifier of p patch-clamp Axopatch 200B (Axon Instruments Inc.). The pipette contained (in mM): 150 NMDG, 150 aspartic acid, 5 CaCh, 2 MgCl ² and 10 HEPES (pH adjusted to 7.35 with Tris base). The bath contained (in mM): 150 NMDG-Cl, 2 MgCh, 5 EGTA, 10 TES and 14 Tris base (pH adjusted to 7.35 with HCl). After cleavage, both wt- and AF508-CFTR were activated by adding 1 mM Mg-ATP, 75 nM of the catalytic subunit of cAMP-dependent protein kinase (PKA; Promega Corp. Madison, WI) and 10 mM NaF to inhibit protein phosphatases, which prevented current reduction. The pipet potential was kept at 80 mV. Channel activity was analyzed from membrane patches containing <2 active channels. The maximum number of simultaneous openings determined the number of active channels during the course of an experiment. To determine the current amplitude of a single channel, the recorded data from 120 seconds of AF508-CFTR activity was filtered "off-line" at 100 Hz and then used to construct amplitude histograms of all points that were fitted with multigaussian functions using Bio-Patch Analysis software (Bio-Logic Comp. France). Total microscopic current and open probability (Po) were determined from 120 seconds of channel activity. Po was determined using the Bio-Patch software or from the relationship Po = I / i (N), where I = mean current, i = current amplitude of a single channel and N = number of active channels in the patch.
[0948] Cell culture
[0950] NIH3T3 mouse fibroblasts stably expressing AF508-CFTR are used for excised membrane patchclamp recordings. The cells were kept at 37 ° C in 5% CO ² and 90% humidity in Dulbecco's modified Eagle's medium supplemented with 2 mM glutamine, 10% fetal bovine serum, 1 X NEAA, p-ME, 1 X pen. / strep, and 25 mM HEPES in 175 cm2 culture flasks. For single channel records, they were seeded 2,500-5,000 cells on poly-L-lysine coated glass coverslips and cultured for 24-48 hours at 27 ° C prior to use.
[0951] PROTOCOL 2
[0952] Assays to detect and measure AF508-CFTR correction properties of compounds
[0953] Optical Membrane Potential Methods to Analyze AF508-CFTR Modulation Properties of Compounds.
[0954] The optical membrane potential assay used voltage-sensitive FRET sensors described by González and Tsien (See Gonzalez, JE and RY Tsien (1995) "Voltage sensing by fluorescence resonance energy transfer in single cells" Biophys J 69 (4): 1272- 80, and Gonzalez, JE and RY Tsien (1997) "Improved indicators of cell membrane potential that use fluorescence resonance energy transfer" Chem Biol 4 (4): 269-77) in combination with instrumentation to measure changes in fluorescence such as the Voltage / Ion Reader (VIPR) (See Gonzalez, JE, K. Oades, et al. (1999) "Cell-based assays and instrumentation for screening ion-channel targets" Drug Discov Today 4 (9): 431-439).
[0955] These voltage-sensitive assays are based on the change in fluorescence resonant energy transfer (FRET) between the membrane-soluble, voltage-sensitive dye, DiSBAC2 (3), and a fluorescent phospholipid, CC2-DMPE, which binds to the outer leaflet of the plasma membrane and acts as a FRET donor. Changes in membrane potential (Vm) cause negatively charged DiSBAC2 (3) to redistribute across the plasma membrane and the amount of energy transfer from CC2-DMPE changes accordingly. Changes in fluorescence emission were monitored using VIPR ™ II, which is an integrated liquid handler and fluorescence detector designed to perform cell-based screens in 96- or 384-well microtiter plates.
[0956] Identification of correction compounds
[0957] To identify small molecules that correct the trafficking defect associated with AF508-CFTR a single addition HTS assay format was developed. Cells were incubated in serum-free medium for 16 hours at 37 ° C in the presence or absence (negative control) of the test compound. As a positive control, cells in 384-well plates were incubated for 16 hours at 27 ° C to "correct the temperature" of AF508-CFTR. Subsequently, the cells were rinsed 3 times with Krebs Ringers solution and loaded with the voltage-sensitive dyes. To activate AF508-CFTR, 10 pM forskolin and the CFTR enhancer, genistein (20 pM), along with Cl- free medium were added to each well. The addition of Cl- free medium promoted Cl- efflux in response to activation of AF508-CFTR and the resulting membrane depolarization was optically monitored using the FRET-based voltage detector dyes.
[0958] Identification of enhancing compounds
[0959] To identify AF508-CFTR enhancers, a double-spiked HTS assay format was developed. During the first addition, Cl- free medium with or without test compound was added to each well. After 22 seconds, a second addition of Cl'-free medium containing 2-10 pM forskolin was added to activate AF508-CFTR. The extracellular concentration of Cl- after both additions was 28 mM, which promoted C- flux in response to the activation of AF508-CFTR and the resulting membrane depolarization was optically monitored using the voltage-based detecting dyes. in FRET.
[0960] Solutions
[0961] Bath solution # 1: (in mM) NaCl 160, KCl 4.5, CaCh2, MgCh 1, HEPES 10, pH 7.4 with NaOH. Chloride-Free Bath Solution: The chloride salts in Bath Solution No. 1 (above) are replaced by gluconate salts.
[0962] CC2-DMPE: prepared as a 10 mM stock solution in DMSO and stored at -20 ° C. DiSBAC2 (3): prepared as a 10 mM stock solution in DMSO and stored at -20 ° C. Cell culture
[0963] Mouse NIH3T3 fibroblasts stably expressing AF508-CFTR are used for optical measurements of membrane potential. The cells were kept at 37 ° C in 5% CO ² and 90% humidity in Dulbecco's modified Eagle's medium supplemented with 2 mM glutamine, 10% fetal bovine serum, 1 X NEAA, p-ME, 1 X pen. / strep, and 25 mM HEPES in 175 cm2 culture flasks. For all optical assays, cells were seeded at 30,000 / well in 384-well matrigel coated plates and cultured for 2 hours at 37 ° C before culturing at 27 ° C for 24 hours for enhancer assay. For correction assays, cells are cultured at 27 ° C or 37 ° C with and without compounds for 16-24 hours.
[0964] Electrophysiological Assays to Analyze AF508-CFTR Modulating Properties of Compounds Ussing Chamber Assay
[0965] Ussing chamber experiments were performed on polarized epithelial cells expressing AF508-CFTR to further characterize the enhancers or inducers of AF508-CFTR identified in the optical assays. ^{FRT aF508'cFtr} epithelial cells cultured in Costar Snapwell cell culture inserts were mounted in a Ussing chamber (Physiologic Instruments, Inc., San Diego, CA), and the monolayers were continuously short-circuited using a voltage clamp system (Department of Bioengineering, University of Iowa, Iowa, and Physiologic Instruments, Inc., San Diego, CA). Transepithelial resistance was measured by applying a 2 mV pulse. Under these conditions, the FRT epithelium demonstrated resistance of 4 KQ / cm2 or more. The solutions were kept at 27 ° C and bubbled with air. Electrode offset potential and fluid resistance were corrected using a cell-free insert. Under these conditions, the current reflects the flux of Cl- through AF508-CFTR expressed in the apical membrane. The I ^sc was acquired digitally using an MP100A-CE interface and AcqKnowledge software (v3.2.6; BIOPAC Systems, Santa Barbara, CA).
[0966] Identification of correction compounds
[0967] The typical protocol used a basolateral to apical membrane Cl- concentration gradient. To establish this gradient, normal ringer was used on the basolateral membrane, while the apical NaCl was replaced by equimolar sodium gluconate (titrated to pH 7.4 with NaOH) to give a large Cl- concentration gradient across the epithelium. . All experiments were carried out with intact monolayers. Fully activate AF508-to CFTR, forskolin (10 j M) and the PDE inhibitor, IBMX (100 | ^j M) were applied, followed by the addition of the CFTR potentiator, genistein (50 M j).
[0968] As seen in other cell types, low-temperature incubation of FRT cells stably expressing AF508-CFTR increases the functional density of CFTR on the plasma membrane. To determine the activity of the correction compounds, cells were incubated with 10 µM of the test compound for 24 hours at 37 ° C and subsequently washed 3 times before recording. ^{CAMP- and genistein-mediated sc} I in compound-treated cells was normalized to controls at 27 ° C and 37 ° C and expressed as percent activity. Preincubation of cells with correction compound significantly increased ^{cAMP- and genistein-mediated I sc} compared to controls at 37 ° C.
[0969] Identification of enhancing compounds
[0970] The typical protocol used a basolateral to apical membrane Cl- concentration gradient. To establish this gradient, normal ringers on the basolateral membrane were used and permeabilized with nystatin (360 pg / ml), while the apical NaCl was replaced by equimolar sodium gluconate (titrated to pH 7.4 with NaOH) to give a Large Cl- concentration gradient across the epithelium. All experiments were performed 30 minutes after nystatin permeabilization. Forskolin (10 ^j M) and all test compounds on both sides of the cell culture inserts were added. The efficacy of the putative AF508-CFTR enhancers was compared with that of the known enhancer, genistein.
[0971] Solutions
[0972] Basolateral solution (in mM): NaCl (135), CaCh (1.2), MgCh (1.2), K ² HPO ⁴ (2.4), KHPO ⁴ (0.6), N-2-hydroxyethylpiperazine acid -N'-2-ethanesulfonic acid (HEPES) (10) and dextrose (10). The solution was titrated to pH 7.4 with NaOH. Apical solution (in mM): Same as basolateral solution with NaCl replaced with sodium gluconate (135).
[0973] Cell culture
[0974] Fisher rat epithelial cells (FRT) expressing AF508-CFTR (FRTaF508'cFtr) were used for chamber of Ussing experiments for the putative AF508-CFTR inducers or enhancers identified from our optical assays. Cells were grown in Costar Snapwell cell culture inserts and cultured for five days at 37 ° C and 5% CO ² in Ham's modified Coon's F-12 medium supplemented with 5% fetal calf serum, 100 U / ml of penicillin and 100 pg / ml of streptomycin. Before use to characterize the enhancing activity of the compounds, cells were incubated at 27 ° C for 16-48 hours to correct for AF508-CF ^t R. To determine the activity of the correction compounds, cells were incubated at 27 ° C or 37 ° C with and without the compounds for 24 hours.
[0975] Whole cell records
[0976] The macroscopic current of AF508-CFTR (I to ^af508 ) in NIH3T3 cells corrected for the compound of Test and temperature stably expressing AF508-CFTR were monitored using the perforated patch whole cell recording. Briefly, voltage clamp recordings of I to ^{f508 were made} at room temperature using an Axopatch 200B patch-clamp amplifier (Axon Instruments Inc., Foster City, CA). All records were acquired at a 10 kHz sample rate and were low-pass filtered at 1 kHz. The pipettes had a resistance of 5-6 MQ when filled with the intracellular solution. Under these recording conditions, the inversion potential calculated for CI- (E ^ci ) at room temperature was -28 mV. All registers had a sealing resistance> 20 GQ and a series resistance <15 MQ. Pulse generation, data acquisition, and analysis were performed using a PC equipped with a Digidata 1320 A / D interface in conjunction with Clampex 8 (Axon Instruments Inc.). The bath contained <250 µl saline and was continuously infused at a rate of 2 ml / min using a gravity driven perfusion system.
[0977] Identification of correction compounds
[0978] To determine the activity of the correction compounds to increase the density of functional AF508-CFTR in the plasma membrane, we used the perforated patch recording techniques described above to measure the current density after 24 hours of treatment with the correction compounds. . To fully activate AF508-CFTR, 10 jM forskolin and 20 jM genistein were added to the cells. Under our recording conditions, the current density after 24 hours of incubation at 27 ° C was higher than that observed after 24 hours of incubation at 37 ° C. These results are consistent with the known effects of incubation at low temperature on the density of AF508-CFTR in the plasma membrane. To determine the effects of correction compounds on CFTR current density, cells were incubated with 10 | ^jM of the test compound for 24 hours at 37 ° C and the current density was compared to the controls at 27 ° C and 37 ° C (% activity). Before recording, cells were washed 3 times with extracellular recording medium to remove any remaining test compound. Preincubation with 10 µM of correction compounds significantly increased cAMP and genistein-dependent current compared to controls at 37 ° C.
[0979] Identification of enhancing compounds
[0980] The ability of AF508-CFTR enhancers to increase macroscopic AF508-CFTR Cf current (I to ^af508 ) in NIH3T3 cells stably expressing AF508-CFTR was also investigated using perforated patch recording techniques. ^Enhancers identified from optical assays elicited a dose-dependent increase in I at f508 with similar potency and efficacy seen in optical assays. In all cells examined, the reversal potential before and during enhancer application was approximately -30 mV, which is the ^{calculated E ci} (-28 mV).
[0981] Solutions
[0982] Intracellular solution (in mM): Cs-aspartate (90), CsCI (50), MgCh (1), HEPES (10) and 240 µg / ml of amphotericin-B (pH adjusted to 7.35 with CsOH).
[0983] Extracellular solution (in mM): N-methyl-D-glucamine (NMDG) -CI (150), MgCh (2), CaCh (2), HEPES (10) (pH adjusted to 7.35 with HCl).
[0984] Cell culture
[0985] NIH3T3 mouse fibroblasts stably expressing AF508-CFTR were used for whole cell recordings. Cells were kept at 37 ° C in 5% CO ² and 90% humidity in Dulbecco's modified Eagle's medium supplemented with 2 mM glutamine, 10%% fetal calf serum, 1 X NEAA, p-ME, 1 X pen / strep, and 25 mM HEPES in 175 cm2 culture flasks. For whole cell recordings, 2,500-5,000 cells were seeded on poly-L-Iisin coated glass coverslips and cultured for 24-48 hours at 27 ° C prior to use to test the activity of enhancers; and incubated with or without the correction compound at 37 ° C to measure the activity of the correctors.
[0986] Single channel records
[0987] The activities of a single channel of temperature-corrected AF508-CFTR stably expressed in NIH3T3 cells and the activities of the enhancer compounds were observed using an inside-out cleaved membrane patch. Briefly, voltage clamp recordings of single channel activity were performed at room temperature with an Axon Instruments 200B patch-clamp amplifier (Axon Instruments Inc.). All recordings were acquired at a sampling rate of 10 kHz and low-pass filtered at 400 Hz. Patch pipettes were made from Corning Kovar Sealing No. 7052 glass (World Precision Instruments, Inc., Sarasota, ^f L) and they had a resistance of 5-8 MQ when filled with the extracellular solution. AF508-CFTR was activated after cleavage by adding 1 mM Mg-ATP and 75 nM of the cAMP-dependent protein kinase, catalytic subunit (PKA; Promega Corp. Madison, WI.). After stabilizing channel activity, the patch was peripheralized using a gravity driven microperfusion system. The entrance was placed adjacent to the patch, resulting in a complete solution exchange in 1-2 seconds. To maintain AF508-CFTR activity during rapid peripusion, the nonspecific phosphatase inhibitor F- (10 mM NaF) was added to the bath solution. Under these recording conditions, channel activity remained constant throughout the duration of the patch recording (up to 60 min). The currents produced by positive charges moving from intracellular to extracellular solutions (anions moving in the opposite direction) are shown as positive currents. The pipet potential (Vp) was kept at 80 mV.
[0988] Channel activity was analyzed from membrane patches containing <2 active channels. The maximum number of simultaneous openings determined the number of active channels during the course of an experiment. To determine the current amplitude of a single channel, the data recorded from 120 seconds of AF508-CFTR activity was filtered "off-line" at 100 Hz and then used to construct amplitude histograms of all points that were fitted with multigaussian functions using Bio-Patch Analysis software (Bio-Logic Comp. France). Total microscopic current and opening probability (Po) were determined from 120 seconds of channel activity. Po was determined using the Bio-Patch software or from the relation Po = I / i (N), where I = mean current, i = current amplitude of a single channel and N = number of active channels in the patch.
[0989] Solutions
[0990] Extracellular solution (in mM): NMDG (150), aspartic acid (150), CaCh (5), MgCh (2) and HEPES (10) (pH adjusted to 7.35 with Tris base).
[0991] Intracellular solution (in mM): NMDG-Cl (150), MgCh (2), EGTA (5), TES (10) and Tris base (14) (pH adjusted to 7.35 with HCl).
[0992] Cell culture
[0993] NIH3T3 mouse fibroblasts stably expressing AF508-CFTR are used for excised membrane patchclamp recordings. Cells are kept at 37 ° C in 5% CO ² and 90% humidity in Dulbecco's Modified Eagle's Medium supplemented with 2 mM glutamine, 10% fetal calf serum, 1 X NEAA, p-ME, 1 X pen. / strep, and 25 mM HEPES in 175 cm2 culture flasks. For single channel recordings, 2,500-5,000 cells were seeded on poly-L-lysine coated glass coverslips and cultured for 24-48 hours at 27 ° C prior to use.
[0994] Compound 1 and Compound 2 of the invention are useful as enhancers or inducers of CFTR activity. Table 9 below illustrates the EC50 and relative efficacy of Compound 1 and Compound 2. In Table 9 below, the following meanings apply. EC50: "+++" means <10 uM; "++" means between 10 uM and 25 uM; "+" Means between 25 uM and 60 uM. % efficiency: "+" means <25%; "++" means between 25% and 100%, "+++" means> 100%.
[0995] Table 9

权利要求:
Claims (34)
[1]
1. A continuous process for preparing a tablet comprising Compound 1 Form I (3- (6- (1- (2,2-difluorobenzo [d] [1,3] dioxol-5-yl) acid propanecarboxamido) acid) - 3-methylpyridin-2-yl) benzoic) and a solid dispersion comprising Compound 2 substantially amorphous (N- (5-hydroxy-2,4-ditert-butyl-phenyl) -4-oxo-1H-quinolin-3- carboxamide) comprising the steps of:
a) mixing Compound 1 Form I, a solid dispersion comprising substantially amorphous Compound 2, a filler, and a disintegrant in a mixer to form a mixture;
b) preparing a granulation solution with water, a binder and a surfactant;
c) feeding the mixture from step a) into a continuous twin screw granulator while adding the granulating solution from step b) to produce granules;
d) drying the granules from step c) and grinding them;
e) mixing the ground granules from step d) with a filler, a disintegrant and a lubricant to form a mixture; Y
f) compressing the mixture from step e) into a tablet;
wherein at least one of the above steps comprises process analytical technology.
[2]
2. The process of claim 1, wherein step a) comprises process analytical technology, wherein the process analytical technology is NIR spectroscopy to monitor the uniformity of the mixture.
[3]
The process of claim 1 or claim 2, wherein step b) comprises process analytical technology.
[4]
4. The process of any of claims 1-3, wherein step c) comprises process analytical technology.
[5]
5. The process of any of claims 1 to 4, wherein step d) comprises process analytical technology, wherein the process analytical technology is NIR spectroscopy to monitor the uniformity of the granules and / or to monitor the content of moisture, or where the analytical process technology is laser diffraction to monitor particle size distribution.
[6]
6. The process of any of claims 1-5, wherein step e) comprises process analytical technology, wherein the process analytical technology is NIR spectroscopy to monitor the uniformity of the mixture.
[7]
7. The process of any of claims 1 to 6, wherein step e) comprises process analytical technology, wherein the process analytical technology is NIR spectroscopy to monitor moisture content.
[8]
8. The process of any of claims 1-7, wherein step f) comprises process analytical technology, wherein the process analytical technology is Raman spectroscopy to monitor the identity of the solid form of the active pharmaceutical ingredient.
[9]
9. The process of any of claims 1-8, wherein step f) comprises process analytical technology, wherein the process analytical technology is a tablet tester to monitor tablet weight.
[10]
The process of any of claims 1-9, wherein step f) comprises process analytical technology, wherein the process analytical technology is a tablet tester to monitor tablet thickness.
[11]
The process of any of claims 1-10, wherein step f) comprises process analytical technology, wherein the process analytical technology is a tablet tester to monitor tablet hardness.
[12]
12. The process of any of claims 1-11, wherein the process comprises coating the tablet and controlling the thickness of the coating using Raman spectroscopic techniques.
[13]
The process of any of claims 1-12, wherein the process analytical technology comprises at least one laser diffraction, tablet checker, NIR and Raman spectroscopic techniques to monitor defined standards.
[14]
The process of claim 13, wherein the defined standard is selected from mixing uniformity, granule uniformity, moisture, particle size distribution, active pharmaceutical ingredient solid form identity, active pharmaceutical ingredient concentration, weight, thickness, hardness and coating thickness.
[15]
The process of claim 13 or 14, wherein the defined standard is monitored for real-time release testing (RTRT).
[16]
16. The process of any one of claims 1-15, wherein Form I is characterized as a crystalline form having a monoclinic crystal system, a P2-i / n space group, and the following unit cell dimensions: '
a = 4.9626 (7) A
b = 12,299 (2) Ap = 93,938 (9) °
c = 33.075 (4) A. and / or
wherein Form I is characterized by one or more peaks at 15.4 ± 0.2 degrees, 16.3 ± 0.2 degrees, and 14.5 ± 0.2 degrees in X-ray powder diffraction obtained by radiation Cu K alpha
[17]
17. The process of claim 16, characterized in that Form I of Compound 1 is characterized by one or more peaks, within one or more ranges of 20 values, selected from 15.2 to 15.6 degrees, 16.1 to 16.5 degrees and 14.3 to 14.7 degrees in X-ray powder diffraction obtained by Cu K alpha radiation.
[18]
The process of claim 17, characterized in that Form I of Compound 1 is characterized by a peak having a value of 20 to 15.2 to 15.6 degrees in an X-ray powder diffraction obtained using Cu K alpha radiation. .
[19]
19. The process of claim 18, characterized in that Form I of Compound 1 is characterized by a peak having a value of 20 to 15.4 degrees in an X-ray powder diffraction obtained using Cu K alpha radiation.
[20]
20. The process of claim 17, characterized in that Form I of Compound 1 is characterized by a peak having a value of 20 to 16.1 to 16.5 degrees in an X-ray powder diffraction obtained using Cu K alpha radiation. .
[21]
The process of claim 20, characterized in that Form I of Compound 1 is characterized by a peak having a value of 20 to 16.3 degrees in an X-ray powder diffraction obtained using Cu K alpha radiation.
[22]
22. The process of claim 17, characterized in that Form I of Compound 1 is characterized by a peak having a value of 14.3 to 14.7 degrees in an X-ray powder diffraction obtained using Cu K alpha radiation. .
[23]
23. The process of claim 22, characterized in that Form I of Compound 1 is characterized by a peak having a value of 20 to 14.5 degrees in an X-ray powder diffraction obtained using Cu K alpha radiation.
[24]
24. The process of claim 17, characterized in that Form I of Compound 1 is further characterized by a peak having a value of 17.6 to 18.0 degrees in an X-ray powder diffraction obtained using Cu K radiation alpha.
[25]
25. The process of claim 17, characterized in that Form I of Compound 1 is further characterized by a peak having a value of 7.6 to 8.0 degrees in an X-ray powder diffraction obtained using Cu K radiation alpha.
[26]
26. The process of any of claims 1 to 15, characterized in that Form I of Compound 1 is characterized by at least one peak having a value of 20 ± 0.2 degrees, selected from 14.41 degrees; 14.64 degrees; 15.23 degrees; 16.11 degrees; 17.67 degrees; 19.32 degrees; 21.67 degrees; 23.40 degrees; 23.99 degrees; 26.10 degrees; and 28.54 degrees in a powder X-ray diffraction obtained using Cu K alpha radiation.
[27]
27. The process of any of claims 1 to 15, characterized in that Form I of Compound 1 is characterized by at least one peak having a value of 20 ± 0.2 degrees, selected from 7.83 degrees; 14.51 degrees; 14.78 degrees; 15.39 degrees; 16.26 degrees; 16.62 degrees; 17.81 degrees; 21.59 degrees; 23.32 degrees; 24.93 degrees; and 25.99 degrees in an X-ray powder diffraction obtained using Cu K alpha radiation.
[28]
28. The process of any of claims 1-15, characterized in that Form I of Compound 1 is characterized by the diffraction pattern of Figure 1.
[29]
29. The process of any of claims 1-15, characterized in that Form I of Compound 1 is characterized by the diffraction pattern of Figure 2.
[30]
30. The process of claim 16, characterized in that Form I of Compound 1 is characterized as a monoclinic crystalline system and a P2-i / n space group, and has the following unit cell dimensions: a = 4.9626 (7 ) TO
b = 12,299 (2) Ap = 93,938 (9) °
c = 33.075 (4) A.
[31]
31. A tablet prepared by the process of any of claims 1-30.
[32]
32. The tablet of claim 31 for use in treating cystic fibrosis in a patient.
[33]
33. The tablet for use of claim 32, characterized in that the patient has an AF508 mutation in CFTR.
[34]
34. The tablet for use of claim 33, characterized in that the patient is homozygous for the AF508 mutation in CFTR.

类似技术:

---

公开号 | 公开日 | 专利标题

---

ES2865600T3|2021-10-15|Process for preparing pharmaceutical compositions for the treatment of diseases mediated by CFTR

---

US20200338063A1|2020-10-29|Pharmaceutical compositions for the treatment of cftr mediated diseases

---

ES2742277T3|2020-02-13|Pharmaceutical compositions of 3- | cyclopropane carboxamido) -3-methylpyridin-2-yl) benzoic acid and its administration

---

TWI619515B|2018-04-01|Pharmaceutical compositions of |-1-|-n-|-6-fluoro-2-|-1h-indol-5-yl)cyclopropanecarboxamide and administration thereof

---

ES2604480T3|2017-03-07|Pharmaceutical compositions of 3- | cyclopropanecarboxamido) -3-methylpyrididin-2-yl) benzoic acid and administration thereof

---

EP2560651A1|2013-02-27|Pharmaceutical compositions and administrations thereof

---

AU2016213697B2|2018-04-05|Pharmaceutical compositions of 3-| cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid and administration thereof

同族专利:

---

公开号 | 公开日

---

AU2014349010A1|2016-06-30|

---

RU2019107168A3|2019-10-11|

---

SI3068392T1|2021-07-30|

---

JP2016535791A|2016-11-17|

---

HRP20210516T2|2021-10-01|

---

EP3068392B1|2021-02-24|

---

IL277470D0|2020-11-30|

---

SG10201803930QA|2018-07-30|

---

PL3068392T3|2021-07-19|

---

HRP20210516T1|2021-05-14|

---

JP6963896B2|2021-11-10|

---

HUE054389T2|2021-09-28|

---

EP3068392A4|2017-05-31|

---

US20160354316A1|2016-12-08|

---

MX2016006118A|2016-07-21|

---

CN105848657B|2020-05-22|

---

CA2930199A1|2015-05-21|

---

WO2015073231A9|2015-07-16|

---

KR102280372B1|2021-07-22|

---

KR20160086885A|2016-07-20|

---

DK3068392T3|2021-05-25|

---

AU2014349010C1|2020-08-06|

---

ZA201603973B|2019-09-25|

---

DK3068392T5|2021-09-20|

---

PT3068392T|2021-05-14|

---

JP2021165300A|2021-10-14|

---

US10231932B2|2019-03-19|

---

RU2019107168A|2019-05-20|

---

EP3068392A1|2016-09-21|

---

RU2718044C2|2020-03-30|

---

AU2014349010B2|2020-01-30|

---

RU2016122882A|2017-12-19|

---

CN105848657A|2016-08-10|

---

ES2865600T3|2021-10-15|

---

EP3068392B9|2021-08-04|

---

RS61790B1|2021-06-30|

---

IL245584D0|2016-06-30|

---

WO2015073231A1|2015-05-21|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

---

US3758475A|1971-07-20|1973-09-11|Sandoz Ag|Pyridopyrimidin 2 ones|

---

EP0081756B1|1981-12-14|1985-05-15|MEDEA RESEARCH S.r.l.|New compounds with antiinflammatory and antitussive activity, process for their preparation and relative pharmaceutical compositions|

---

IT1226048B|1981-12-14|1990-12-10|Medea Res Srl|COMPOUNDS WITH ANTI-INFLAMMATORY ACTIVITY, PROCESS FOR THEIR PREPARATION AND RELATIVE PHARMACEUTICAL COMPOSITIONS|

---

US4501729A|1982-12-13|1985-02-26|Research Corporation|Aerosolized amiloride treatment of retained pulmonary secretions|

---

US5981714A|1990-03-05|1999-11-09|Genzyme Corporation|Antibodies specific for cystic fibrosis transmembrane conductance regulator and uses therefor|

---

JP3167762B2|1990-11-27|2001-05-21|武田薬品工業株式会社|Pyridopyridazine derivatives and uses thereof|

---

US5612360A|1992-06-03|1997-03-18|Eli Lilly And Company|Angiotensin II antagonists|

---

CA2107196A1|1992-09-29|1994-03-30|Mitsubishi Chemical Corporation|Carboxamide derivatives|

---

GB9317764D0|1993-08-26|1993-10-13|Pfizer Ltd|Therapeutic compound|

---

DE69416848T2|1993-10-21|1999-07-08|Searle & Co|AMIDINO DERIVATIVES AS NO-SYNTHETASE INHIBITORS|

---

DE4405712A1|1994-02-23|1995-08-24|Basf Ag|Substituted naphthyridines and their use|

---

RU2151145C1|1994-04-11|2000-06-20|Санкио Компани Лимитед|Intermediate compound for synthesis of heterocyclic compounds showing antidiabetic activity|

---

JP3953097B2|1994-09-27|2007-08-01|ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ|N-substituted piperidinyl bicyclic benzoate derivatives|

---

US5656256A|1994-12-14|1997-08-12|The University Of North Carolina At Chapel Hill|Methods of treating lung disease by an aerosol containing benzamil or phenamil|

---

US5510379A|1994-12-19|1996-04-23|Warner-Lambert Company|Sulfonate ACAT inhibitors|

---

US5585115A|1995-01-09|1996-12-17|Edward H. Mendell Co., Inc.|Pharmaceutical excipient having improved compressability|

---

EP0891334A1|1996-04-03|1999-01-20|Merck & Co., Inc.|Inhibitors of farnesyl-protein transferase|

---

EP0984778B1|1996-08-23|2002-06-12|Agouron Pharmaceuticals, Inc.|Neuropeptide-y ligands|

---

CA2276081A1|1996-12-30|1998-07-09|Lekhanh O. Tran|Inhibitors of farnesyl-protein transferase|

---

CO4920215A1|1997-02-14|2000-05-29|Novartis Ag|OXACARBAZEPINE TABLETS COATED WITH A FILM AND METHOD FOR THE PRODUCTION OF THESE FORMULATIONS|

---

US5948814A|1997-02-20|1999-09-07|The Curators Of The University Of Missouri|Genistein for the treatment of cystic fibrosis|

---

WO1998047868A1|1997-04-18|1998-10-29|Smithkline Beecham Plc|Heterocycle-containing urea derivatives as 5ht1a, 5ht1b and 5ht1d receptor antagonists|

---

CA2305808A1|1997-10-02|1999-04-15|Sankyo Company Limited|Amidocarboxylic acid derivatives|

---

WO1999041405A1|1998-02-17|1999-08-19|G.D. Searle & Co.|Process for the enzymatic resolution of lactams|

---

PE20000564A1|1998-06-08|2000-07-05|Schering Corp|NEUROPEPTIDE Y5 RECEPTOR ANTAGONISTS|

---

US6426331B1|1998-07-08|2002-07-30|Tularik Inc.|Inhibitors of STAT function|

---

AUPP609198A0|1998-09-22|1998-10-15|Curtin University Of Technology|Use of non-peptidyl compounds for the treatment of insulin related ailments|

---

AU770042B2|1998-12-18|2004-02-12|Bristol-Myers Squibb Pharma Company|N-ureidoalkyl-piperidines as modulators of chemokine receptor activity|

---

EP1394150B1|1999-02-24|2011-01-19|F. Hoffmann-La Roche AG|4-Phenylpyridine derivatives and their use as NK-1 receptor antagonists|

---

CZ20013046A3|1999-02-24|2002-02-13|F. Hoffmann-La Roche Ag|Phenyl and pyridinyl derivatives|

---

EP1157005B1|1999-02-24|2004-10-20|F. Hoffmann-La Roche Ag|3-phenylpyridine derivatives and their use as nk-1 receptor antagonists|

---

GB2347739A|1999-03-09|2000-09-13|Pfizer Ltd|Powder Analysis|

---

DE60017894T2|1999-06-04|2005-12-29|Agouron Pharmaceuticals, Inc., La Jolla|DIAMINOTHIAZOLE AND ITS USE IN THE INHIBITION OF PROTEIN KINASES|

---

EP1194417A1|1999-06-18|2002-04-10|Bayer Ag|Phenoxy fluoropyrimidines|

---

BR0008088A|1999-12-08|2002-04-09|Pharmacia Corp|Crystal form and solid form of celecoxib, pharmaceutical composition and processes for treating or preventing a cyclooxygenase-2 mediated condition or disorder in an individual and for preparing celecoxib and a crystalline form of celecoxib|

---

WO2001046165A2|1999-12-16|2001-06-28|Novartis Ag|N-heteroaryl-amides and their use as parasiticides|

---

MXPA02006660A|2000-01-07|2002-12-13|Transform Pharmaceuticals Inc|Highthroughput formation, identification, and analysis of diverse solidforms.|

---

AU3306901A|2000-01-28|2001-08-07|Biogen Inc|Pharmaceutical compositions containing anti-beta 1 integrin compounds and uses|

---

WO2001056989A2|2000-02-01|2001-08-09|Cor Therapeutics, Inc.|Inhibitors of factor xa|

---

WO2001081317A1|2000-04-26|2001-11-01|Gliatech, Inc.|Chiral imidazoyl intermediates for the synthesis of 2--cyclopropyl derivatives|

---

WO2001083517A1|2000-05-03|2001-11-08|Tularik Inc.|Stat4 and stat6 binding dipeptide derivatives|

---

US6499984B1|2000-05-22|2002-12-31|Warner-Lambert Company|Continuous production of pharmaceutical granulation|

---

EP1268450A1|2000-06-01|2003-01-02|Bristol-Myers Squibb Pharma Company|Lactams substituted by cyclic succinates as inhibitors of a-beta protein production|

---

TWI259180B|2000-08-08|2006-08-01|Hoffmann La Roche|4-Phenyl-pyridine derivatives|

---

WO2002022608A1|2000-09-15|2002-03-21|Vertex Pharmaceuticals Incorporated|Pyrazole compounds useful as protein kinase inhibitors|

---

JP4272338B2|2000-09-22|2009-06-03|バイエルアクチェンゲゼルシャフト|Pyridine derivatives|

---

AU1137902A|2000-10-04|2002-04-15|Philadelphia Children Hospital|Compositions and methods for treatment of cystic fibrosis|

---

GB2367816A|2000-10-09|2002-04-17|Bayer Ag|Urea- and thiourea-containing derivatives of beta-amino acids|

---

WO2002034739A1|2000-10-20|2002-05-02|Merck Patent Gmbh|Chiral binaphthol derivatives|

---

US6884782B2|2000-11-08|2005-04-26|Amgen Inc.|STAT modulators|

---

DE60142921D1|2000-12-01|2010-10-07|Eisai Inc|AZAPHENANTHRIDONE DERIVATIVES AND THEIR USE AS PARP INHIBITORS|

---

GB0102687D0|2001-02-02|2001-03-21|Pharmacia & Upjohn Spa|Oxazolyl-pyrazole derivatives active as kinase inhibitors,process for their preparation and pharmaceutical compositions comprising them|

---

US6531597B2|2001-02-13|2003-03-11|Hoffmann-La Roche Inc.|Process for preparation of 2-phenyl acetic acid derivatives|

---

EP1383799A4|2001-04-10|2008-08-06|Transtech Pharma Inc|Probes, systems and methods for drug discovery|

---

AU2002250876B2|2001-04-23|2005-03-03|F. Hoffmann-La Roche Ag|Use of NK-1 receptor antagonists against benign prostatic hyperplasia|

---

EP1392302A1|2001-05-22|2004-03-03|Neurogen Corporation|5-substituted-2-arylpyridines as crf1 modulators|

---

US20030083345A1|2001-07-10|2003-05-01|Torsten Hoffmann|Method of treatment and/or prevention of brain, spinal or nerve injury|

---

US6627646B2|2001-07-17|2003-09-30|Sepracor Inc.|Norastemizole polymorphs|

---

CA2448737C|2001-07-20|2010-06-01|Boehringer Ingelheim Ltd.|Viral polymerase inhibitors|

---

WO2003007888A2|2001-07-20|2003-01-30|Adipogenix, Inc.|Fat accumulation-modulating compounds|

---

WO2003022852A2|2001-09-11|2003-03-20|Smithkline Beecham Corporation|Furo-and thienopyrimidine derivatives as angiogenesis inhibitors|

---

PA8557501A1|2001-11-12|2003-06-30|Pfizer Prod Inc|BENZAMIDA, HETEROARILAMIDA AND INVESTED AMIDAS|

---

JP2003155285A|2001-11-19|2003-05-27|Toray Ind Inc|Cyclic nitrogen-containing derivative|

---

JP2003221386A|2001-11-26|2003-08-05|Takeda Chem Ind Ltd|Bicylic derivative, method for producing the same, and use of the same|

---

UA84390C2|2001-12-21|2008-10-27|Ново Нордиск А/Я|Amide derivatives as glucokinase activators|

---

TW200307539A|2002-02-01|2003-12-16|Squibb Bristol Myers Co|Cycloalkyl inhibitors of potassium channel function|

---

TW200304820A|2002-03-25|2003-10-16|Avanir Pharmaceuticals|Use of benzimidazole analogs in the treatment of cell proliferation|

---

TW200403058A|2002-04-19|2004-03-01|Squibb Bristol Myers Co|Heterocyclo inhibitors of potassium channel function|

---

FR2840807B1|2002-06-12|2005-03-11|COSMETIC CARE AND / OR MAKEUP COMPOSITION, STRUCTURED BY SILICONE POLYMERS AND ORGANOGELATORS, IN RIGID FORM|

---

CN1703395A|2002-08-09|2005-11-30|特兰斯泰克制药公司|Aryl and heteroaryl compounds and methods to modulate coagulation|

---

GB0221443D0|2002-09-16|2002-10-23|Glaxo Group Ltd|Pyridine derivates|

---

JP3546208B2|2002-10-02|2004-07-21|明治製菓株式会社|Antibacterial pharmaceutical composition with improved oral absorption|

---

US20050215614A1|2002-10-15|2005-09-29|Rigel Pharmaceuticals, Inc.|Substituted indoles and their use as hcv inhibitors|

---

US7514431B2|2002-10-30|2009-04-07|Merck & Co., Inc.|Piperidinyl cyclopentyl aryl benzylamide modulators of chemokine receptor activity|

---

SI1565258T1|2002-11-26|2012-04-30|Univ Gent|Process and apparatus for continuous wet granulation of powder material|

---

MXPA05006367A|2002-12-12|2005-08-29|Pharmacia Corp|Method of using aminocyanopyridine compounds as mitogen activated protein kinase-activated protein kinase-2 inhibitors.|

---

WO2004063179A1|2003-01-06|2004-07-29|Eli Lilly And Company|Substituted arylcyclopropylacetamides as glucokinase activators|

---

CA2515669A1|2003-02-10|2004-08-26|Vertex Pharmaceuticals Incorporated|Processes for the preparation of n-heteroaryl-n-aryl-amines by reacting an n-aryl carbamic acid ester with a halo-heteroaryl and analogous processes|

---

US7223788B2|2003-02-14|2007-05-29|Sanofi-Aventis Deutschland Gmbh|Substituted N-aryl heterocycles, process for their preparation and their use as medicaments|

---

EP1601657A1|2003-03-12|2005-12-07|Vertex Pharmaceuticals Incorporated|Pyrazole modulators of atp-binding cassette transporters|

---

BRPI0409914A|2003-04-30|2006-04-25|Inst For Pharm Discovery Inc|substituted carboxylic acids|

---

AT440825T|2003-06-06|2009-09-15|Vertex Pharma|PYRIMIDIN DERIVATIVES FOR USE AS MODULATORS OF ATP-BINDING CASSETTE TRANSPORTER|

---

EP1638505B1|2003-06-27|2012-04-25|Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc.|Amphiphilic pyridinium compounds, method of making and use thereof|

---

GB0315111D0|2003-06-27|2003-07-30|Cancer Rec Tech Ltd|Substituted 5-membered ring compounds and their use|

---

JP2005053902A|2003-07-18|2005-03-03|Nippon Nohyaku Co Ltd|Phenylpyridines, intermediate therefor, and herbicide containing the same as effective ingredient|

---

EP1680424A2|2003-09-05|2006-07-19|Neurogen Corporation|Heteroaryl fused pyridines, pyrazines and pyrimidines as crf1 receptor ligands|

---

KR20060088537A|2003-09-06|2006-08-04|버텍스 파마슈티칼스 인코포레이티드|Modulators of atp-binding cassette transporters|

---

US7534894B2|2003-09-25|2009-05-19|Wyeth|Biphenyloxy-acids|

---

US20050070718A1|2003-09-30|2005-03-31|Abbott Gmbh & Co. Kg|Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them|

---

ZA200603515B|2003-10-08|2007-11-28|Vertex Pharma|Modulators of ATP-binding cassette transporters|

---

JPWO2005037269A1|2003-10-21|2006-12-28|住友製薬株式会社|Novel piperidine derivatives|

---

FR2861304B1|2003-10-23|2008-07-18|Univ Grenoble 1|CFTR CHANNEL MODULATORS|

---

GB0325956D0|2003-11-06|2003-12-10|Addex Pharmaceuticals Sa|Novel compounds|

---

WO2005049018A1|2003-11-14|2005-06-02|Vertex Pharmaceuticals Incorporated|Thiazoles and oxazoles useful as modulators of atp-binding cassette transporters|

---

WO2005049034A2|2003-11-19|2005-06-02|Glaxo Group Limited|Use of cyclooxygenase-2 selective inhibitors for the treatment of schizophrenic disorders|

---

ES2238001B1|2004-01-21|2006-11-01|Vita Cientifica, S.L.|NEW POLYMORPHIC FORMS OF ONDANSETRON, PROCEDURES FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE AS ANANTIMETICS.|

---

ES2631362T3|2004-01-30|2017-08-30|Vertex Pharmaceuticals Incorporated|ATP binding cassette conveyor modulators|

---

WO2005080348A1|2004-02-19|2005-09-01|Banyu Pharmaceutical Co., Ltd.|Novel sulfone amide derivative|

---

CA2561167C|2004-03-25|2012-09-11|Astellas Pharma Inc.|Composition of solifenacin or salt thereof for use in solid formulation|

---

ES2241496B1|2004-04-15|2006-12-01|Almirall Prodesfarma, S.A.|NEW DERIVATIVES OF PIRIDINA.|

---

US20080015196A1|2004-04-16|2008-01-17|Neurogen Corporation|Imidazopyrazines, Imidazopyridines, and Imidazopyrimidines as Crf1 Receptor Ligands|

---

US7618978B2|2004-04-22|2009-11-17|Eli Lilly And Company|Amides as BACE inhibitors|

---

US7585885B2|2004-04-22|2009-09-08|Eli Lilly And Company|Pyrrolidine derivatives useful as BACE inhibitors|

---

AU2005249154B2|2004-06-01|2011-02-10|Luminex Molecular Diagnostics, Inc.|Method of detecting cystic fibrosis associated mutations|

---

TWI547431B|2004-06-09|2016-09-01|史密斯克萊美占公司|Apparatus and method for pharmaceutical production|

---

MX341797B|2004-06-24|2016-09-02|Vertex Pharmaceuticals Incorporated |Modulators of atp-binding cassette transporters.|

---

US20140343098A1|2004-06-24|2014-11-20|Vertex Pharmaceuticals Incorporated|Modulators of atp-binding cassette transporters|

---

US8354427B2|2004-06-24|2013-01-15|Vertex Pharmaceutical Incorporated|Modulators of ATP-binding cassette transporters|

---

WO2006003504A1|2004-07-01|2006-01-12|Warner-Lambert Company Llc|Preparation of pharmaceutical compositions containing nanoparticles|

---

AU2005269981A1|2004-07-02|2006-02-09|Bonck, John A|Tablet for pulsed delivery|

---

RU2416608C2|2004-08-06|2011-04-20|Оцука Фармасьютикал Ко., Лтд.|Aromatic compound|

---

US7977322B2|2004-08-20|2011-07-12|Vertex Pharmaceuticals Incorporated|Modulators of ATP-binding cassette transporters|

---

EP1794135A1|2004-09-27|2007-06-13|Amgen Inc.|Substituted heterocyclic compounds and methods of use|

---

AT540935T|2004-10-12|2012-01-15|Astrazeneca Ab|quinazoline derivatives|

---

CA2587461A1|2004-11-15|2006-05-18|Pfizer Products Inc.|Azabenzoxazoles for the treatment of cns disorders|

---

RS50962B|2004-12-15|2010-10-31|Dompe Pha.R.Ma S.P.A.|2-arylpropionic acid derivatives and pharmaceutical compositions containing them|

---

JP4790260B2|2004-12-22|2011-10-12|出光興産株式会社|Organic electroluminescence device using anthracene derivative|

---

WO2006080884A1|2005-01-27|2006-08-03|Astrazeneca Ab|Novel biaromatic compounds, inhibitors of the p2x7-receptor|

---

US7888374B2|2005-01-28|2011-02-15|Abbott Laboratories|Inhibitors of c-jun N-terminal kinases|

---

JPWO2006082952A1|2005-02-01|2008-06-26|武田薬品工業株式会社|Amide compounds|

---

US8242149B2|2005-03-11|2012-08-14|Vertex Pharmaceuticals Incorporated|Modulators of ATP-binding cassette transporters|

---

US7297700B2|2005-03-24|2007-11-20|Renovis, Inc.|Bicycloheteroaryl compounds as P2X7modulators and uses thereof|

---

TWI377206B|2005-04-06|2012-11-21|Theravance Inc|Crystalline form of a quinolinone-carboxamide compound|

---

EP1710246A1|2005-04-08|2006-10-11|Schering Aktiengesellschaft|Sulfoximine-pyrimidine Macrocycles and the salts thereof,a process for making them, and their pharmaceutical use against cancer|

---

AR053712A1|2005-04-18|2007-05-16|Neurogen Corp|HETEROARILOS SUBSTITUTED, ANTAGONISTS OF CB1 |

---

WO2006113919A2|2005-04-19|2006-10-26|Bayer Pharmaceuticals Corporation|Aryl alkyl acid derivatives for and use thereof|

---

US20090123538A1|2005-04-20|2009-05-14|Alani Laman L|Angiotensin II Receptor Antagonists|

---

WO2006116218A1|2005-04-22|2006-11-02|Wyeth|Crystal forms of {[-7--5-fluoro-2,3-dihydro-1-benzofuran-2-yl]methyl}amine hydrochloride|

---

GB0510139D0|2005-05-18|2005-06-22|Addex Pharmaceuticals Sa|Novel compounds B1|

---

US8822451B2|2005-05-24|2014-09-02|Vertex Pharmaceuticals Incorporated|Modulators of ATP-binding cassette transporters|

---

JP2008545744A|2005-06-02|2008-12-18|バイエル・クロツプサイエンス・アクチエンゲゼルシヤフト|Phenylalkyl-substituted heteroaryl derivatives|

---

JP2008543919A|2005-06-21|2008-12-04|アステックス・セラピューティクス・リミテッド|Pharmaceutical compounds|

---

ES2367844T3|2005-08-11|2011-11-10|Vertex Pharmaceuticals, Inc.|MODULATORS OF THE REGULATOR OF THE TRANSMEMBRANE CONDUCTANCE OF THE CHYSICAL FIBROSIS.|

---

KR20080053297A|2005-08-11|2008-06-12|버텍스 파마슈티칼스 인코포레이티드|Modulators of cystic fibrosis transmembrane conductance regulator|

---

BRPI0615787B8|2005-09-09|2021-05-25|Glaxosmithkline Llc|Pyridine derivatives and their use in the treatment of psychotic disorders|

---

PT1928427E|2005-09-23|2010-03-01|Hoffmann La Roche|Novel dosage formulation|

---

KR20080064971A|2005-10-06|2008-07-10|버텍스 파마슈티칼스 인코포레이티드|Modulators of atp-binding cassette transporters|

---

PE20110285A1|2005-10-19|2011-06-04|Gruenenthal Chemie|SULFONAMIDOPHENYL PROPIONAMIDE DERIVATIVES AS LIGANDS OF THE VANILOID RECEPTOR SUBTYPE 1|

---

US7754739B2|2007-05-09|2010-07-13|Vertex Pharmaceuticals Incorporated|Modulators of CFTR|

---

WO2007054480A1|2005-11-08|2007-05-18|N.V. Organon|2--acetamide biaryl derivatives and their use as inhibitors of the trpv1 receptor|

---

KR20150041174A|2005-11-08|2015-04-15|버텍스 파마슈티칼스 인코포레이티드|Heterocyclic modulators of ATP-binding cassette transporters|

---

US20120232059A1|2005-11-08|2012-09-13|Vertex Pharmaceuticals Incorporated|Modulators of ATP-Binding Cassette Transporters|

---

WO2007067506A2|2005-12-05|2007-06-14|Smithkline Beecham Corporation|2-pyrimidinyl pyrazolopyridine erbb kinase inhibitors|

---

CA2634113A1|2005-12-24|2007-07-05|Vertex Pharmaceuticals Incorporated|Quinolin- 4 - one derivatives as modulators of abc transporters|

---

EP1974212A1|2005-12-27|2008-10-01|Vertex Pharmaceuticals Incorporated|Compounds useful in cftr assays and methods therewith|

---

CN101395147B|2005-12-28|2013-05-29|弗特克斯药品有限公司|1- dioxol-5-yl) -n- cyclopropane- carboxamide derivatives and related compounds as modulators of ATP-binding cassette transporters for the treatment of cystic fibrosis|

---

PT3219705T|2005-12-28|2020-05-20|Vertex Pharma|Pharmaceutical compositions of the amorphous form of n-[2,4-bis-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide|

---

US7671221B2|2005-12-28|2010-03-02|Vertex Pharmaceuticals Incorporated|Modulators of ATP-Binding Cassette transporters|

---

WO2007079257A2|2005-12-30|2007-07-12|Caliper Life Sciences, Inc.|Integrated dissolution processing and sample transfer system|

---

GB0606891D0|2006-04-05|2006-05-17|Council Cent Lab Res Councils|Raman Analysis Of Pharmaceutical Tablets|

---

US10022352B2|2006-04-07|2018-07-17|Vertex Pharmaceuticals Incorporated|Modulators of ATP-binding cassette transporters|

---

US7645789B2|2006-04-07|2010-01-12|Vertex Pharmaceuticals Incorporated|Indole derivatives as CFTR modulators|

---

NZ596889A|2006-04-07|2013-06-28|Vertex Pharma|Use of amide indole derivatives as modulators of ATP-binding cassette transporters|

---

EP2021797B1|2006-05-12|2011-11-23|Vertex Pharmaceuticals, Inc.|Compositions of n-ý2,4-bis-5-hydroxyphenyl¨-1,4-dihydro-4-oxoquinoline-3-carboxamide|

---

US20090252790A1|2006-05-13|2009-10-08|Novo Nordisk A/S|Tablet formulation|

---

WO2008127399A2|2006-11-03|2008-10-23|Vertex Pharmaceuticals Incorporated|Azaindole derivatives as cftr modulators|

---

US8563573B2|2007-11-02|2013-10-22|Vertex Pharmaceuticals Incorporated|Azaindole derivatives as CFTR modulators|

---

BRPI0719345A2|2006-11-27|2014-03-18|Novartis Ag|REPLACED DI-HYDROIMIDAZOLS AND ITS USE IN TREATMENT TREATMENT.|

---

JP2008183168A|2007-01-30|2008-08-14|Ebara Corp|Tablet manufacturing system|

---

US20080260820A1|2007-04-19|2008-10-23|Gilles Borrelly|Oral dosage formulations of protease-resistant polypeptides|

---

EA020045B1|2007-05-02|2014-08-29|Портола Фармасьютиклз, Инк.|Combination therapy with a compound acting as a platelet adp receptor inhibitor|

---

CN101687842B|2007-05-09|2013-03-06|沃泰克斯药物股份有限公司|Modulators of CFTR|

---

WO2008147952A1|2007-05-25|2008-12-04|Vertex Pharmaceuticals Incorporated|Modulators of cystic fibrosis transmembrane conductance regulator|

---

WO2009023509A2|2007-08-09|2009-02-19|Vertex Pharmaceuticals Incorporated|Therapeutic combinations useful in treating cftr related diseases|

---

CA2696298C|2007-08-24|2016-09-06|Vertex Pharmaceuticals Incorporated|Modulators of cystic fibrosis transmembrane conductance regulator|

---

DE102007042754A1|2007-09-07|2009-03-12|Bayer Healthcare Ag|Substituted 6-phenyl-nicotinic acids and their use|

---

NZ600865A|2007-09-14|2014-01-31|Vertex Pharma|Solid forms of n-[2,4-bis-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide|

---

JP5461405B2|2007-09-14|2014-04-02|バーテックスファーマシューティカルズインコーポレイテッド|Regulators of cystic fibrosis membrane conductance regulator|

---

FR2921657A1|2007-09-28|2009-04-03|Sanofi Aventis Sa|New nicotinamide derivatives useful for the preparation of a medicament for the treatment or prevention of cancer|

---

CN101952254B|2007-11-16|2012-09-05|沃泰克斯药物股份有限公司|Isoquinoline modulators of ATP-binding cassette transporters|

---

KR20100098545A|2007-12-07|2010-09-07|버텍스 파마슈티칼스 인코포레이티드|Formulations of 3-cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid|

---

DK2639222T3|2007-12-07|2016-10-03|Vertex Pharma|Methods for preparing cycloalkylcarboxamido-pyridinbenzoesyrer|

---

US20100036130A1|2007-12-07|2010-02-11|Vertex Pharmaceuticals Incorporated|Processes for producing cycloalkylcarboxamido-pyridine benzoic acids|

---

BRPI0821039B8|2007-12-07|2021-05-25|Vertex Pharma|solid forms of 3-cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid, process for their preparation , pharmaceutical compositions comprising the same and uses|

---

WO2009076593A1|2007-12-13|2009-06-18|Vertex Pharmaceuticals Incorporated|Modulators of cystic fibrosis transmembrane conductance regulator|

---

CN103467554A|2008-02-05|2013-12-25|哈博生物科学公司|Pharmaceutical solid state forms|

---

CA2716109C|2008-02-28|2016-07-19|Vertex Pharmaceuticals Incorporated|Heteroaryl derivatives as cftr modulators|

---

PL2615085T3|2008-03-31|2016-02-29|Vertex Pharma|Pyridyl derivatives as CFTR modulators|

---

GB0813709D0|2008-07-26|2008-09-03|Univ Dundee|Method and product|

---

US20100256184A1|2008-08-13|2010-10-07|Vertex Pharmaceuticals Incorporated|Pharmaceutical composition and administrations thereof|

---

US20100074949A1|2008-08-13|2010-03-25|William Rowe|Pharmaceutical composition and administration thereof|

---

KR20110042356A|2008-08-13|2011-04-26|버텍스 파마슈티칼스 인코포레이티드|Pharmaceutical composition and administrations thereof|

---

EP2349223A2|2008-09-29|2011-08-03|Vertex Pharmaceuticals Incorporated|Dosage units of 3- cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid|

---

US20110257223A1|2008-10-23|2011-10-20|Vertex Pharmaceuticals Incorporated|Modulators of Cystic Fibrosis Transmembrane Conductance Regulator|

---

MX2011004374A|2008-10-23|2011-05-23|Vertex Pharma|Solid forms of n--2-phenyl)-4-oxo-5--1,4-dihydroquinoline-3- carboxamide.|

---

DK2349263T3|2008-10-23|2014-07-21|Vertex Pharma|Modulators of the transmembrane conductance regulator for cystic fibrosis|

---

JP5645834B2|2008-10-23|2014-12-24|バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ|Modulator of cystic fibrosis membrane conductance regulator|

---

NZ609962A|2008-11-06|2014-11-28|Vertex Pharma|Modulators of atp-binding cassette transporters|

---

UA104876C2|2008-11-06|2014-03-25|Вертекс Фармасьютікалз Інкорпорейтед|Modulators of atp-binding cassette transporters|

---

JP5699090B2|2008-12-30|2015-04-08|バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ|Modulator of cystic fibrosis membrane conductance regulator|

---

LT2408749T|2009-03-20|2018-09-25|Vertex Pharmaceuticals Incorporated|Modulators of cystic fibrosis transmembrane conductance regulator|

---

KR101852173B1|2009-03-20|2018-04-27|버텍스 파마슈티칼스 인코포레이티드|Process for making modulators of cystic fibrosis transmembrane conductance regulator|

---

WO2010114638A1|2009-03-30|2010-10-07|E. I. Du Pont De Nemours And Company|Peptide-based tooth whitening reagents|

---

ES2441446T3|2009-05-07|2014-02-04|Gea Pharma Systems Limited|Pill production module and method for continuous pill production|

---

JP5355269B2|2009-07-16|2013-11-27|大日本住友製薬株式会社|Measuring method of particle size of dispersed particles in solid materials by micro Raman spectroscopy|

---

CA2772792A1|2009-09-17|2011-03-24|Vertex Pharmaceuticals Incorporated|Process for preparing azabicyclic compounds|

---

EP2813227A1|2009-10-22|2014-12-17|Vertex Pharmaceuticals Incorporated|Compositions for treatment of cystic fibrosis and other chronic diseases|

---

NZ599703A|2009-10-23|2014-06-27|Vertex Pharma|Solid forms of n--2-trifluoromethyl)phenyl)-4-oxo-5--1,4-dihydroquinoline-3-carboxamide|

---

RU2553989C2|2009-10-23|2015-06-20|Вертекс Фармасьютикалз Инкорпорейтед|Method for obtaining modulators of cystic fibrousis transmembrane conductance regulator|

---

US8802700B2|2010-12-10|2014-08-12|Vertex Pharmaceuticals Incorporated|Modulators of ATP-Binding Cassette transporters|

---

US8471029B2|2010-03-19|2013-06-25|Vertex Pharmaceutical Incorporated|Solid forms of N-[2,4-bis-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide|

---

MX347804B|2010-03-25|2017-05-15|Vertex Pharmaceuticals Incorporated |Solid forms of -1 -n--6-fluoro-2--1h-indol-5-yl) cyclopropanecarboxamide.|

---

US8802868B2|2010-03-25|2014-08-12|Vertex Pharmaceuticals Incorporated|Solid forms of -1-N--1H-Indol-5-yl)-Cyclopropanecarboxamide|

---

MX364937B|2010-04-07|2019-05-15|Vertex Pharmaceuticals Incorporated Star|Pharmaceutical compositions of 3- cyclopropanecarboxamido)-3-methylpyriodin-2-yl)benzo ic acid and administration thereof.|

---

RS54783B1|2010-04-07|2016-10-31|Vertex Pharma|Solid forms of 3- cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid|

---

WO2011133951A1|2010-04-22|2011-10-27|Vertex Pharmaceuticals Incorporated|Pharmaceutical compositions and administrations thereof|

---

WO2011133751A2|2010-04-22|2011-10-27|Vertex Pharmaceuticals Incorporated|Process of producing cycloalkylcarboxamido-indole compounds|

---

CA2796646A1|2010-04-22|2011-10-27|Vertex Pharmaceuticals Incorporated|Pharmaceutical compositions and administrations thereof|

---

WO2011133953A1|2010-04-22|2011-10-27|Vertex Pharmaceuticals Incorporated|Pharmaceutical compositions and administrations thereof|

---

CA2798412A1|2010-05-20|2011-11-24|Vertex Pharmaceuticals Incorporated|Pharmaceutical compositions and administrations thereof|

---

US8404849B2|2010-05-20|2013-03-26|Vertex Pharmaceuticals|Processes for producing modulators of cystic fibrosis transmembrane conductance regulator|

---

US8563593B2|2010-06-08|2013-10-22|Vertex Pharmaceuticals Incorporated|Formulations of -1--N--6-fluoro-2--1H-indol-5-yl)cyclopropanecarboxamide|

---

MX2013002035A|2010-08-23|2013-03-25|Vertex Pharma|Pharmaceutical composition of -1--n--6-fluoro-2--1h-indol-5-yl) cyclopropanecarboxamide and administration therof.|

---

EP2608775A2|2010-08-27|2013-07-03|Vertex Pharmaceuticals Incorporated|Pharmaceutical composition and administrations thereof|

---

CN102058889A|2010-11-05|2011-05-18|王定豪|Dispersible tablet containing anticoagulants and application thereof|

---

US10092660B2|2011-04-25|2018-10-09|Stc.Unm|Solid compositions for pharmaceutical use|

---

JP5798400B2|2011-07-26|2015-10-21|富士電機株式会社|Pharmaceutical manufacturing control device, pharmaceutical manufacturing control method, pharmaceutical manufacturing control program, pharmaceutical manufacturing system|

---

AU2012332225A1|2011-11-02|2014-05-15|Vertex Pharmaceuticals Incorporated|Use of - 5 - hydroxyphenyl] - 1, 4 - dihydro - 4 - oxoquinoline - 3 - ca rboxamide) for treating CFTR mediated diseases|

---

ES2622154T3|2011-11-08|2017-07-05|Vertex Pharmaceuticals Incorporated|Atp-binding cassette conveyor modulators|

---

PL2806859T3|2012-01-25|2019-11-29|Vertex Pharma|Formulations of 3- cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid|

---

AU2013226076B2|2012-02-27|2017-11-16|Vertex Pharmaceuticals Incorporated|Pharmaceutical composition and administration thereof|

---

US8674108B2|2012-04-20|2014-03-18|Vertex Pharmaceuticals Incorporated|Solid forms of N-[2,4-bis-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide|

---

EP2659890A1|2012-04-30|2013-11-06|Orphan Synergy Europe - Pharma|Methods and compositions for the treatment of fibrosis|

---

AU2013270681A1|2012-06-08|2014-12-18|Vertex Pharmaceuticals Incorporated|Pharmaceutical compositions for the treatment of CFTR -mediated disorders|

---

US9012496B2|2012-07-16|2015-04-21|Vertex Pharmaceuticals Incorporated|Pharmaceutical compositions of -1--N--6-fluoro-2--1H-indol-5-yl)cyclopropanecarboxamide and administration thereof|

---

US20140092376A1|2012-10-01|2014-04-03|Momentive Performance Materials, Inc.|Container and method for in-line analysis of protein compositions|

---

ES2694290T3|2012-11-02|2018-12-19|Vertex Pharmaceuticals Incorporated|Pharmaceutical compositions for the treatment of diseases mediated by CFTR|

---

US20140127901A1|2012-11-08|2014-05-08|Taiwan Semiconductor Manufacturing Company, Ltd.|Low-k damage free integration scheme for copper interconnects|

---

US20140221424A1|2013-01-30|2014-08-07|Vertex Pharmaceuticals Incorporated|Pharmaceutical compositions for use in the treatment of cystic fibrosis|

---

CN110840847A|2014-04-15|2020-02-28|沃泰克斯药物股份有限公司|Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases|

---

SG10201902963PA|2014-10-06|2019-05-30|Vertex Pharma|Modulators of cystic fibrosis transmembrane conductance regulator|

---

AU2015330923B2|2014-10-07|2020-03-12|Vertex Pharmaceuticals Incorporated|Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator|

---

WO2016086136A1|2014-11-26|2016-06-02|Catabasis Pharmaceuticals, Inc.|Fatty acid cysteamine conjugates of cftr modulators and their use in treating medical disorders|

---

MA41031A|2014-11-26|2017-10-03|Catabasis Pharmaceuticals Inc|CYSTEAMINE-FATTY ACID CONJUGATES AND THEIR USE AS AUTOPHAGIC ACTIVATORS|

---

WO2016087665A2|2014-12-05|2016-06-09|Centre National De La Recherche Scientifique |Compounds for treating cystic fibrosis|

---

CA2974900A1|2015-01-26|2016-08-04|Rigel Pharmaceuticals, Inc.|Tetrazolones as carboxylic acid bioisosteres|

---

UY36680A|2015-05-19|2016-12-30|Glaxosmithkline Ip Dev Ltd|HETEROCYCLIC AMIDES AS QUINASA INHIBITORS|MX341797B|2004-06-24|2016-09-02|Vertex Pharmaceuticals Incorporated |Modulators of atp-binding cassette transporters.|

---

KR20150041174A|2005-11-08|2015-04-15|버텍스 파마슈티칼스 인코포레이티드|Heterocyclic modulators of ATP-binding cassette transporters|

---

PT3219705T|2005-12-28|2020-05-20|Vertex Pharma|Pharmaceutical compositions of the amorphous form of n-[2,4-bis-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide|

---

NZ596889A|2006-04-07|2013-06-28|Vertex Pharma|Use of amide indole derivatives as modulators of ATP-binding cassette transporters|

---

US7645789B2|2006-04-07|2010-01-12|Vertex Pharmaceuticals Incorporated|Indole derivatives as CFTR modulators|

---

US10022352B2|2006-04-07|2018-07-17|Vertex Pharmaceuticals Incorporated|Modulators of ATP-binding cassette transporters|

---

US20100074949A1|2008-08-13|2010-03-25|William Rowe|Pharmaceutical composition and administration thereof|

---

US8802868B2|2010-03-25|2014-08-12|Vertex Pharmaceuticals Incorporated|Solid forms of -1-N--1H-Indol-5-yl)-Cyclopropanecarboxamide|

---

MX364937B|2010-04-07|2019-05-15|Vertex Pharmaceuticals Incorporated Star|Pharmaceutical compositions of 3- cyclopropanecarboxamido)-3-methylpyriodin-2-yl)benzo ic acid and administration thereof.|

---

WO2011133751A2|2010-04-22|2011-10-27|Vertex Pharmaceuticals Incorporated|Process of producing cycloalkylcarboxamido-indole compounds|

---

AU2013226076B2|2012-02-27|2017-11-16|Vertex Pharmaceuticals Incorporated|Pharmaceutical composition and administration thereof|

---

US9012496B2|2012-07-16|2015-04-21|Vertex Pharmaceuticals Incorporated|Pharmaceutical compositions of -1--N--6-fluoro-2--1H-indol-5-yl)cyclopropanecarboxamide and administration thereof|

---

CN110840847A|2014-04-15|2020-02-28|沃泰克斯药物股份有限公司|Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases|

---

SG10201902963PA|2014-10-06|2019-05-30|Vertex Pharma|Modulators of cystic fibrosis transmembrane conductance regulator|

---

US10653622B1|2015-04-13|2020-05-19|Pharmacoustics Technologies LLC|Individualized solid dosage products and a system and method for the globally integrated pharmaceutical manufacturing and its monitoring thereof|

---

US20180250232A1|2015-09-03|2018-09-06|Merck Sharp & Dohme Corp.|Process for preparing spray dried solid dispersions of -n--1h-indazol-5-yl)-1-phenyl)-3,6-dihydropyridin-1-yl)-2-oxoethyl)-3-pyrrolidine-3-carboxamide for pharmaceutical preparations|

---

TW201735928A|2016-03-31|2017-10-16|大日本住友製藥股份有限公司|Oral formulation having good dissolution property|

---

US10206915B2|2016-04-25|2019-02-19|Druggability Technologies Ip Holdco Limited|Complexes of Ivacaftor and its salts and derivatives, process for the preparation thereof and pharmaceutical compositions containing them|

---

HU1600270A2|2016-04-25|2017-10-30|Druggability Tech Ip Holdco Ltd|Complexes of ivacaftor and its salts and derivatives, process for the preparation thereof and pharmaceutical compositions containing them|

---

US10383865B2|2016-04-25|2019-08-20|Druggability Technologies Ip Holdco Limited|Pharmaceutical combination composition comprising complex formulations of Ivacaftor and Lumacaftor and their salts and derivatives, process for their preparation thereof and pharmaceutical compositions containing them|

---

HU1600271A2|2016-04-25|2017-10-30|Druggability Tech Ip Holdco Ltd|Pharmaceutical composition comprising complex formulations of ivacaftor and lumacaftor and their salts and derivatives, process for their preparation thereof and pharmaceutical compositions containing them|

---

HU1600269A2|2016-04-25|2017-10-30|Druggability Tech Ip Holdco Ltd|Complexes of lumacaftor and its salts and derivatives, process for the preparation thereof and pharmaceutical compositions containing them|

---

US10376501B2|2016-04-25|2019-08-13|Druggability Technologies Ip Holdco Limited|Complexes of lumacaftor and its salts and derivatives, process for the preparation thereof and pharmaceutical compositions containing them|

---

WO2018037350A1|2016-08-23|2018-03-01|Laurus Labs Limited|Solid forms of lumacaftor, process for its preparation and pharmaceutical compositions thereof|

---

CA3037986A1|2016-09-30|2018-04-05|Vertex Pharmaceuticals Incorporated|Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator|

---

PT3551622T|2016-12-09|2020-11-12|Vertex Pharma|Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator|

---

WO2018227049A1|2017-06-08|2018-12-13|Vertex Pharmaceuticals Incorporated|Methods of treatment for cystic fibrosis|

---

EP3697774A1|2017-10-19|2020-08-26|Vertex Pharmaceuticals Incorporated|Crystalline forms and compositions of cftr modulators|

---

TW201944994A|2018-02-05|2019-12-01|美商維泰克斯製藥公司|Pharmaceutical compositions for treating cystic fibrosis|

---

WO2019161078A1|2018-02-15|2019-08-22|Vertex Pharmaceuticals Incorporated|Macrocycles as modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions thereof, their use in the treatment of cycstic fibrosis, and process for making them|

---

EP3818975A1|2019-11-08|2021-05-12|Roquette Freres|Use of sodium octenyl-succinate starches as a binder in continuous wet granulation|

法律状态:

优先权:

---

申请号 | 申请日 | 专利标题

---

US201361903010P| true| 2013-11-12|2013-11-12|

---

US201461929604P| true| 2014-01-21|2014-01-21|

---

US201462000659P| true| 2014-05-20|2014-05-20|

---

PCT/US2014/063506|WO2015073231A1|2013-11-12|2014-10-31|Process of preparing pharmaceutical compositions for the treatment of cftr mediated diseases|

---